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Abstract 
The work described in this thesis concerns the synthesis of novel rotaxanes and 
pseudorotaxanes as intermediates towards molecular cages. The area of 
rotaxanes and cage molecules was reviewed and selected examples discussed in 
detail. 
Three main strategies to synthesise a fumaramide thread were investigated, 
however these were unsuccessful. By changing the templating station and the 
stopper groups, several novel azo-dicarboxylate threads were synthesised, as well 
as their [2]- and [3]rotaxanes. Unusual reductions of the azo-dicarboxylate stations 
during the clipping processes were observed and these were studied in detail. 
A couple of different stopper groups from those initially used, provided several 
novel double fumaramide threads and rotaxanes in high yields 
Linking reactions of the two macrocycles of the newly synthesised [3]rotaxanes to 
form a molecular cage were investigated. However, reduction of the macrocycles 
was required, which led to deslipping of the macrocycles. Therefore, new routes to 
generate rotaxanes with bulkier stopper groups were explored.  
In the final section, novel pseudorotaxanes were synthesised and detected via 
1H NMR spectroscopy and mass spectrometry. By linking the two macrocycles of a 
[3]pseudorotaxane, a molecular cage was formed.  
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1 Chapter 1: Introduction 
 
1.1 Supramolecular chemistry 
In 1987 the Nobel prize in chemistry was awarded to Cram, Pedersen and Lehn. 
Jean-Marie Lehn is still one of the leading proponents in the area of 
supramolecular chemistry and defined it as “chemistry beyond the molecule”.1 The 
most important attribute of a supramolecular system is that several components 
(host and guest) are held together via reversible intermolecular interactions. In 
contrast to supramolecular systems, molecular systems are mainly connected via 
covalent bonds. Supramolecular chemists are able to synthesise covalently 
bonded molecular building blocks, which are held together by intermolecular 
forces to create functional architectures.2 These intermolecular forces can be 
electrostatic (ion-ion, ion-dipole and dipole-dipole), hydrogen bonding, - 
stacking, van der Waals, hydrophobic or solvatophobic interactions. These 
non-covalent interactions are generally much weaker than covalent bonds. The 
combination of several of these weak interactions generates a powerful interlocked 
system, and thus host molecules are able to selectively recognise a specific guest. 
As these interactions are reversible, host-guest products can sit either in a local or 
global thermodynamic energy minimum.  
This type of lock and key principle can be compared to that used by Nature itself, 
e.g. in the reaction of a substrate with the active site of an enzyme as described by 
Emil Fischer in 1894.3 Base pairing in DNA is another example, where two 
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antiparallel strands are held together by hydrogen bonds between complementary 
base pairs.4 The receptor sites on the host (lock) are sterically and electronically 
complementary to the guest (key). Therefore, the host is highly selective for only 
one substrate favouring one single product. 
 
1.2 Rotaxanes and catenanes 
Rotaxanes and catenanes are the two main classes of mechanically interlocked 
molecules.5 Mechanically interlocked molecules possess two or more separate 
covalent components. These components are connected via mechanical bonds, 
which are described as bonds that prevent dissociation. When one of the covalent 
bonds is cleaved, the components will dissociate. Catenanes are formed of two or 
more interlocked macrocycles (Figure 1.1)6, while rotaxanes are made of at least 
one macrocycle and one thread with two stoppers, which prevent the dissociation 
of the components (Figure 1.2).7,8 
 
Figure 1.1: Structure of a [2]catenane.6 
 
Catenanes are topological isomers and their rings cannot be dissociated without 
notionally breaking at least one covalent bond. In the other hand, rotaxanes can 
be separated via deformations of one of the components, e.g. a macrocycle can 
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stretch and this might cause its slipping over the stoppers and therefore 
dissociation from the thread. In other words, rotaxanes are threaded species 
stabilised by steric interactions.  
 
Figure 1.2: First [2]rotaxane synthesised by Harrison and Harrison (left)9 and the 
graphical representation of a [2]rotaxane (right).  
 
The term rotaxane was first proposed by Schill and Zollkopf in 1967.10 The 
nomenclature used is derived from the Latin where the word rota means wheel 
and the word axis means axle. In the same year, Harrison and Harrison 
synthesised the first [2]rotaxane with an overall yield of 6% (Figure 1.2).9 
Due to the fascinating structure of rotaxanes, the development of straightforward 
procedures to synthesise this kind of compounds has been extensively explored, 
leading to synthetic strategies which generally follow one of three main routes. 
These three methods involve threading followed by stoppering, slipping or clipping 
(Figure 1.3).11-19 
In the threading method, a preformed macrocycle is first coordinated onto a thread 
via attractive interactions. Stopper groups are then attached to the end of the 
thread, which prevent dissociation of the newly formed rotaxane.11 In the slipping 
strategy, a pre-synthesised macrocycle is slipped over an already stoppered 
thread. The macrocycle and the stoppers have to be of the correct size to allow 
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the formation of the rotaxane. The rotaxane is formed by applying the right amount 
of thermal energy, e.g. by lowering the temperature, the macrocycle becomes 
kinetically trapped, thus forming the rotaxane.19 The third approach is the clipping 
method, where a macrocycle is formed in the presence of a thread.16 Usually an 
attractive interaction between the ring forming components and the thread is used 
to initially entrap the macrocycle to be, followed by a ring-closing reaction to form 
the rotaxane. 
 
Figure 1.3: The three main methods for rotaxane assembly. 
 
In 2007, Leigh and co-workers developed a new strategy for the synthesis of 
rotaxanes called the active metal template method, where a metal is used to 
promote the formation of the thread and the coordination of the preformed 
macrocycle (Figure 1.4).20,21 This method was directly inspired by the work of 
Sauvage.20 
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Figure 1.4: Active-metal template method for rotaxane formation; (i) template assembly 
and covalent bond forming catalysis, (ii) subsequent demetalation. 
 
The two stopper units (shown in green and orange) generate the thread by the aid 
of the metal (shown in pink). At the same time the metal coordinates through the 
cavity of the macrocycle (shown in black) via metal to ligand interactions. In many 
cases, once the rotaxane is formed the metal can bind to another free macrocycle, 
as this is more favoured and can promote the next threading process.  
 
1.2.1 Nomenclature of rotaxanes 
Harrison and Harrison’s first rotaxane shows the simplest rotaxane topology 
(Figure 1.2). It is designated as a [2]rotaxane, where the number in square 
brackets indicates the number of components, two, that is one macrocycle and 
one thread.  
Generally, an [n]rotaxane consists of one thread and (n – 1) macrocycles or (n - 1) 
threads and one macrocycle. Figure 1.5 shows some fundamental rotaxane 
topologies. 
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Figure 1.5: Some rotaxanes topologies. 
 
[3]- and [4]rotaxanes are the corresponding higher analogues of the [2]rotaxane, 
with [3]rotaxanes being more common than [4]rotaxanes.21,22 
The development of [2]rotaxanes with two separate sites or stations has been an 
important breakthrough for the synthesis of molecular switches, motors and 
machines.23 These two stations, that can be either identical or different, can act as 
binding sites for the macrocycle. When the two stations are different, they can be 
addressed selectively using an external input. Hence, chemical, electrochemical, 
or photochemical stimulation can induce changes in the binding site by generating 
repulsive or attractive supramolecular interactions and therefore, the macrocycle 
can be ‘shuttled’ between the two stations along the thread (see Section 1.2.4). 
This induced discrimination process between the two stations is not possible when 
the two sites are identical, however shuttling can still occur.24 
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1.2.2 Hydrogen bonding based rotaxanes 
Hydrogen bond interactions are known to assemble and stabilise various 
supramolecular complexes, such as catenanes and rotaxanes.25 The first example 
of a hydrogen bond templated catenane was reported by Hunter et al. in 1992.26 
High dilution for the macrocyclisation yielded a [2]catenane in 34% yield, 
accompanied by the expected macrocycle in 51% yield. In 1995, Vögtle et al. 
reported the first example of an amide based [2]rotaxane via a three component 
threading procedure in a 11% yield.27 This threading process was later improved 
by employing a more rigid thread with the preparation of a fumaric thread, which 
yielded the desired [2]rotaxane in 18% yield.28 Leigh and co-workers have also 
described various examples of catenanes and rotaxanes templated via hydrogen 
bonding interactions. These rotaxanes are produced via a five component clipping 
reaction, as shown in Scheme 1.1.29 Reaction of isophthaloyl dichloride and 
p-xylylenediamine forms the intermediate amide I in a syn anti conformation. In 
solution, this intermediate can undergo either a dimerisation, as described by 
Hunter30 or a catenane formation process, as reported by Leigh.31 However, in the 
presence of a suitable template (e.g. peptide thread 1) a syn syn conformation 
(intermediate II) is favoured, as it is stabilised by multicomponent bifurcated 
hydrogen bonds. The terminal amine and the acid chloride are then close enough 
and a rapid cyclisation around the thread occurs (Scheme 1.1).29  
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Scheme 1.1: Rotaxane formation around a peptide thread. 
 
Several oligopeptide threads bearing at least one non N-terminal glycine residue 
were also investigated by Leigh and co-workers.29 Figure 1.6 shows the crystal 
structures for the obtained Gly-Gly 3, Gly-Sar 4 and Gly-L-Ala 5 [2]rotaxanes. By 
comparing the yields of the resulting [2]rotaxanes with the conformational 
structures of their macrocycles, Leigh rationalised that there is a relationship 
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between the final rotaxane and the intermediate II, which is key for the formation of 
the resulting rotaxane.  
 
 
 
Gly-Gly 3 Gly Sar 4 Gly-L-Ala 5 
   
Figure 1.6: Crystal structures of three different peptide based [2]rotaxanes.29 
 
The Gly-Gly rotaxane 3 has the least steric hindrance for the assembly of the 
pre-macrocycle around the thread, therefore the most favourable hydrogen bond 
interaction is realised in the chair conformation and 3 is obtained in a 62% yield. 
The Gly-Sar rotaxane 4 (60% yield) has an additional methyl group which distorts 
the hydrogen boding between the macrocycle and the thread and consequently 
the macrocycle has a half chair / twist boat like conformation. The macrocycle of 
the Gly-L-Ala rotaxane 5 has an unfavoured boat conformation and this rotaxane 
is obtained in only 45% yield.29  
In 2001, Leigh and co-workers reported the first highly efficient template-directed 
synthesis of an amide based [2]rotaxane.32 The very rigid fumaric thread 6 is able 
to template the formation of the [2]rotaxane 7 via clipping reaction of 4 equivalents 
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of p-xylylenediamine and isophthaloyl dichloride in a solvent mixture of chloroform 
and acetonitrile (9 : 1) (Scheme 1.2). Filtration and spontaneous crystallisation 
delivered the clean product in 97% yield.32 
 
Scheme 1.2: Highly efficient [2]rotaxane formation. 
 
It is believed that the high yield was due to the incorporation of multiple 
cooperative binding sites on a structurally rigid backbone, facilitating the hydrogen 
bond assisted synthesis of the rotaxane 7. The effective templation of the 
tetraamide macrocycle in a chair conformation around the rigid fumaramide thread 
6 maximises the hydrogen bond interactions between the two substrates, making 
this method one of the most accessible and efficient syntheses described to 
date.32  
 
 
Chapter 1 
Introduction 
11 
 
1.2.3 Higher order rotaxanes 
It is more challenging to form [3]- than [2]rotaxanes, for this reason there are fewer 
examples reported in the literature. Several high yielding [n]rotaxanes, with 
n = 3-20, were recently reported by the groups of Stoddart and Cronin.33 
The threads (8 - 10), with n = 0-2, were synthesised in a short four step synthesis 
shown in Scheme 1.3. For the longer threads a protecting group strategy was 
applied.  
 
Scheme 1.3: Thread synthesis in four steps. 
 
The rotaxanes (11 - 13) were synthesised via a clipping process (Scheme 1.4). 
The quaternary ammonium cation templating station proved to be very effective for 
the formation of the polyether macrocycles.  
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Scheme 1.4: Templated [n]rotaxane formation with NH2+ as station. 
 
The aromatic rings of each macrocycle facilitate the formation of the adjacent 
macrocycle via - stacking. The [3]- to [20]rotaxanes (11 - 13) were formed in 
yields ranging from 90 – 93%. 
 
1.2.4 Shuttling 
One of the key properties of rotaxanes is the possibility to shuttle the macrocycle 
along the thread. Shuttling can occur when the thread has more stations than 
macrocycles. The stations can be the same or different, as mentioned in 
Section 1.2.1. 
Chapter 1 
Introduction 
13 
 
The first molecular shuttle was synthesised by the Stoddart group in 1991 
(Scheme 1.5).24 The rotaxane was obtained via the clipping method of the 
macrocycle around one of the stations. The two stations were identical and in 
deuterated acetone the macrocycle shuttled 500 times per second between the 
two stations. 
 
Scheme 1.5: First molecular shuttle synthesised by Stoddart and co-workers. 
 
Stoddart reasoned that a switch to a rotaxane with two different stations would 
result in the opportunity to control the shuttling process of the macrocycle.34 In 
1997, Fyfe and Stoddart reported the first switchable [2]rotaxane incorporating a 
benzidine and a biphenol unit.35 
The Leigh group has also formed several symmetrical [2]rotaxanes with two 
identical stations (Figure 1.7).36 The amide macrocycle can shuttle fast between 
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the stations in deuterated chloroform, hence only one pair of signals is observed in 
the 1H NMR spectrum. When cooling the sample, the macrocycle slows down until 
it stops, resulting in a splitting of the 1H NMR signals for the CH2 protons adjacent 
to the amide carbonyl on the thread.  
 
Figure 1.7: A symmetrical [2]rotaxane with a tetraamide macrocycle and a peptide thread. 
 
At room temperature and in deuterated methanol the binding interactions are 
weakened and therefore the rate of shuttling is increased, while in deuterated 
DMSO the shuttling stops completely. In the latter case, the macrocycle is located 
on the hydrophobic part of the thread, enabling the peptide stations to maximise 
their hydrogen bonding interactions with the solvent. 
In 2004, Leigh et al. reported the first pH-switchable amide based molecular 
shuttle (Scheme 1.6).37 At room temperature the amide macrocycle is located over 
the succinamide station. When adding a suitable base, such as potassium 
tert-butoxide, the phenol ring gets deprotonated and forms an anion. This anion is 
more attracted to the macrocycle and the shuttling occurs. The majority of the 
macrocycle is then over the phenolate anion. Addition of TFA results in the 
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protonation and reshuttling of the macrocycle to the now more favoured 
succinamide station. A solvent effect was also observed for the rate of shuttling as 
as described in the previous example. This system works in optimal conditions 
with non competing solvents, such as deuterated chloroform. 
 
Scheme 1.6: First pH-switchable amide-based molecular shuttle. 
 
These are some of the most outstanding examples of shuttling processes in 
rotaxanes, however more examples can be found in the literature.38-40 The rate of 
shuttling is determined by the attractive interactions between the macrocycle and 
the station. When the interactions between the macrocycle and one station are 
strong, the ring does not shuttle and is mainly located on this particular station. 
When the interactions are weak due to repulsive forces, or solvent effects, or there 
are similar strong attractions on the two stations, the macrocycle can shuttle to 
and fro along the thread.  
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1.2.5 Rotaxanes used for sensing 
Another main application of rotaxanes is the recognition and binding of ions.41 
Beer et al. has recently reported a sulphate-selective binding and sensing 
[3]rotaxane (Scheme 1.7).42  
 
Scheme 1.7: Anion templated synthesis of a [3]rotaxane. 
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This rotaxane was synthesised via the anion template clipping process in 33% 
yield. The incorporation of the naphthalene group allows the rotaxane to exhibit 
room temperature fluorescence. The chloride counter-ions were exchanged by 
PF6- anions to enable an easier conversion to other anions. When replacing just 
one of the PF6- anions with one SO4-
 
anion,
 
the fluorescence was quenched. 
However, exchange of the second PF6- anion resulted in an enhancement of the 
emission. The reason for the quenching and enhancement of the emission lies in 
the structural changes that the rotaxane suffers. The first SO4- anion causes the 
rotaxane to bend both macrocycles towards the anion. When the second PF6- 
anion is exchanged by a SO4- anion, each macrocycle captures one SO4- anion 
and the rotaxane returns to its linear geometry.  
Catenanes can also be synthesised via the ion template clipping technique and 
these catenanes can sense and bind to various ions.43 
 
1.2.6 Threaded structures with cross-linked macrocycles 
Stoddart has also explored other interlocked structures beyond catenanes and 
rotaxanes.44 This new class, of anthropomorphic molecules were named suitanes, 
which consist of two independent compounds: the ‘body’ and the ‘limbs’. The body 
could be compared to an unstoppered thread and the limb to a macrocycle. The 
number between suit and ane indicates how many limbs were used to form the 
suitane, e.g. a suit[2]ane has one torso and two limbs and a suit[3]ane has one 
torso and three limbs.  
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Scheme 1.8: The three steps for the synthesis of a suit[2]ane. 
 
Suitanes are usually formed in three steps (Scheme 1.8). In the first step a 
torso-limb complex is formed. The torso (illustrated in blue) requires at least two 
stations (shown in yellow). These stations are capable of interacting with the limbs, 
which are highlighted as red squares. The limb components are then covalently 
linked under thermodynamic control. In the final synthetic step, the "suit" is 
kinetically fixed, which does not allow the components of the suitane to 
disassemble. 
In order to synthesise the suit[2]ane 14, three components are required (Scheme 
1.9). For this synthesis, Stoddart and co-workers used a dynamic covalent 
protocol, which they developed in 2004.45  
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Scheme 1.9: Components used to form the first suit[2]ane. 
 
Computer calculations suggested that the polyether macrocycles recognise the 
NH2+ stations and form a pseudo[3]rotaxane.† This pseudo[3]rotaxane can be 
captured via imine condensation of p-phenylenediamine and the two aldehydes, 
which are located on top of each macrocycle, to form the suit[2]ane 14 (Figure 
1.8). Even when the imines were not reduced to amines, it was found that imine 14 
was very stable and could be considered a suit[2]ane. To ensure that the suitane 
is in fact an interlocked structure, the sample was heated in deuterated acetonitrile 
for 30 days at 70 °C and no change was observed in the 1H NMR spectrum. 
Suitanes could be considered as a threaded cage-like molecule. 
                                            
†Pseudorotaxanes are unstoppered rotaxanes. By adding stoppers at the ends of the 
pseudorotaxanes, they become rotaxanes. 
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Figure 1.8: Crystal structure of suit[2]ane 14.44 
 
Another method to cross-link two macrocycles was described by Vögtle et al. in 
1996.46,47 An initial sulfonamide [3]rotaxane was synthesised in 4% yield via a 
three component clipping process (Scheme 1.10).  
 
Scheme 1.10: Synthesis of a sulfonamide [3]rotaxane. 
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This [3]rotaxane can then be cross-linked on the sulfonamide units of the two 
macrocycles using flexible or rigid halide containing chains (Scheme 1.11).  
 
Scheme 1.11: Cross-linking event to form bonnanes. 
 
This newly formed architectures can be obtained in yields ranging from 65 - 90% 
and are called bonnanes. 
 
1.3 Cage structures 
Cage molecules have received great attention over the last decades, driven by the 
surge in ‘bottom-up’ strategies to create small and defined supramolecular 
devices. These devices can then be modified for specific purposes and as a result 
there are many reports of novel syntheses in the literature.  
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1.3.1 Metal organic cages 
In 1996, Fujita postulated that transition metals could coordinate compounds to 
form definite structures. The coordinated product is therefore the result of a 
templated synthesis and this can be controlled by the structure and size of the 
building blocks.48 Following these principles, Fujita has described a 
self-assembled nanometre-sized organic host framework (Scheme 1.12).49 
 
 
 
Scheme 1.12: Self-assembled nanometre-sized organic host framework synthesised by 
Fujita. 
 
More recently, Fujita and co-workers showed that these compounds are able to 
function as molecular flasks and help to perform unusual reactions.50 One of such 
unusual reaction is the naphthalene Diels-Alder reaction (Scheme 1.13). These 
reactions normally require very harsh conditions (e.g. high temperature) due to the 
lack of reactivity of the naphthalene molecule. However, quantum-mechanical 
calculations showed that this reaction is exothermic. Therefore, the entropic cost 
of the multi-centered reaction is important. The molecular flask (shown as a circle) 
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pre-organises the reactants and greatly reduces the entropic cost, allowing the 
Diels-Alder reaction to occur.  
 
Scheme 1.13: Unusual Diels-Alder reaction promoted by Fujita's cage. 
 
The reaction profile was changed from a bimolecular pathway to a 
pseudo-intramolecular one.   
 
1.3.2 Boronic ester based cages 
Boronic acids are very powerful motifs to assemble molecular and polymeric 
nanostructures.51 The condensation reaction of 1,2- and 1,3-diols with boronic 
acids is reversible and the equilibrium is established very quickly.52 
In 2008, Kobayashi and co-workers reported a self-assembled boronic ester based 
cage.53 The tetraboronic acid 15 and the di-catechol linker 16 formed the cage 17 
via a condensation reaction in quantitative yield (Scheme 1.14). The cage 17 is 
capable of encapsulating several guest molecules, such as biphenyl or anthracene 
derivatives. This encapsulation process is solvent dependent, e.g. by removal or 
addition of methanol, an on/off switch was observed. 
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Scheme 1.14: Synthesis of the boronic ester cage 17, being 16 the four edges of the 
cage. 
 
Severin et al. recently reported the first example of a molecular cage with dative 
B-N bonds (Scheme 1.15).54 Boronate esters are known to be Lewis acidic and 
therefore the B-atoms are capable of forming dative bonds to N-donors, such as 
pyridines.  
 
Scheme 1.15: Synthesis of the first boronic ester cage with dative B-N bonds. 
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These cage molecules were obtained via multicomponent reactions of diboronic 
acids with catechols and tripyridyl linkers. The cages have six dative B-N bonds 
and the length of the cages can be varied by the choice of the diboronic acid 
component. The cages were not particularly stable, however they were capable of 
encapsulating polyaromatic compounds such as triphenylene.54   
 
1.3.3 Imine cages 
Recently, Cooper and co-workers have synthesised the imine cage 20 via 
condensation reaction of the trialdehyde 18 and the diamine 19 (Scheme 1.16).55 
This particular imine cage is able to incorporate (bind) around 12 to 13 water 
molecules. This result is very impressive given that imine bond formation is 
reversible by Nature. Even after 4 hours in refluxing water, the cage did not 
decompose. However, exposure to acidic media led to decomposition of the cage 
since the equilibrium was shifted to the starting aldehyde and amine.  
 
            
     
                                                                                                        
Scheme 1.16: Synthesis of the imine cage 20.55 
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Cage-like molecular structures are interesting for a number of applications, such 
as compound separations,56 catalysis,57-59 sensing,60 and drug delivery61,62. The 
thermo- and hydrolytic stability of the cages is the main drawback for these 
applications.63 This imine cage 20 addresses the hydrolytic stability issue and 
might have opened a new pathway that requires further investigation for future 
applications. A tertiary amine based cage might be able to solve the thermo- and 
hydrolytic problems. 
A great number of examples of cage-like structures more or less closely related to 
the areas described in this introduction have been reported. Further examples 
have been reported in the literature and these include MOFs,64 MORFs,65 
PMOFs,66 hemicarcerands,67 hydrogen bond capsules68,69 and COFs70.  
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2 Chapter 2: Results and Discussion 
 
2.1 Research aims 
As discussed in Chapter 1 many research groups have synthesised molecular 
cages (boxes) via different approaches. The aim of this project is to synthesise a 
novel molecular box via the construction of a [3]rotaxane as key intermediate. 
The first step towards the formation of a molecular box is to access a thread, 
which should be able to form a [3]rotaxane. Thread 21 is a double fumaric thread 
with diphenylethyl secondary amides as stopper groups (Figure 2.1). 
 
Figure 2.1: Double fumaric thread 21. 
 
Its structure is closely related to that of the fumaric thread used by Leigh and 
co-workers in 2001, which allowed them to synthesise a [2]rotaxane in high yield 
(see Section 1.2.2).  
In order to build a molecular box, a [3]rotaxane is necessary. If the desired 
[3]rotaxane 22 (Scheme 2.1) can be synthesised, a cross linking event would be 
required to connect the two macrocycles. The nitrogen of the amide of the 
macrocycle or alternative functional groups on the aromatic rings should allow this 
linking process. If functional groups on the aromatic rings are used, a suitane type 
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structure would be formed (see Section 1.2.6). Connecting the two macrocycles by 
using the amide groups would lead to a tertiary amide cage. Reduction of these 
amides to amines, followed by linking would lead to a tertiary amine cage.  
 
Scheme 2.1: Retrosynthesis for the desired templated [3]rotaxane 22. 
 
When the two macrocycles are linked, a “threaded box” is formed. A method by 
which to liberate the box must be then developed (Scheme 2.2).  
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Scheme 2.2: Proposed synthesis of a novel molecular box. 
 
This could be achieved with a cleavable spacer group or by removing the 
stoppers. This would yield a novel molecular box, synthesised by an unusual 
route, which hopefully will enable a novel access to even more complex structures. 
 
2.2 Attempted syntheses of the double fumaric thread 21 
Three main synthetic routes (A, B and C) towards the synthesis of thread 21 were 
identified (Figure 2.2).  
 
Figure 2.2: The three main synthetic routes (A, B and C) towards the fumaric thread 21.  
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Route A involves the synthesis of a stoppered station. Then, two of these 
stoppered stations have to be connected via a spacer group to from thread 21. In 
route B, the two stations are already connected via the spacer group and a 
stoppering event would afford the desired thread 21. Route C involves the 
synthesis of a stoppered half thread, which could be dimerised to form the desired 
fumaric thread 21. 
 
2.2.1 Synthetic route A towards thread 21 
In the synthetic route A, the desired fumaric thread 21 could be formed by reaction 
of the known fumaric acid 23 and different diamines in one or two steps (Scheme 
2.3). The fumaric acid 23 could be generated by reaction of the protected acid 
chloride 25 and 2,2-diphenylethylamine, followed by deprotection of the carboxylic 
acid. 
 
Scheme 2.3: Retrosynthetic analysis of route A towards synthesis of the thread 21. 
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Treatment of the acid chloride 26 with 2,2-diphenylethylamine gave the ester 27 in 
94% yield. The ester 27 was hydrolysed to afford the fumaric thread precursor 23 
in quantitative yield. The acid chloride 26 is commercially available, however it is 
expensive and it was synthesised in quantitative yield in one step from mono-ethyl 
fumarate and thionyl chloride under reflux (Scheme 2.4). 
 
Scheme 2.4: Synthesis of the fumaric thread precursor 23. 
 
Once the fumaric thread precursor 23 was synthesised several amide coupling 
reactions were investigated. Since the fumaric thread precursor 23 is a carboxylic 
acid, it needs to be activated prior the reaction with the diamine. 
Computational calculations on the fumaric thread 21 with 1,3-diaminopropane as 
spacer group showed that four carbon atoms are sufficient to form four linkages 
between the two macrocycles to build a “threaded box” (Figure 2.3). These 
calculations‡ were performed using ArgusLab71 and optimised from the crystal 
structure of the [2]rotaxane 2 (see Section 1.2.2) synthesised by Leigh. The results 
from this calculation were then exported to Mercury72 to be visualised.  
 
                                            
‡ Molecular mechanics universal force field 1000 steps.  
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Figure 2.3: Threaded box model created via computational calculations. 
 
Amide coupling reactions are very important in organic chemistry, and therefore 
they are well established. However, these reactions are not trivial and there are 
many different coupling reagents commercially available.73 Unfortunately, there is 
still not a universal coupling reagent and if the coupling does not occur, different 
coupling reagents need to be sought. 
The fumaric thread 6 was used as a model for the activation of the thread 
precursor 23 via an amide coupling. The fumaric thread 6 was therefore 
synthesised using N,N′-dicyclohexylcarbodiimide (DCC) as coupling reagent 
(Scheme 2.5). 
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Scheme 2.5: DCC coupling of the thread precursor 23 with 2,2-diphenylethylamine. 
 
Coupling of the fumaric thread precursor 23 with 2,2-diphenylethylamine was 
successful, however it was low yielding (37%). 
Despite the low yield of this test reaction, several diamines (Figure 2.4) were 
tested in a coupling reaction with the thread precursor 23 (Table 2.1).  
 
Figure 2.4: Different diamines for use as spacer groups. 
 
None of the conditions tested were suitable for the synthesis of the double fumaric 
thread 21. 
All reactions with ethylenediamine, 1,3-propyldiamine and 1,4-butyldiamine 
resulted in a complex mixture of side products or decomposition of the starting 
materials. 
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Table 2.1: Different coupling reaction conditions studied. 
Entry Reagent Additive Solvent Time Temp. Result 
1 DCC - THF 48 h RT complex mixture 
2 DCC HOBt THF 48 h RT complex mixture 
3 HATU Hünigs base CH3CN 24 h RT complex mixture 
4 HATU Hünigs base DCM 24 h RT complex mixture 
5 EDC - MeOH 16 h RT 50% yield a) 
6 EDC HOBt DCM 16 h 0 °C to RT complex mixture 
7 NMM / IBCF - THF 30 min -15 °C 27% yield a) 
8 SOCl2 - neat 3 h 80 °C - 
b) 
9 SOCl2 - DCM 3 h 80 °C - 
b) 
10 (COCl)2 DMF DCM 30 min 70 °C - 
b) 
11 DCC - DCM 1 h 150 °C complex mixture 
a) Reaction occurred only with p-phenylendiamine, however only the mono reacted product 28 was 
detected (Scheme 2.6). b) Decomposition of the starting materials occurred. 
 
These reactions were followed by Matrix-Assisted Laser Desorption Ionisation 
(MALDI) and did not show the expected mass peaks. Figure 2.5 shows the 
general principle behind MALDI-ToF mass spectrometry. A sample of analyte 
(shown in red) dispersed within a highly absorbing matrix is irradiated by a UV 
laser beam. The most commonly used UV lasers for MALDI spectrometry are 
nitrogen lasers (337 nm) and Nd:YAG lasers (355 nm and 266 nm). During the 
irradiation, a thin upper layer of matrix gets ablated. This method of energy 
transfer is very mild and excessive energy, which could lead to decomposition, is 
not required. The matrix must absorb the UV laser light extensively and 
2,5-dihydroxy benzoic acid, also called gentisic acid, is used for this purpose. 
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Gentisic acid can work in a mass range from 500 to 3,000 dalton (Da). Below 
500 Da, signals corresponding to the matrix can be observed. 
               
Figure 2.5: Schematic representation of MALDI spectrometer. 
 
The mono reacted product 28 was obtained in two different reaction conditions 
when using p-phenylenediamine as diamine. Coupling of 23 with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) resulted in the mono reacted product 28 
in 50% yield (Scheme 2.6). N-methylmorpholine (NMM) and isobutyl chloroformate 
(IBCF), which forms a mixed anhydride of the carboxylic acid, gave 28 in 27% 
yield. 
 
Scheme 2.6: EDC mediated amide coupling to the mono reacted product 28. 
 
Unfortunately, it was not possible to transform the mono reacted product 28 into 
the desired double fumaric thread 29 despite screening a number of peptide 
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coupling reagents (Scheme 2.7). Instead, only the starting material 28 was 
recovered. 
 
Scheme 2.7: Attempted reactions towards the synthesis of the double fumaric thread 29. 
 
After the failure of route A to provide the desired thread 21, route B was 
investigated, whereby the diamine component is introduced in the first step.  
 
2.2.2 Synthetic route B towards thread 21 
In synthetic route B, the proposed retrosynthetic analysis involves the reaction of 
the diamine 30 with the protected fumaric acid chloride 25 to yield the diamide 31, 
which could be deprotected and coupled with 2,2-diphenylethylamine to afford the 
fumaric thread 21 (Scheme 2.8). 
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Scheme 2.8: Retrosynthetic analysis of route B towards the synthesis of the thread 21. 
 
The reactions between ethyl fumaroyl chloride and different diamines were 
optimised easily by varying the amount of solvent, reaction time and amount of 
base. Optimisation allowed access to the diamides (32 - 34) in yields ranging from 
42% to 65% (Scheme 2.9). 
 
Scheme 2.9: Synthesis of diamide thread precursors. 
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These diamides could potentially form pseudorotaxanes (see Section 2.6).  
Considering the moderate yields for the reactions of the diamide thread 
precursors, an alternative synthetic approach was investigated.  
Katrizky et al. have reported the formation of amides mediated by NEt3 starting 
from benzotriazole and an amine.74 As shown in Scheme 2.10 the synthesis of the 
benzotriazole 35 was high yielding. Unfortunately, the reaction with ethylendiamine 
proceeded in only 33% yield.  
 
Scheme 2.10: Benzotriazole synthetic route to diamide thread precursor 32. 
 
Saponification of the ester groups of the diamide thread precursor 33 was 
performed in quantitative yield using sodium hydroxide in methanol (Scheme 
2.11). The resulting diacid 36 was used in several coupling reactions with 
2,2-diphenylethylamine. 
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Scheme 2.11: Saponification of the diamide thread precursor 33. 
 
Amide coupling reactions of 36 with EDC or DCC as the coupling reagent did not 
form the desired product and the starting material was recovered. The major 
reason for this result may be the lack of solubility in organic media of the diacid 36. 
Therefore an activation of the diacid as the acid chloride intermediate followed by 
reaction with 2,2-diphenylethylamine was tested. Unfortunately, all attempted 
approaches were unsuccessful and resulted in recovery or decomposition of the 
starting material. 
Due to the insolubility and unreactivity of the diacid 36, an alternative approach to 
the double fumaric thread 21 was investigated.  
The direct synthesis of an amide starting from an ester and an amine is well 
known. This type of amide coupling is normally catalysed by Zr(OtBu)4 with 
1-hydroxy-7-azabenzotriazole (HOAt) and can be very potent, as described by 
Porco (Scheme 2.12).75  
 
Scheme 2.12: Zr-mediated amide coupling. 
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These reaction conditions were used to synthesise the known fumaric thread 6; 
which was isolated in 60% yield (Scheme 2.13).  
 
Scheme 2.13: Zr-mediated amide coupling to synthesise thread 6. 
 
Unfortunately, under analogous conditions conversion of the ester 33 to the amide 
37 was not observed (Scheme 2.14). The double amide thread 33 was not soluble 
in any solvent previously described for this reaction. The thread 33 is readily 
soluble in methanol, however methanol is not a suitable solvent for this reaction. 
 
Scheme 2.14: Attempted Zr-mediated amide coupling. 
 
In view of these disappointing results, an alternative synthetic route was 
investigated (Scheme 2.15). The reaction of the ester 22 with ethylenediamine 
was carried out in different solvents using various Lewis acids. However in no 
instance was the desired product obtained. A possible explanation for this lack of 
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reactivity could be binding of ethylenediamine to Zr, effectively poisoning the 
catalyst. 
 
Scheme 2.15: Attempted Zr-mediated amide coupling using ethylenediamine and ester 
22. 
 
As alternatives to Zr(OtBu)4, aluminium chloride and zirconium chloride were used 
in stoichiometric quantities. These catalysts did not show any reactivity either. 
It is possible that the aluminium chloride and zirconium chloride are not strong 
enough to promote this reaction. Unfortunately, Zr(OtBu)4 seems to be very 
powerful and produces numerous products. MALDI analysis did not show the 
desired mass peaks of either single or double coupling products.   
 
2.2.3 Synthetic route C towards thread 21 
Route C does not involve the use of diamines as spacer groups (Scheme 2.16). 
The key intermediate is the amide 38 bearing a functional group suitable for 
dimerisation to afford the desired thread 21, e.g. via Grubbs-metathesis, or ether 
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or anhydride formation. The amide 38 could be formed by reaction between the 
fumaric acid 23 and an amine with an appropriate functional group. 
 
Scheme 2.16: Retrosynthetic analysis of route C towards the synthesis of the thread 21. 
 
As previously discussed, several attempts to couple the thread precursor 23 with 
diamines proved unsuccessful. However, a mono reacted amide coupling 
mediated by EDC was detected (see Scheme 2.6). Therefore, EDC as coupling 
agent was tested for the coupling of acid 23 and allylamine (Scheme 2.17).  
 
Scheme 2.17: EDC mediated amide coupling between the thread precursor 23 with 
allylamine. 
Chapter 2 
Results and Discussion 
43 
 
The desired product was observed however its purity and yield were low. For this 
reason several attempts to optimise this reaction were carried out (Table 2.2). 
 
Table 2.2: Different coupling reaction conditions studied for the thread precursor 23 with 
allylamine. 
Entry Reagent Additive Solvent Time Temp. Result 
1 DCC - THF 48 h RT 7% 
2 EDC - MeOH 18 h RT 18% 
3 NMM/IBCF - THF 30 min -15 °C 3% 
 
However, the EDC mediated coupling reaction gave the best results. Since the 
thread precursor 39 was synthesised in only 18% yield and the product was not 
completely pure, this approach was not investigated any further. Nevertheless, a 
possible reaction could be dimerisation by Grubbs-metathesis. The 
Grubbs-metathesis should lead to an E / Z mixture, which might be difficult to 
purify. 
A Zr(OtBu)4 mediated coupling reaction was also tested (Scheme 2.18). However, 
only the starting ester 27 was recovered. This might be due to reaction or 
coordination of allylamine with to the Zr. Therefore, no other Lewis acid was 
investigated. 
 
Scheme 2.18: Attempted Zr-mediated amide coupling. 
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The desired thread 21 has a diphenylethane motif as the secondary amide 
stopper, however this particular stopper group did not prove easily amenable for 
the proposed synthesis of the thread 21 (Sections 2.2.1 to 2.2.3). Therefore, an 
alternative thread system with similar templating-effect was investigated. 
 
2.3 Synthesis of azo rotaxanes 
In July 2010, Berná et al.76 reported an azodicarboxamide thread system (Scheme 
2.19) with a similar templating-effect to the fumaric threads described by Leigh and 
co-workers (see Section 1.2.2). 
 
Scheme 2.19: Synthesis of the azodicarboxamide [2]rotaxane 41 by Berná.76 
 
To gain a fuller understanding of this new thread system the previously reported 
thread 40, as well as its building blocks, and the [2]rotaxane 41 were synthesised. 
The yields obtained were comparable to those reported and were easily 
reproducible (Scheme 2.20). 
Chapter 2 
Results and Discussion 
45 
 
 
Scheme 2.20: Synthesis of the known azodicarboxamide [2]rotaxane 41. 
 
In the first step, phenylchloroformate was reacted with hydrazine to form the 
hydrazophenylcarbamate 42 in 91% yield. Phenylcarbamates are not very 
reactive, however they can be activated with heat and the addition of a base (e.g. 
triethylamine).77 The phenylcarbamate 42 reacted with dibenzylamine under basic 
conditions in refluxing CHCl3 to form the hydrazoamide 43. Oxidation with 
N-bromosuccinimide (NBS) afforded the azo thread 40. In a clipping process the 
azo [2]rotaxane 41 was formed using p-xylylenediamine and isophthaloyl 
dichloride. The yield was significantly lower than that reported by Leigh and 
co-workers for their [2]rotaxane, which suggests that the templating station is not 
as potent as the fumaric one. Despite the lower yield for the clipping process, the 
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efficient synthesis of the azo [2]rotaxane 41 might to enable a new route towards 
the synthesis of the desired [3]rotaxane. 
Following an analogous pathway to that described for synthetic route A in 
Section 2.2.1, the azo thread 46 could be obtained via oxidation of the hydrazo 
thread 45 using NBS (Scheme 2.21). The desired hydrazo thread 45 could be 
formed by reaction of the hydrazophenylester 44 with various diamines. The 
hydrazophenylester 44 can be generated from the reaction between the 
diphenylester 42 and dibenzylamine. 
 
Scheme 2.21: Retrosynthesis of azo thread 46. 
 
Berná et al. described the synthesis of the building block 44 in 74% yield, which 
was used to form a two station [2]rotaxane with the ability to shuttle its macrocycle.  
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This building block was synthesised in 81% yield and purified via recrystallisation 
instead of by column chromatography as Berná described.  
 
Scheme 2.22: Synthesis of the hydrazophenylester 44. 
 
By conducting the reaction at room temperature and decreasing the number of 
equivalents of dibenzylamine used, the formation of the mono-reacted 
hydrazophenylester 44 is favoured over the di-reacted azo dicarboxamide 43.  
 
2.3.1 Synthesis of azo rotaxanes with a three carbon spacer unit 
The initial studies on the double fumaric thread system indicated that the use of 
1,3-diaminopropane provided the highest yields compared to other diamines 
(see Section 2.2.2). Therefore, hydrazophenylester 44 was coupled with 
1,3-diaminopropane in refluxing chloroform using NEt3 as base (Scheme 2.23). 
The resulting reaction mixture was challenging to purify. Column chromatography 
resulted in crystallisation of the new hydrazo thread 47 on the column and only 
38% of the product was isolated. An attempt to recrystallise the crude hydrazo 
thread 47 proved unsuccessful. Therefore, the moderate yield of 38% after 
chromatography was deemed acceptable.  
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Scheme 2.23: Synthesis of the hydrazo thread 47. 
 
The hydrazo thread was then oxidised to the corresponding azo thread 48 using 
NBS (Scheme 2.24). 
 
Scheme 2.24: Oxidation of the hydrazo thread 47 to the corresponding azo thread 48. 
 
It is noteworthy that in the process of changing the double fumaric thread 
(described in Section 2.2) to the azo thread, three important modifications to the 
synthetic route and to the overall thread structure have been introduced:  
 the templating station has been altered from fumaric to azo-dicarboxylate;  
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 the activated species to couple the station with the spacer unit has been 
changed from an activated acid to a phenylester; 
 the amines that generate the stopper groups have been modified from 
primary amines to secondary amines. 
The azo thread 48 was then used in a rotaxane formation reaction via the clipping 
method using p-xylylenediamine and isophthaloyl dichloride.  
MALDI analysis of the crude sample suggested the formation of a [2]rotaxane with 
a mass of 1192 Da and a [3]rotaxane with a mass of 1726 Da (Figure 2.6).  
 
Figure 2.6: MALDI spectrum of rotaxane reaction using azo thread 48. 
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Both of the mass peaks suggested that complete reduction of the azo stations had 
occured during the clipping process. 
When attempting to purify the crude sample the major product of this reaction was 
found to be the unwanted catenane described by Leigh and co-workers,78 
accompanied by three different rotaxanes, the [2]rotaxanes 49 and 50 and the 
[3]rotaxane 51 (Scheme 2.25).  
 
Scheme 2.25: Synthesis of three different azo rotaxanes with a three carbon spacer unit. 
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High Pressure Liquid Chromatography (HPLC) proved to be very useful for the 
identification and isolation of the diazo [2]rotaxane 50 and the partially reduced 
[2]rotaxane 49 (Figure 2.7). 
A gradient method using a ramp from 100% water to 100% methanol over a period 
of 1 hour was used on a HPLC reverse phase column at a flow rate of 1 mL/min. 
This initial chromatogram helped to determine the ratio between the [2]- and 
[3]rotaxanes in the crude mixture. The presence of [2]rotaxanes was in an excess 
of 10:1 with respect to the desired [3]rotaxane. At this stage it was not obvious that 
two different [2]rotaxanes were formed. 
There are several possible explanations for this product distribution. Assuming that 
the [2]rotaxane is formed first, the macrocycle could shuttle rapidly between the 
two stations and diminish the formation of the [3]rotaxane 51. Another possibility is 
that the two macrocycles are too close together such that the first formed 
macrocycle blocks the second one from assembling at the other station. 
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Figure 2.7: Analytical HPLC chromatogram of the rotaxane reaction using the azo thread 
48. The first peak (39.87 min) corresponds to the reduced [2]rotaxane 49, the peak at 
40.14 min corresponds to the diazo [2]rotaxane 50 and the third highlighted peak at 
40.64 min corresponds to the [3]rotaxane 51. 
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2.3.2 Synthesis of azo rotaxanes with a four carbon spacer unit 
In order to further investigate these hypotheses, an azo thread with a four carbon 
spacer unit was synthesised. Initially, the hydrazophenylester 44 was coupled with 
1,4-diaminobutane in refluxing chloroform using NEt3 as base (Scheme 2.26).  
 
Scheme 2.26: Synthesis of the azo thread 53. 
 
The newly synthesised hydrazo thread 52 presented similar purification issues to 
those observed for the hydrazo thread 47. Therefore, the thread 52 could only be 
purified via column chromatography in 32% yield. Oxidation of 52 using NBS 
afforded the azo thread 53 in 73% yield. 
The azo thread 53 was subsequently reacted under the previously described 
clipping conditions and analysed via HPLC and MALDI. The HPLC chromatogram 
showed an increased in the formation of the [3]rotaxane, with a ratio of 6:1 
between the [2]- and [3]rotaxanes. 
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Scheme 2.27: Synthesis of three different azo rotaxanes with a four carbon spacer unit 
 
However, only the two different [2]rotaxanes could be isolated using HPLC. When 
trying to isolate these [2]rotaxanes via flash column chromatography an interesting 
phenomenon was observed. The [2]rotaxane 54 and the free macrocycle co-eluted 
with nearly a perfect 1:1 ratio. Consequently, the 1H NMR spectrum suggested the 
isolation of the [3]rotaxane 56, which contradicted the results observed by ES+ 
and MALDI mass spectrometries.  
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Figure 2.8: 1H NMR spectrum of [2]rotaxane 54 and free macrocycle. 
 
Figure 2.8 shows the aromatic region of the 1H NMR spectrum of the purified 
material. A doubling of the signals of the distinctive A, B and C protons is 
observed. The protons with a star correspond to the free macrocycle and the ones 
without, to the [2]rotaxane 54. The integration is nearly 1:1, which suggested the 
isolation of the desired [3]rotaxane. However, the splitting of the signals for the A, 
B and C protons into two pair of sets contradicts the existence of the [3]rotaxane. 
In order to elucidate whether some sort of uncommon conformer issue was 
A A* C C* 
 
B* B 
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observed, saturation transfer experiments (GOSY) and variable temperature NMR 
studies (Figure 2.9) were performed.  
 
Figure 2.9: VT-NMR spectra of the 1:1 mixture of [2]rotaxane 54 and free macrocycle. 
 
At lower temperature only the signals of the [2]rotaxane 54 are sharp and definite, 
while the signals of the free macrocycle are broad. The two sets of signals did not 
convert into one set either, which strongly implies the existence of two different 
compounds. 
The existence of the two species was further proven by injecting the NMR sample 
into a HPLC column to separate the two compounds. The 1H NMR spectra of the 
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HPLC purified [2]rotaxane 54 showed the expected A, B and C protons and the 
lack of the macrocyclic A*, B* and C* protons. 
 
2.3.3 Synthesis of azo rotaxanes with a five carbon spacer unit 
Since a significant increase in the formation of [3]rotaxane was observed when 
increasing the spacer length (from three to four carbons), a five-carbon linker was 
investigated next. The hydrazophenylester 44 was coupled with 
1,5-pentanediamine in refluxing chloroform using NEt3 as base (Scheme 2.28). 
The hydrazo thread 57 was isolated in moderate 29% yield as it presented the 
same behaviour observed for threads 47 and 52. The hydrazo thread 57 was 
oxidised to the azo thread 58 in 88% yield. 
 
Scheme 2.28: Synthesis of the azo thread 58. 
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The azo thread 58 was used to synthesise the desired [3]rotaxane 61, although in 
a very low yield (3%). Unsurprisingly, the azo [2]rotaxane 59 and the hydrazo 
[2]rotaxane 60 were also observed and these were isolated. 
 
Scheme 2.29: Synthesis of three different azo rotaxanes with a five carbon spacer unit. 
 
Isolation and characterisation of the desired [3]rotaxane 61 was realised via an 
isocratic HPLC method using a mixture of methanol and water (75 : 25). 
Significant quantities of the azo 59 and hydrazo 60 [2]rotaxanes were also isolated 
and fully characterised. Figure 2.10 show the resulting HPLC chromatogram. 
Chapter 2 
Results and Discussion 
59 
 
 
Figure 2.10: Analytical HPLC chromatogram of the rotaxane reaction using the azo 
thread 58. Hydrazo [2]rotaxane 60 at 17.53 min, azo [2]rotaxane 59 at 20.48 min and 
[3]rotaxane 61 at 40.17 min. 
 
Attempts to increase the yield of the desired [3]rotaxane 61 were unsuccessful. 
Neither slower addition nor changing the monomer concentration led to an 
increase in the formation of the [3]rotaxane 61. 
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Figure 2.11: 1H NMR spectra of the three different azo rotaxanes with a five carbon 
spacer unit. The hydrazo [2]rotaxane 60 in blue, the azo [2]rotaxane 59 in green and the 
azo [3]rotaxane 61 in red.  
 
Figure 2.11 shows the 1H NMR spectra of the three different azo rotaxanes with a 
five carbon spacer unit. In the aromatic region, the A, B and C protons were clearly 
identified. The aromatic signals of the stopper groups are less defined for the azo 
and hydrazo [2]rotaxanes. The benzylic region is quite complex and it is expanded 
in Figure 2.12. The benzylic protons belong to the two benzylic groups of the 
stoppers and the four benzylic units of the macrocycle. 
A 
B 
C 
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Figure 2.12: Benzylic region of the 1H NMR spectra of the three azo rotaxanes with a five 
carbon spacer unit. The hydrazo [2]rotaxane 60 in blue, the azo [2]rotaxane 59 in green 
and the azo [3]rotaxane 61 in red.  
 
The 1H NMR spectrum for the partially reduced hydrazo [2]rotaxane 60 (shown in 
blue) is rather complex, since the macrocycle is mainly located over the azo 
station and therefore the [2]rotaxane 60 is unsymmetrical. Consequently, separate 
benzylic signals are observed for the stoppers on the azo station, hydrazo station 
and the macrocycle. The aliphatic signals of the [2]rotaxane 60 are also split 
indicating that the shuttling is stopped. The 1H NMR spectrum of the azo 
[2]rotaxane 59 (shown in green) presents just three signals in the benzylic region. 
This is due to the shuttling process between the two stations. Since both stations 
are identical, a simpler 1H NMR spectrum is observed. The [3]rotaxane 61 
(1H NMR spectrum shown in red) has two fully occupied stations and cannot 
shuttle, therefore five signals are detected. These observations are in agreement 
with those recently reported by Berná and co-workers.79 
hydrazo [2]rotaxane 60 
azo [2]rotaxane 59 
azo [3]rotaxane 61 
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Berná has reported that only the azo stations and not their reduced counter parts 
are able to form a rotaxane in good yield.76 Since a 12% yield of unwanted 
[2]rotaxanes was obtained and given that the oxidised [2]rotaxane 59 might form 
the desired [3]rotaxane 61, it was investigated whether the reduced [2]rotaxane 60 
could be re-oxidised to the [2]rotaxane 59. After the HPLC purification, the 
reduced hydrazo [2]rotaxane 60 could not be completely purified. Therefore, the 
obtained 4:1 (reduced : oxidised) mixture was oxidised to completion using NBS 
(Scheme 2.30).  
 
Scheme 2.30: Oxidation of the [2]rotaxane 60. 
 
A second clipping reaction was then performed on the azo [2]rotaxane 59 and the 
[3]rotaxane 61 was successfully isolated in 22% yield (Scheme 2.31). Not 
surprisingly, spontaneous reduction of one of the azo stations on the [2]rotaxane 
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59 to yield 60 was also observed. This is the main drawback of this approach as 
only 13% combined yield of the starting and reduced [2]rotaxanes could be 
obtained. 
 
Scheme 2.31: Clipping reaction starting from [2]rotaxane 59. 
 
Colourless crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a dichloromethane : methanol (1:1) solution of [3]rotaxane 61. The X-ray crystal 
structure confirms the formation of a [3]rotaxane as shown in Figure 2.13, where 
the macrocycles are highlighted in blue and the thread in orange. 
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Figure 2.13: Crytal structure of [3]rotaxane 61. Solvent molecules have been omitted for 
clarity. 
 
The macrocycles have a twisted boat-like structure. As previously discussed 
(see Section 1.2.2), this conformation suggests that the critical cyclic syn syn 
intermediate around the thread is not effectively formed, which is also represented 
in the low yield obtained. The macrocycles are twisted with respect to one another 
by 38° and they are located at 11.6 Å from each other. Hydrogen bonds (shown in 
purple) are observed between the thread and the macrocycles. The bond length 
distance between donor and acceptor ranges from 2.834(10) to 3.279(9) Å. The 
macrocycle on the right is twisted and one carbonyl group can hydrogen bond to 
one NH group of the spacer unit on the thread. 
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2.3.4 Spontaneous reduction of azo systems 
In order to further investigate the spontaneous reduction observed on the azo 
rotaxanes, a series of experiments were undertaken on the simple azo thread 40. 
This thread system can be readily synthesised in large quantities in three steps, 
providing access to a simple model system on which the spontaneous reduction 
reaction can be studied. 
 
Scheme 2.32: Benchmark reaction for the spontaneous reduction. 
 
Several reagents to reduce the azo thread 40 to its hydrazo analogue 43 (Scheme 
2.32) were tested and these are shown in Table 2.3. 
 
Table 2.3: Reaction conditions studied for the reduction of the azo compound 40. 
Entry Reagent Amount Time Conversion 
1 NEt3 48 eq. 8 h 18% 
2 HCl 48 eq. 8 h 1% 
3 NEt3 / HCl 48 eq. 8 h 2% 
4 DMAP 500 eq. 6 d - 
5 NEt3 500 eq. 6 d quant. 
 
When 48 equivalents of NEt3 were used over a period of eight hours, the same 
conditions used in the clipping process, a conversion of 18% from the azo to the 
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hydrazo compound was observed. On the other hand, if HCl was used a 
conversion of only 1% was detected, although this may be due to a different 
reaction pathway. A mixture of NEt3 and HCl yielded 2% conversion. This result 
suggests that the rates of reduction for NEt3 and HCl are different since a higher 
yield was observed when the combination of both reagents was used. 500 
equivalents of NEt3 led to full conversion of the azo compound 40 to the reduced 
hydrazo analogue after six days at RT. DMAP did not give any conversion.  
These reactions were monitored by 1H NMR spectroscopy and the percentage of 
conversion was calculated according to the integration of the different peaks 
(Figure 2.14). The benzylic region is significantly different in the azo and hydrazo 
compounds. 
 
Figure 2.14: 1H NMR spectra from the azo thread 40 (in blue), the hydrazo thread 43 (in 
green) and the reaction mixture of the azo thread 40 and 48 eq. of NEt3 (in red). 
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The 1H NMR spectrum shown in blue corresponds to the azo thread 40 and 
presents two benzylic signals, since 40 is conformationally locked due to amide 
rotamer restriction. However, in the hydrazo thread 43 (1H NMR spectrum shown 
in green) these benzylic protons coalesced at RT and a singlet is observed. In the 
spectrum shown in red, which corresponds to the reaction mixture of the azo 
compound 40 with 48 equivalents of NEt3, a new peak at 4.46 ppm corresponding 
to the hydrazo compound is observed. 
As mentioned above, there are several possible mechanisms for this spontaneous 
reduction process. However, to date, it has not been possible to clearly elucidate 
it. The most feasible reaction pathway is depicted in Scheme 2.33.  
 
Scheme 2.33: Proposed mechanism for the formation of the hydrazo compound 43. 
 
In the first step, NEt3 might add to the azo compound in the same way that PPh3 
does in a Mitsunobu reaction, and the zwitterionic intermediate I might be formed. 
An -hydrogen abstraction, via a five-membered ring transition state, followed by 
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elimination might lead to the negatively charged hydrazo species II and the 
positively charged iminium intermediate III. Hydrolysis might yield the hydrazo 
compound 43, diethylamine and acetaldehyde. This proposed mechanism could 
be considered as an addition / elimination / hydrolysis sequence. However, the 
term reduction seems appropriate in order to compare the azo and hydrazo 
compounds. 
 
2.4 Synthesis of fumaric rotaxanes 
An alternative approach intending to overcome the spontaneous reduction, the low 
yield for the formation of the desired [3]rotaxanes, and the fact that the two 
macrocycles are quite separated from each other, was explored. The idea that a 
change of the stopper group could lead to a double fumaric thread was explored. 
 
2.4.1 Synthesis of a fumaric [2]rotaxane with dibenzylamide stopper groups 
As a starting point, the successful dibenzyl motif used on the azo rotaxanes was 
chosen as the stopper group for the new fumaric threads. The thread 62 was 
synthesised in order to test the effect of using dibenzylamine as a stopper group in 
the formation of a simple thread (Scheme 2.34).  
 
Scheme 2.34: Synthesis of the fumaric thread 62. 
Chapter 2 
Results and Discussion 
69 
 
The thread 62 was then reacted under the previously used clipping reaction 
conditions for rotaxane formation and the [2]rotaxane 63 could be purified via 
column chromatography and was isolated in 84% yield (Scheme 2.35). 
 
Scheme 2.35: Synthesis of the [2]rotaxane 63. 
 
In the aromatic region of the [2]rotaxane 63 the A, B, C and D protons of the 
macrocycle were clearly identified. 
 
Figure 2.15: 1H NMR of thread 62 (in blue) and [2]rotaxane 63 (in red). 
 
D 
CH 
A 
B 
C 
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The olefinic protons (highlighted in green) of the thread 62 shifted upfield (from 
7.61 to 6.04 ppm) upon formation of the [2]rotaxane 63. This shielding effect is 
well documented and observed in several supramolecular systems, e.g. the 
fumaramides reported by Leigh et al..80 This shielding effect of the olefinic protons 
was observed in all of the following fumaramide based rotaxanes synthesised. 
Colourless crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a chloroform : methanol (10 : 1) solution of [2]rotaxane 63.  
 
Figure 2.16: Crystal structure of [2]rotaxane 63. Solvent molecules have been omitted for 
clarity. 
 
The crystal structure confirms the formation of the desired fumaric [2]rotaxane with 
hydrogen bonds between the two O-atoms of the station and the NH of the 
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macrocycle being observed (Figure 2.16). The bond length distance between 
donor and acceptor ranges from 2.9772(18) to 3.2685(19) Å. The macrocycle is 
quite packed in between the two stopper groups, leaving little space between 
them. For this reason, the high yield formation of [2]rotaxane 63 is quite surprising. 
On the other hand, the macrocycle has a chair-like structure indicating that the 
cyclic syn syn intermediate around the thread is effectively formed, which results in 
a good yield. The centre of the molecule is located on an inversion centre such 
that only half of the [2]rotaxane is crystallographically unique with a symmetry 
relation of -x,-y,-z. In contrast with the twisting observed for the macrocycles of the 
[3]rotaxane 61, the tetraamide macrocycle of this [2]rotaxane is at a near right 
angle with the thread.  
 
2.4.2 Synthesis of a fumaric [3]rotaxane with a two carbon spacer unit 
Encouraged by these promising results, a new synthetic route based on that 
described in Section 2.2.1 (route A) was investigated. Treatment of the acid 
chloride 26 with dibenzylamine gave the ester 64 in 86% yield. The ester 64 was 
then hydrolysed to afford the fumaric thread precursor 65 in essentially 
quantitative yield (99%). As discussed in Section 2.2, the acid chloride 26 is 
commercially available, however it was synthesised in quantitative yield in one 
step from mono-ethyl fumarate using thionyl chloride under reflux conditions.  
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Scheme 2.36: Synthesis of the thread precursor 65. 
 
The thread precursor 65 was transformed into the corresponding acid chloride 
using thionyl chloride under reflux conditions. Treatment of the acid chloride with 
ethylenediamine gave the desired double fumaric thread 66 in 66% yield (Scheme 
2.37). This positive result emphasises that the previously chosen amide stopper 
group (Section 2.2) was not optimal to create the desired double fumaric thread.  
 
Scheme 2.37: Synthesis of the thread 66. 
 
The newly synthesised double fumaric thread 66 was able to form the desired 
[3]rotaxane 67 in 8% yield (Scheme 2.38). This [3]rotaxane is very insoluble in any 
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organic solvent other than methanol and had to be isolated via HPLC using a 
mixture of methanol and water (75 : 25). The corresponding [2]rotaxane was also 
detected, however it could not be isolated. Many different purification techniques 
such as column chromatography, recrystallisation or different HPLC methods were 
attempted, however these did not lead to bigger amounts of pure product.  
 
Scheme 2.38: Clipping reaction to form the [3]rotaxane 67. 
 
Thus, by changing the templating station from azo dicarboxamide to fumaramide 
and shortening the spacer unit from five to two carbons, the yield of the 
[3]rotaxane was significantly increased from 3 to 8%.  
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2.4.3 Synthesis of a fumaric [3]rotaxane with a three carbon spacer unit 
In order to investigate whether a longer spacer group would promote a higher 
yield, 1,3-diaminopropane was tested as spacer group. The thread precursor 65 
was transformed into the corresponding acid chloride. Treatment of the acid 
chloride with 1,3-diaminopropane gave the desired double fumaric thread 68 in 
42% yield (Scheme 2.39). 
 
Scheme 2.39: Synthesis of double fumaric thread 68. 
 
The newly synthesised double fumaric thread 68 was able to form the desired 
[3]rotaxane 69 in 17% yield (Scheme 2.40). The purification of this [3]rotaxane was 
challenging, as it presents poor solubility in organic solvents. Column 
chromatography gave a mixture of [3]rotaxane and catenane. Recrystallisation 
was also unsuccessful. However, the [3]rotaxane 69 could be purified and isolated 
via HPLC. The corresponding [2]rotaxane was also formed as a minor product. 
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Scheme 2.40: Clipping reaction to from the [3]rotaxane 69. 
 
Colourless crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a dichloromethane : ethanol (1:1) solution of [3]rotaxane 69. The crystal 
structure confirms the formation of a [3]rotaxane (Figure 2.17). Hydrogen bonds 
between the thread and the macrocycles are observed, the bond length distance 
between donor and acceptor being in a range from 2.670(9) to 3.398(5) Å. The 
macrocycles are in a half chair / twisted boat conformation indicating a 
semi-efficient cyclic syn syn intermediate around the thread, which leads to a 
moderate yield. The macrocycles are twisted with respect to one another by 30° 
and they are located at 9.2 Å from each other. A cross coupling linking event 
between both macrocycles seems now more likely to occur, since the two 
macrocycles are closer to each other and the angle between them has been 
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reduced. However, the conformation in the solid state might be different from that 
in solution. 
 
Figure 2.17: Crystal structure of [3]rotaxane 69. Solvent molecules have been omitted for 
clarity. 
 
Therefore, by increasing the length of the spacer group in the double fumaric 
thread the yield for the formation of the [3]rotaxane has increased considerably 
(from 8% to 17%). Consequently, a three carbon spacer unit seems a good 
compromise between an acceptable yield for the desired [3]rotaxane and the 
distance between the two macrocycles. 
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2.4.4 Synthesis of a fumaric [3]rotaxane with a three carbon spacer unit and 
a phenylbenzyl amide stopper 
In 2008, Leigh and co-workers81 reported a secondary amide stopper group using 
phenylbenzylamine. This stopper group was also investigated in this study in order 
to assess the effect of different stopper groups upon rotaxane formation. The yield 
for the formation of the ester 70 was improved using the previously described acid 
chloride protocol. The saponification step was carried out by using the same 
conditions described by Leigh et al. to yield the desired acid precursor 71 in 68% 
yield (Scheme 2.41). 
 
Scheme 2.41: Synthesis of the carboxylic acid 71. 
 
The carboxylic acid 71 was transformed into the corresponding acid chloride using 
thionyl chloride. Treatment of the resulting acid chloride with 1,3-diaminopropane 
gave the desired double fumaric thread 72 in an acceptable 84% yield (Scheme 
2.42). 
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Scheme 2.42: Synthesis of the fumaric thread 72. 
 
This new double fumaric thread 72 was able to form the desired [3]rotaxane 73 in 
a notable 40% yield (Scheme 2.43). The [3]rotaxane 73 could be purified by 
column chromatography and this might be a reason for the higher yield compared 
to its predecessors that needed to be purified by HPLC methods. The 
corresponding [2]rotaxane 74 was also observed and isolated (5% yield).  
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Scheme 2.43: Synthesis of [3]rotaxane 73. 
 
Colourless crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a dichloromethane : ethanol (1:1) solution of pure [3]rotaxane 73. The crystal 
structure confirms the formation of a [3]rotaxane (Figure 2.18). 
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Figure 2.18: Crystal structure of [3]rotaxane 73. Solvent molecules have been omitted for 
clarity. 
 
The two macrocycles are twisted with respect to one another by 73º, which is a 
greater twist compared to that observed for the [3]rotaxane 61 (30º). However, the 
distance between both macrocycles remains 9.2 Å. The macrocycles are in a 
perfect chair conformation, which indicates that the cyclic syn syn intermediate 
around the thread is formed effectively and this is represented by the higher yield. 
Hydrogen bonds are observed between the thread and the macrocycles, with bond 
length distances between donor and acceptor ranging from 2.711(4) to 3.127(3) Å. 
 
2.5 Further reactions towards a molecular cage 
The next step to obtain the desired box is to link the two macrocycles together. 
Initially, allylation or propargylation of the N-atoms of the macrocycles were 
investigated for the [2]rotaxane 63. However, these reactions proved ineffective. 
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This might result from the direction in which the amide protons of the macrocycle 
point towards the carbonyl groups of the templating stations, due to the attractive 
hydrogen bonding interaction. The high rigidity of the tetraamide macrocycle can 
also limit the reactivity of the amide protons. In contrast, the methylation reaction 
of [2]rotaxane 63 was successful, as confirmed by MALDI spectrometry. This 
could be due to the smaller size of the methyl groups that might have enough 
space to fit in between the macrocycle and the thread. 
 
Scheme 2.44: Methylation of [2]rotaxane 63. 
 
The reactivity of the nitrogen atoms of the amide macrocycle could be enhanced 
by reduction of the amides to amines. This would create a more flexible 
macrocycle and lead to more reactive N-atoms. This new strategy was therefore 
investigated. 
 
2.5.1 Reduction of the tetraamide macrocycles 
In 2001, Takata et al. demonstrated the possibility to methylate and reduce the 
same tetraamide macrocycle used in this study (Scheme 2.45).82  
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Scheme 2.45: Methylation and reduction of [2]rotaxane 76.82 
 
The methylation of all eight amides in the [2]rotaxane 76 was achieved in 58% 
yield by using potassium hydroxide as the base and iodomethane as methylating 
agent. Reduction of the resulting tertiary amides to the corresponding tertiary 
amines by employing 200 equivalents of borane in THF was performed in a 30% 
yield.82 This low yield indicates that the reduction of multiple amides is not trivial. 
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Takata proposed that a reduction followed by an alkylation of the resulting 
secondary amines would also be possible. Reduction of the secondary amide 
[2]rotaxane 76 using borane in THF to its corresponding secondary amine 
[2]rotaxane was performed in 24% yield.83 Full characterisation of this secondary 
amine [2]rotaxane was not achieved. However, the resulting 1H NMR spectrum 
was partially assigned and a mass spectrometric analysis was performed.  
The reduction of the azo [2]rotaxane 41 using 200 equivalents of borane in 
refluxing THF provided the hydrazo [2]rotaxane 77 in 35% yield, indicating the high 
sensitivity of the azo station in the presence of reducing agents (Scheme 2.46). 
 
Scheme 2.46: Reduction of the azo [2]rotaxane 41. 
 
Full reduction of the macrocycle of the fumaric [2]rotaxane 63 was not observed 
when using borane in refluxing THF, however the borane DMS complex as 
reducing agent provided the desired [2]rotaxane 78 after column chromatography. 
The characterisation of this reduced [2]rotaxane 78 proved to be quite challenging. 
The 1H NMR spectrum was inconclusive questioning the formation of this new 
rotaxane. However, a high resolution mass spectrum could be obtained indicating 
the formation of the [2]rotaxane 78. 
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Scheme 2.47: Reduction of the fumaric [2]rotaxane 63. 
 
Alternative reducing agents listed in Table 2.4 were also investigated. However, 
the borane DMS complex in refluxing DCM provided the best results for the 
reduction of the tetraamide macrocycle. 
Table 2.4: Reduction conditions tested. 
Entry Reagent Solvent Time Temp. Result 
1 LiAlH THF 17 h 70 °C full reduction 
2 NaBH4 MeOH 17 h 70 °C - 
3 Superhydride THF 48 h 70 °C reduction of 1 CO 
4 Borane in THF THF 4 days 70 °C full reduction 
5 Borane DMS DCM 3 days 50 °C full reduction 
6 9-BBN THF 4 days 70 °C - 
7 
1) Lawesson's Reagent  
2) NaBH4 
toluene 
MeOH 
12 h 
3 h 
100 °C 
0 °C - RT 
- 
 
Since the hydrazo [2]rotaxane 77 could be isolated, the reduction of the azo 
[3]rotaxane 61 was attempted by employing the borane DMS complex in refluxing 
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DCM, which are the same conditions used for the fumaric [2]rotaxane (Scheme 
2.48). 
 
Scheme 2.48: Reduction of the [3]rotaxane 61 using borane DMS. 
 
The outcome of this reaction was analysed via MALDI spectrometry and two main 
peaks were observed (Figure 2.19). The peak at 1619 Da corresponds to the 
desired hydrazo [3]rotaxane 79. However, the major peak at 1142 Da is assigned 
to the presence of a hydrazo [2]rotaxane. Unfortunately, isolation of the 
[3]rotaxane 79 could not be achieved due to the small amount of material available 
and its difficult purification. 
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Figure 2.19: MALDI spectra of the crude mixture after reduction of 61. 
 
Since the fumaric [3]rotaxane 69 is easier to synthesise, it was then tested under 
the same reduction reaction conditions. The resulting reaction mixture was also 
analysed via MALDI spectrometry. A complex MALDI spectrum was obtained, 
where a mixture of reduced [2]rotaxanes, free reduced macrocycle, reduced 
thread and several [3]rotaxanes were detected (Figure 2.20). The major peaks at 
1097 and 1573 Da correspond to the [2]- and [3]rotaxanes with fully reduced 
macrocycles, respectively. In each product distribution, the mass peaks with 
higher molecular weight correspond to partially reduced macrocycles and the 
mass peaks with lower molecular weight involve a reduction of carbonyl groups on 
the thread. These reduced rotaxanes can undergo a deslipping event, which 
explains the presence of reduced [2]rotaxanes. Although secondary amines are 
still competent hydrogen bond donors, the increased conformational freedom in 
the reduced tetraamine macrocycle clearly facilitates the deslipping process. The 
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reduction of the stations, i.e. removal of the supramolecular glue, also promotes 
the deslipping event. 
 
Figure 2.20: MALDI spectra after reduction of [3]rotaxane 69. 
 
In 2009, Smith and co-workers discussed the effect of the dibenzyl stopper groups 
on the solvent dependent stability of some squaraine rotaxanes bearing a 
tetraamide macrocycle (Figure 2.21).84 In non-polar solvents, the squaraine 
[2]rotaxane 80 is stable due to strong hydrogen bonds between the macrocycle 
and the station. In polar aprotic solvents, such as DMSO, an unthreading event 
occurs, such that within 40 days at RT in DMSO, half of the squaraine is 
dethreaded. Smith suggested that the two phenyl groups acting as stoppers can 
interact via  stacking to form a more compact structure, enabling the deslipping 
process.  
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Figure 2.21: Squaraine [2]rotaxane 80. 
 
The stopper group used by Smith is the same dibenzyl motif used in the fumaric 
and azo rotaxanes reported above, and the deslipping process occurs in the 
squaraine system with the more rigid tetraamide macrocycle. In addition, the 
squaraine rotaxane hydrogen bonding interactions are stronger when compared to 
those observed for the fumaric or azo rotaxanes. 
For these reasons, the reduction of the [3]rotaxane 73 was tested. This 
[3]rotaxane is formed with two phenylbenzyl stopper groups which will disable the 
 stacking interaction. However, the reaction outcome was analogous to that 
obtained for the dibenzyl [3]rotaxane 69. Therefore, it seems that this stopper 
group is not bulky enough to prevent the deslipping of the tetraamine macrocycle. 
 
2.5.2 Attempts to use alternative stopper groups 
In order to overcome this deslipping issue, different sized stopper groups were 
investigated. A diphenyl amide motif was explored first, since this group appears 
somewhat inflexible and might prevent the ring deslipping. The fumaric thread 83 
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was synthesised (Scheme 2.49) following an analogous protocol to that previously 
reported (see Section 2.4). Interestingly, the ester 81 and the acid 82 showed rota 
conformers in the 13C NMR resulting in broad signals and this was confirmed via 
VT-NMR studies. 
 
Scheme 2.49: Synthesis of the double fumaric thread 83. 
 
The newly synthesised double fumaric thread 83 was able to form the desired 
[3]rotaxane 84 in 8% yield and the corresponding [2]rotaxane 85 in 6% yield 
(Scheme 2.50). These striking low yields may be due to the poor solubility of these 
rotaxanes and therefore the need to isolate them via HPLC using a mixture of 
methanol and water (80 : 20). 
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Scheme 2.50: Synthesis of the [3]rotaxane 84.  
 
The reduction of the [3]rotaxane 84 using the borane DMS complex in refluxing 
DCM resulted in a similar product distribution to that observed in the reduction of 
[3]rotaxane 69, as seen by MALDI spectrometry. However, the formation of the 
corresponding [2]rotaxanes via deslipping was significantly increased. This 
deslipping process seems to occur easily, as mass peaks corresponding to three 
remaining carbonyl groups on the macrocycle were also observed. This can be 
due to the smaller size of this diphenyl stopper group. 
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For this reason, dibromodiphenylamine as building block for the stopper group was 
investigated. Dibromodiphenylamine reacts with ethyl fumaroyl chloride in 33% 
yield to afford the ester 86. This ester was then hydrolysed to the corresponding 
carboxylic acid 87. This acid was then reacted with thionyl chloride in refluxing 
THF to form the corresponding acid chloride, which was reacted with 
1,3-diaminopropane in 19% yield over the two steps (Scheme 2.51). This novel 
fumaric thread 88 was able to form the corresponding [2]- and [3]rotaxanes. 
However, purification of these was not possible. Several HPLC methods only 
yielded a mixture of the two different rotaxanes. 
 
Scheme 2.51: Synthesis of the double fumaric thread 88. 
 
The reduction of the mixture of these two rotaxanes was not investigated, since 
that would result in a product distribution of various [2]- and [3]rotaxanes, which 
would not indicate whether a deslipping event is occurring. 
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The hypothesis of increasing the stopper group size without significantly modifying 
the developed synthetic route was further explored with an anthracene benzyl 
motif as stopper group. Since anthrabenzylamine is not commercially available, it 
was synthesised via condensation of 9-anthraldehyde and benzylamine (Scheme 
2.52). 
 
Scheme 2.52: Synthesis of anthrabenzylamine. 
 
The reaction between anthrabenzylamine and ethyl fumaroyl chloride did not form 
the desired ester. Instead, the addition of ethyl fumaroyl chloride followed by an 
intramolecular Diels-Alder reaction to form the pentacyclic product 89 had 
occurred (Scheme 2.53).  
 
Scheme 2.53: Synthesis of the Diels-Alder adduct 89. 
 
The groups of Ciganek and Hahn have reported an intramolecular Diels-Alder 
reaction at high temperature which forms an analogous pentacyclic product under 
reflux conditions.85,86 In contrast to the observations of Ciganek and Hahn, the 
reaction described in Scheme 2.53 was performed at RT, suggesting that the ester 
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group on the dienophile lowers the lowest molecular orbital to promote this very 
mild intramolecular Diels-Alder reaction. 
Colourless crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a DCM solution of compound 89. The crystal structure confirms the formation of 
the pentacyclic structure with the expected anti geometry for the bridged six 
membered ring, arising from the E double bond of the ethyl fumaroyl chloride 
(Figure 2.22). Several attempts to perform a cycloreversion were unsuccessful; 
therefore alternative stopper groups were investigated. 
 
Figure 2.22: Crystal structure of the Diels-Alder adduct 89. 
 
Trityl groups are significantly larger and have been effectively used as stopper 
groups in rotaxane synthesis.87 Therefore, the possibility to use a trityl motif as 
stopper group to synthesise a new double fumaric thread was investigated and a 
secondary amine (tritylphenyl amine) was the first choice. Tritylphenyl amine is not 
commercially available and was synthesised via reaction of trityl chloride with 
aniline following a literature procedure.88 
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Scheme 2.54: Attempted synthesis of amide ester 90. 
 
The reaction of tritylphenyl amine with ethyl fumaroyl chloride did not produce the 
desired ester (Scheme 2.54). Mass spectrometry analysis suggested that the trityl 
group had been lost instead. This result can be attributed to the fact that trityls are 
known to be reasonable good leaving groups.89 
As a result of this, the trityl motif as stopper group was investigated as a primary 
amine instead. Tritylamine is commercially available, however it was synthesised 
in a simple one pot reaction using trityl chloride and aqueous ammonia (Scheme 
2.55).90 
 
Scheme 2.55: Synthesis of tritylamine. 
 
Tritylamine was reacted with ethyl fumaroyl chloride to give the ester 91 in 78% 
yield. This ester was then hydrolysed to the corresponding carboxylic acid 92 in 
81% yield (Scheme 2.56). 
Chapter 2 
Results and Discussion 
95 
 
 
Scheme 2.56: Synthesis of the carboxylic acid 92. 
 
This acid 92 was then treated with thionyl chloride in refluxing THF to form the 
corresponding acid chloride, which was coupled with 1,3-diaminopropane in 20% 
yield over the two steps (Scheme 2.57).  
 
Scheme 2.57: Synthesis of the double fumaric thread 93. 
 
This novel fumaric thread 93 was able to form the expected [2]- and [3]rotaxanes. 
However, the formation of the [2]rotaxane was considerably favoured over the 
desired [3]rotaxane and only the [2]rotaxane 94 could be isolated in sufficient 
amount to be fully characterised (Scheme 2.58). This might be due to the close 
proximity of the very bulky trityl stopper groups to the templating stations. 
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Scheme 2.58: Synthesis of the [2]rotaxane 94. 
 
Consequently, the distance between the bulky stopper and the templating station 
needed to be increased without significantly changing the established synthetic 
route. For this reason, 4-tritylaniline was chosen as a new stopper group. 
4-Tritylaniline was reacted with ethyl fumaroyl chloride in 59% yield to afford the 
ester 95 (Scheme 2.59).  
 
Scheme 2.59: Synthesis of the amide ester 95. 
 
This ester was hydrolysed under standard conditions to give the corresponding 
carboxylic acid 96. This acid was reacted with thionyl chloride in refluxing THF to 
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form the corresponding acid chloride, which was further reacted with 
1,3-diaminopropane in 23% yield over the two steps (Scheme 2.60).  
 
Scheme 2.60: Synthesis of the double fumaric thread 97. 
 
The newly synthesised fumaric thread 97 presents poor solubility in organic 
solvents and consequently did not yield in sufficient amount the desired 
[3]rotaxane during the clipping process. The unwanted catenane was the main 
product and no rotaxane could be isolated. This unfavoured rotaxane formation 
can be attributed to the poor solubility of the thread that holds the templating 
stations which remains in the solid state, while the monomers required for the 
macrocycle, catenane and rotaxane formation are in solution.  
In this Section several attempts to synthesise a [3]rotaxane with bulky stoppers 
were investigated. To date, a [3]rotaxane that might allow an overall reduction 
without deslipping of the tetraamine macrocycle could not be synthesised or 
isolated. Nevertheless, the examples shown and discussed above have given a 
better understanding of the complexity of these particular systems, where size, 
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solubility and accessible synthetic routes need to be considered on the molecular 
design of novel [3]rotaxanes. 
 
2.6 Pseudorotaxanes 
A different strategy towards the synthesis of a novel molecular box was also 
explored. This strategy would avoid the reduction step required to link the two 
macrocycles. Therefore, starting from the two already reduced macrocycles, these 
can be located next to each other by the formation of a supramolecular complex, 
e.g. a pseudorotaxane, followed by a cross linking event. 
Pseudorotaxanes are very common synthetic tools used in supramolecular 
chemistry.91 A pseudorotaxane is a host-guest assembly formed of an 
unstoppered threading compound and a cyclic species.92 This host-guest complex 
is a non interlocked system that can become a rotaxane via a stoppering event. As 
previously discussed, the digit in brackets indicates the number of components. 
For example, one macrocycle and one thread will build a [2]pseudorotaxane. 
In 1991, Stoddart and co-workers reported the directed self-assembly of the 
[2]pseudorotaxane 98 (Figure 2.23).93  
The [2]pseudorotaxane 98 was formed by mixing equimolar amounts of the 
tetracationic cyclophane, shown in blue, and the linear polyether, shown in black, 
in MeCN. The host-guest complex is stabilised via - stacking interactions 
between the electron-rich hydroquinone ring on the thread and the 
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electron-deficient bipyridinium units of the macrocycle. The pseudorotaxane is also 
stabilised via electrostatic edge to face interactions involving the p-phenylene units 
in the cyclophane.94 This synthetic approach has allowed the isolation of other 
[2]pseudorotaxanes and a novel [3]pseudorotaxane.95 These pseudorotaxanes 
were characterised via X-ray crystallographic analysis.  
 
Figure 2.23: Pseudorotaxane 98 formed in MeCN. 
 
Since pseudorotaxanes are non interlocked structures, the linear and cyclic 
compounds are in equilibrium and therefore, a binding constant for the host-guest 
complex can be determined by spectroscopic techniques, such as NMR 
spectroscopy96 and UV/Vis spectroscopy,97 or by cyclovoltametry.98,99 
There are some examples involving hydrogen bonding pseudorotaxanes. In 2007, 
Chiu and co-workers reported an urea-based [2]pseudorotaxane (Scheme 
2.61).100 The preformed amide polyether macrocycle 99 is capable of recognising 
the urea thread 100 in solution to build the [2]pseudorotaxane 101. This 
[2]pseudorotaxane is stabilised via hydrogen bonding interactions between the 
amide protons of the macrocycle and the urea carbonyl group of the thread, as 
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well as by hydrogen bonding interactions between the urea amide protons of the 
thread and the ethylene glycol oxygen atoms of the macrocycle.101  
 
Scheme 2.61: Formation of [2]pseudorotaxane 101. 
 
The binding constant of this host-guest complex was determined by 1H NMR 
dilution experiments in CDCl3 and is equal to 180 M-1. When two equivalents of 
tetrabutylammonium acetate were added to a solution of the [2]pseudorotaxane 
101, this dissociated into its components, as seen in the 1H NMR spectrum where 
the free macrocycle and a new complex between the urea thread 100 and the 
acetate anion were observed.100 
In 2010, Jiang et. al found that when employing a pyridine N-oxide derivative in 
place of the urea thread, the magnitude of the complex binding constant was 
increased 1000 fold.102 
More recently, Schalley and co-workers reported several pseudorotaxanes with 
the amide macrocycle 99 and some amide threads bearing 1,6-dicarbonyl 
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groups.103 Several substituents on the thread were tested and the binding 
constants compared. These binding constants were obtained via NMR titrations, 
isothermal titration calorimetry (ITC) and density functional theory (DFT) 
calculations. 
To date, a pseudorotaxane involving amine macrocycles or fumaric based threads 
has not yet been reported. The formation of such pseudorotaxane could be 
monitored via 1H NMR spectroscopy. In Section 2.4, the chemical shift observed 
for the olefinic protons upon formation of the supramolecular complex has been 
discussed. A comparable effect is also expected in an amine macrocycle.  
The macrocycle 102 was synthesised over two steps using a modified literature 
procedure (Scheme 2.62).104 The 30% yield over the two steps could not be 
improved when changing different reaction parameters, such as temperature, rate 
of addition, solvent or reaction time. 
 
Scheme 2.62: Synthesis of the macrocycle 102. 
 
The double fumaric unstoppered thread 33 was synthesised in 89% yield over two 
steps (see Section 2.2.2). A shift of the olefinic protons (highlighted in green), 
Chapter 2 
Results and Discussion 
102 
 
upon addition of the macrocycle, would indicate the formation of a 
pseudorotaxane. By adding one equivalent of macrocycle, the [2]pseudorotaxane 
103 would be formed. A second equivalent should form the [3]pseudorotaxane 104 
(Scheme 2.63). Since both stations are identical, the first equivalent of the 
macrocycle can shuttle between the two stations and this might prevent the 
formation of the [3]pseudorotaxane 104.  
 
Scheme 2.63: Proposed equilibrium upon addition of one and two equivalents of 
macrocycle 102 in the presence of one equivalent of the double fumaric thread 33. 
 
An initial 1H NMR experiment involving the addition of first one equivalent and then 
a second equivalent of macrocycle 102 showed a shift of around 0.05 ppm of the 
double bond protons, indicating the formation of the [2]pseudorotaxane 103 and 
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the [3]pseudorotaxane 104 (Figure 2.24). This small change between the addition 
of one and two equivalents of the macrocycle might indicate that both macrocycles 
are located over the two fumaric stations. No shift was detected when using the 
stoppered thread 72, which indicates that the macrocycles are located over the 
stations on the pseudorotaxanes. 
 
Figure 2.24: 1H NMR spectra of thread 33 (in blue), thread 33 and 1 eq. of macrocycle 
102 (in green) and thread 33 and 2 eq. of macrocycle 102 (in red). 
 
In order to be able to calculate a binding constant for this complex, a 1H NMR 
titration experiment was performed and the resulting 1H NMR spectra are shown in 
Figure 2.25. To a solution of thread 33 (0.03 M) was added a solution of thread 33 
(0.03 M) and macrocycle 102 (0.06 M) in increments of 0.1 equivalents based on 
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the macrocycle. The resulting 1H NMR spectra show a less dramatic shift 
(0.02 ppm) than that observed for the initial 1H NMR spectra (0.05 ppm). A 
possible explanation for this result could be the instrumental error as the two sets 
of spectra were recorded in different instruments, and this error can be significant 
when dealing with small shifts. Consequently, 1H NMR spectroscopy does not 
seem suitable for the determination of the binding constant for the formation of 
pseudorotaxanes 103 and 104. Unfortunately, UV/Vis spectroscopy did not prove 
useful either, as it did not show any differences in the absorption between 
macrocycle 102, thread 33 and the formed pseudorotaxanes 103 and 104. 
 
Figure 2.25: 1H NMR spectra of the titration experiments with 0.1 equivalent effective 
increments of macrocycle 102. 
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MALDI spectrometry analysis did not allow the detection of the anticipated [2]- and 
[3]pseudorotaxanes either. Therefore, a softer ionisation method, such as 
electrospray (ES), was investigated. Acetonitrile, a non competitive solvent, was 
chosen as mobile phase so as to not interfere with the formed pseudorotaxanes. 
The red ES+ spectrum in Figure 2.26 was obtained when injecting a CDCl3 
pseudorotaxane solution with a macrocycle to thread ratio of 2 to 1. The spectrum 
shows the free macrocycle 102 (477 Da) and the [2]pseudorotaxane 103 (803 Da). 
The spectrum in green is a result of the initial injection of macrocycle, followed by 
injection of the thread compound. Peaks at 349 Da and 675 Da correspond to the 
thread 33 and the peak at 477 Da corresponds to the free macrocycle 102. This 
strongly implies that the formation of the [2]pseudorotaxane is not promoted during 
the ES process. 
 
Figure 2.26: ES+ spectra for the pseudorotaxane formation (in red) and the macrocycle 
and thread components separately injected (in green). 
 
The region where the anticipated [3]pseudorotaxane 104 is expected is expanded 
in Figure 2.27, where the experimental spectrum is shown in red and the 
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calculated spectrum is shown in green. The peaks at around 1279 Da confirm the 
formation of the [3]pseudorotaxane, however the signal intensity for this peak is 
quite small. 
 
Figure 2.27: ES+ spectra of the calculated [3]pseudorotaxane 104 (in green) and the 
experimental [3]pseudorotaxane 104 (in red). 
 
A possible explanation for this behaviour could be that there is some difficulty to 
ionize the [3]pseudorotaxane 104, compared to the other species, such as the 
macrocycle, and therefore the state of population of the individual species cannot 
be exactly determined. 
The next step towards the formation of the desired molecular box is a linking event 
of the two macrocycles in the [3]pseudorotaxane 104. Cis-1,4-dichloro-2-butene, 
trans-1,4-dichloro-2-butene and '-dibromo-p-xylene were tested as possible 
linkers. However, only '-dibromo-p-xylene was able to form several linkages 
between the two macrocycles to yield the desired molecular box as depicted in 
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Scheme 2.64, where a box created by computational calculations is shown in grey 
and a symbolic cartoon representation is shown in blue and black.  
 
 
 
Scheme 2.64: Box formation through [3]pseudorotaxane 104. 
 
The linking reaction between [3]pseudorotaxane 104 and '-dibromo-p-xylene 
was monitored via MALDI spectrometry (Figure 2.28). After one week, new peaks 
in the MALDI spectrum were detected. The peak at 1057 Da corresponds to the 
two macrocycles with one linker, the peak at 1159 Da to the two macrocycles 
connected by two linkers, the peak at 1261 Da where three linkers are present and 
the peak at 1363 Da to the molecular box. Within three weeks the desired 
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molecular box was formed. Unfortunately, the purification and full characterization 
of the box 105 is not trivial. Even when the MALDI spectrum suggested the 
complete formation of the box, singly linked, doubly linked and triply linked 
intermediates, as well as starting linker were still present. Several purification 
techniques including recrystallisation, HPLC and column chromatography were 
explored. However, these were not successful. The final NMR spectra showed the 
expected signals and some impurities. 
 
Figure 2.28: MALDI spectra for the formation of the molecular box 105 after 1 day (in 
black), after 1 week (in purple), after 2 weeks (in green) and after 3 weeks (in red). 
 
Increasing the number of equivalents of the linker resulted in faster reaction times. 
However, the purification remained challenging. When adding a base, such as 
NaOH or NaHCO3, hydrolysis of the double fumaric thread and formation of the 
box 105 occurred. However, the purification process was of the same difficulty. 
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Addition of NEt3 as a base resulted in the quenching of the reaction and formation 
of the expected products did not occur. 
In order to ensure that the thread and the [3]pseudorotaxane 104 have a 
significant effect on the formation of the molecular box, studies involving just the 
macrocycle 102 and the linker were also performed. The box 105 is also formed 
without the thread and results in a similar product distribution. However, the 
reaction proceeds over a longer period of time (6 weeks). In fact, related cages 
have been previously synthesised by Murakami, where two tetraamine 
macrocycles were linked by employing methyl 4-(chloroformyl)benzoate. Similar 
purification issues were also observed on these systems.105,106   
A stoppering approach to capture the [3]pseudorotaxane 104 to form a [3]rotaxane 
was also investigated, in order to increase the variety of the linkers used and to 
demonstrate the generality of this synthetic method. An unstoppered thread can 
associate with a macrocycle to form a pseudorotaxane. This pseudorotaxane can 
then be captured irreversibly via a stoppering event to form a rotaxane. However, 
when the unstoppered thread reacts directly with the capping reagent, then a 
thread, which does not contain the macrocycle, is formed (Scheme 2.65).  
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Scheme 2.65: Equilibria between thread, pseudorotaxane and rotaxane. 
To maximise the amount of rotaxane formed via this method, the central 
equilibrium has to be manipulated to increase the population of the 
pseudorotaxane. This could be achieved either by a strong recognition between 
macrocycle and thread as shown by Stoddart (vide supra) or by modifying the 
reaction temperature. Lowering the temperature increases the formation of 
pseudorotaxane. However, it also decreases the efficiency of the capping reaction. 
Douglas et al. have recently discussed the possibility of synthesising rotaxanes via 
capturing pseudorotaxanes at low temperature (Scheme 2.66).107,108  
The amide macrocycle 106 (the same used by Chiu in 2007) and the amide thread 
107 afforded the pseudorotaxane 108 and by addition of PPh3 at low temperature 
the rotaxane 109 was formed. The reaction of azides with phosphines is very 
rapid109 and can therefore be used for this kind of stoppering reaction at low 
temperature. 
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Scheme 2.66: Formation of the [2]pseudorotaxane 108 and its transformation into the 
[2]rotaxane 109. 
 
Terminal alkynes and organic azides can undergo a 1,3-dipolar cycloaddition and 
this was initially studied by Huisgen.110 Its Cu(I)-catalysed version has been 
recently renamed as the “click” reaction.111,112 The CuAAC or click reaction can 
produce under mild reaction conditions 1,4-substituted-1,2,3-triazoles in excellent 
yields.111 In 2011, Schalley et al. reported the synthesis of the [2]rotaxane 110 
using this methodology (Figure 2.29). A novel dipropargyl diketopiperazine is used 
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as a template for a tetraamide macrocycle. The stopper groups were attached to 
the thread through click chemistry.113  
 
Figure 2.29: The diketopiperazines [2]rotaxane 110. 
 
Stoppering the double fumaric thread via click chemistry was chosen as a method 
to capture the [3]pseudorotaxane. Transformation of the diester 33 to the 
corresponding diacid 36 was described in Section 2.2.2. The resulting diacid 
presents poor solubility in any organic solvent, therefore only the transformation 
from the diacid 36 to the dipropargylester 111 was successful (Scheme 2.67).  
 
Scheme 2.67: Synthesis of the dipropargylester 111. 
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Since the dipropargylester 111 presents poor solubility in chloroform, DMSO was 
used as solvent for the rotaxane formation reaction. However, a chemical shift of 
the proton signals in the 1H NMR spectrum was not observed and consequently 
the formation of the expected pseudorotaxane could not be confirmed. The 
attempted click reaction (Scheme 2.68) was unsuccessful with a complex mixture 
being observed. This could be due to either the poor solubility of the thread, the 
Cu catalyst or the macrocycle itself. 
 
Scheme 2.68: Attempted click reaction. 
 
A methyl group on the diamine was introduced to increase the solubility of the 
double fumaric thread. The ester 113 was synthesised in 72% yield and was 
hydrolysed in nearly quantitative yield (99%) (Scheme 2.69).  
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Scheme 2.69: Synthesis of the diacid 114. 
 
The diacid 114 showed better solubility than the diacid 36. However, when 
converting it to the corresponding dipropargylester 115, only an 18% yield of this 
product was obtained (Scheme 2.70).  
 
Scheme 2.70: Synthesis of the dipropargylester 115. 
 
The dipropargylester 115 is soluble in deuterated chloroform and this allows the 
monitoring of the reaction for the formation of the [3]pseudorotaxane and the click 
reaction to capture it. However, when testing different catalysts for the click 
reaction, the formation of the [3]rotaxane 116 could not be detected with a 
complex mixture being observed (Scheme 2.71).  
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Scheme 2.71: Attempted click reaction. 
 
The ES+ spectrum of the free macrocycle was analysed again and a Cu(I) adduct 
was detected. The Cu(I) can be picked up by the macrocycle from the residue of 
the injection tube. The binding of the tetraamine macrocycle to the fumaric station 
is not particularly strong. In contrast, the binding of the macrocycle to a metal such 
as Cu(I), which is the catalyst for the click reaction, seems to be considerable. 
The synthesis of half stoppered thread systems was also investigated. In 
Section 2.2.3 a double fumaric thread via dimerisation was investigated. However, 
the yields of the required precursors were low and this route was therefore 
abandoned. When switching to the azo derivative and using a dibenzyl stopper 
group a high yield for the corresponding hydrazo precursor 117 was achieved. The 
half hydrazo thread was oxidised to the corresponding half azo thread 118 using 
NBS (Scheme 2.72). 
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Scheme 2.72: Synthesis of the half azo thread 118 and attempted synthesis of the double 
azo thread 119. 
 
In order to confirm that the desired double azo thread can be formed in the 
absence of the macrocycle a Grubbs metathesis reaction was investigated. 
Unfortunately, this reaction did not form the desired double azo thread 119. The 
resulting reaction mixture did not show any starting material either. A deallylation 
reaction as described by Alcaide et al.114 would explain the absence of the starting 
material and the double azo thread 119. The same result was observed when 
using the hydrazo derivative 117 in the Grubbs metathesis reaction.  
In summary, a method to form pseudorotaxanes was developed and these 
pseudorotaxanes are able to form molecular cages. However, to date an effective 
stoppering event could not be found and this has to be further investigated.   
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3 Chapter 3: Conclusions and Future Work 
Three main synthetic routes towards the formation of double fumaric threads were 
identified and investigated. However, these were unsuccessful. On the other hand, 
azo-dicarboxylate threads were formed when the stopper groups were changed 
from a primary amine to a secondary one. These new threads allowed the 
synthesis of several novel [2]- and [3]rotaxanes. Nevertheless, a spontaneous 
reduction during the clipping processes affected the formation of the desired 
[3]rotaxanes, and this reduction was studied in detail and a mechanism proposed. 
It was possible to synthesise double fumaric threads when using the secondary 
amine stopper groups used in the azo-dicarboxylate systems. These new threads 
were able to form the desired [3]rotaxanes in dramatically increased yields. As a 
result an effective route for the high yielding synthesis of [3]rotaxanes with 
fumaramide stations was explored. The change from primary to secondary amines 
on the stopper groups seems to be key for the high yielding synthesis of 
rotaxanes. In comparison, the fumaramide station seems to be more effective than 
the azo dicarboxamide station to facilitate the rotaxane formation.  
In order to be able to link the two macrocycles and access the molecular cage, 
direct alkylations on the tetraamide macrocycles were investigated. However, 
these were unsuccessful. Consequently, a reduction of the amide carbonyl groups 
on the macrocycle was investigated, as this would create more conformational 
freedom of the N-atoms on the macrocycle for the anticipated alkylations. 
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However, these reductions prove to be very challenging and deslipping of the 
reduced and partially reduced macrocycles was observed.  
Fumaric threads with larger stopper groups were synthesised with regard to 
overcome the deslipping issues. These new fumaric threads presented solubility 
and purification issues, which prevented the isolation of any [3]rotaxane. 
Therefore, the full reduction of all the amide carbonyls on the macrocycles and the 
isolation of the desired fully reduced rotaxane could not be realised. Different 
stopper groups could be further investigated on this fumaric system. These 
stopper groups will need to be larger and will require solubilising agents, such as 
glycol chains, to overcome the solubility issues. 
A different approach to obtain a novel molecular cage was also explored. This 
strategy involved the formation of pseudorotaxanes with a tetraamine macrocycle. 
A novel [3]pseudorotaxane was synthesised and detected via 1H NMR 
spectroscopy and mass spectrometry. However, the binding constant between the 
unstoppered thread and the tetraamine macrocyle could not be determined since 
the chemical shift observed in the 1H NMR was quite small. 
When coupling the newly synthesised [3]pseudorotaxane with an appropriate 
linker, the desired molecular box was formed and could be detected via MALDI 
spectrometry. However, purification of this novel molecular box proved to be very 
challenging and a completely pure cage could not be isolated. Studies where the 
molecular box is formed in the absence of thread were also explored. However, 
these required longer reaction times. 
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Attempts to perform a stoppering event to capture the pseudorotaxane were 
unsuccessful and have to be further investigated. One possibility could be the 
formation of a metal complex, where one of the ligands can be replaced by a 
pre-formed pseudorotaxane (Figure 3.1). 
 
Figure 3.1: Proposed [3]rotaxane 120 bearing a metal complex as stopper group. 
 
Another possibility could be the capture of an anticipated pseudorotaxane via a 
low temperature stoppering event. Such a stoppering event could be a 
glycosylation reaction between a primary alcohol and a sugar moiety (Figure 3.2). 
Kahne et al. have showed that this kind of reaction can be performed in good 
yields at low temperature via sulfoxide activation using Tf2O.115 A highly reactive 
glycosyl donor could be generated which should react rapidly with the terminal 
alcohols of the preformed pseudorotaxane 121. 
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Figure 3.2: Proposed synthesis of the [3]rotaxane 122 with sugar stopper groups. 
 
A rotaxane with a sugar stopper has been previously synthesised by Leigh.116 It 
was demonstrated, that this sugar stopper group can be easily cleaved. The 
benefit of these stopper groups is that they are unreactive under various reaction 
conditions, which would allow an effective cross linking event of the two 
macrocycles. Once the desired molecular box has been formed, the sugar 
protecting group could be easily removed.  
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4.1 Materials and methods 
Reactions were carried out under dry N2 using dry glassware. Tetrahydrofuran 
(THF) was distilled from sodium/benzophenone. Dichloromethane, diethyl ether, 
methanol and toluene were collected from the Pure Solv-MD Solvent Purification 
System. All other reagents and solvents were used as received from commercial 
suppliers unless otherwise indicated. Liquid volumes less than 1 mL were 
measured and dispensed with Hamilton gastight syringes. Reaction temperatures 
refer to the temperature measured in an external bath. NMR data were recorded 
either on a Bruker AV300, AVIII300, AV400, AVIII400 or DRX500 spectrometers in 
the deuterated solvents indicated and the spectra were calibrated on residual 
solvent peaks. Chemical shifts (δ) are quoted in ppm and J values are quoted in 
Hz. In reporting spectral data, the following abbreviations were used: s (singlet), 
d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), 
tt (triplet of triplets), m (multiplet), br (broad). In the case of ambiguous 
assignments, 2-dimensional homonuclear (1H - 1H) and heteronuclear (1H - 13C) 
NMR experiments were used. All NMR spectra were processed using 
MestReNova.117 NH and OH protons were not reported when these were not 
observed. Progress of reactions was monitored by thin layer chromatography 
(TLC) using Merck Silica Gel 60 F254 aluminium or plastic backed plates that were 
visualized with UV light, p-anisaldehyde or potassium permanganate. Flash 
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column chromatography was carried out using Davisil 60 Å Silica Gel in the 
solvent systems indicated. Melting points were recorded using a Gallenkamp 
melting point apparatus and are uncorrected. Infrared spectra were recorded on a 
Perkin Elmer Spectrum 100 FTIR spectrometer as neat films, wavelengths () are 
quoted in cm-1. Mass spectra were acquired on a Waters Micromass LCT TOF 
spectrometer using electrospray ionisation (ESI). Electron impact (EI) spectra 
were recorded on a Waters Micromass Zabspec/Magnetic sector mass 
spectrometer. Matrix-Assisted Laser Desorption Ionization (MALDI) spectra were 
either recorded on a Bruker Bi-flex MALDI Time of Flight mass spectrometer or a 
Waters Micromass MALDI mirco MX mass spectrometer. X-ray diffraction data 
was collected either at the National Crystallography Service at the University of 
Southampton in a Rigaku FR-E Ultra High Flux diffractometer or at the University 
of Birmingham in a Bruker Smart 6000 CCD diffractometer. COLLECT was used 
for data collection and DENZO to refine the data. SADABS was used to correct the 
experimental absorption. SIR92 was used as method to solve the resulting crystal 
structures, and their refinements were performed by a full-matrix least-squares 
procedure on F2 in SHELXL-97. Via anisotropic displacement parameters all 
non-hydrogen atoms were refined. The hydrogen atoms were fixed as riding 
models. Mercury 3.072 was used to process .cif files of crystal structures solved by 
Dr. Louise Male from the University of Birmingham or Dr. Mateusz Pitak from the 
National Crystallography Service at the University of Southampton. HPLC was 
carried out on a DIONEX summit P580 quaternary low pressure gradient pump 
with a built-in vacuum degasser using a Summit UVD 170s UV/Vis multi-channel 
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detector. Solvents were used as HPLC grade. Chromeleon software was used to 
visualise and process the obtained chromatograms. Analytical separations used a 
flow rate of 1 mL/min, and semi-preparative used a flow rate of 3 mL/min and 
preparative used a flow rate of 20 mL/min. 
 
4.2 Experimental for Section 2.2 
 
(E)-ethyl-4-((2,2-diphenylethyl)amino)-4-oxobut-2-enoate (27)118 
 
Ethyl fumaroyl chloride (162 mg, 1.0 mmol, 1.0 eq.) was dissolved in dry DCM 
(10 mL) at RT. A solution of 2,2-diphenylethylamine (197 mg, 1.0 mmol, 1.0 eq.) 
and NEt3 (2 mL, 14 mmol, 14 eq.) in dry DCM (10 mL) was added using a syringe 
pump over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
EtOAc / pet (1 / 1) as eluent to afford (E)-ethyl-4-((2,2-diphenylethyl)amino)-4-
oxobut-2-enoate (27) as a white solid (258 mg, 80%). m.p. 110 - 113 °C [lit. 112 - 
113 °C]118; FTIR (film) max 3281, 3082, 2981, 2931, 1722, 1652, 1557, 1273, 
1035, 695; 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.17 (m, 10H, Ar, CH), 6.87 – 6.69 
(m, 2H, CH), 6.28 (br s, 1H, NH), 4.34 – 4.11 (m, 3H, CHCH2), 3.99 (q, J = 7.1 Hz, 
2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 165.6 
(COO), 163.7 (CON), 141.6 (Ar, C), 136.2 (CH), 130.4 (CH), 128.8 (Ar, CH), 128.0 
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(Ar, CH), 127.0 (Ar, CH), 61.2 (CH2), 50.4 (CH), 44.2 (CH2), 14.2 (CH3); HRMS 
(ES+) calculated for C20H21NO3Na [M+Na]+ 346.1419, found 346.1418. 
Data were in agreement with those previously reported.118 
 
N1,N6-bis(2,2-diphenylethyl)fumaramide (6)80 
 
HOAt (1.5 mg, 0.01 mmol, 0.05 eq.) followed by Zr(OtBu)4 (4 mL, 0.01 mmol, 
0.05 eq.) was added to a solution of (E)-ethyl-4-((2,2-diphenylethyl)amino)-4-
oxobut-2-enoate (27) (69 mg, 0.18 mmol, 1 eq.) and 2,2-diphenylethylamine 
(39 mg, 0.2 mmol, 1.1 eq.) in acetonitrile (0.8 mL). The reaction mixture was 
heated to reflux for 3 h and quenched by addition of MeOH (2 mL) and DCM 
(2 mL). The solvent was removed in vacuo and the crude product was purified by 
column chromatography with EtOAc / pet (1 / 1) as eluent to afford the titled 
product as a white solid (51 mg, 60%). m.p. 213 - 214 °C; FTIR (film) max 3264, 
3081, 2924, 1631, 1552, 1493, 1330, 1196, 990, 745, 694; 1H-NMR (300 MHz, 
MeOD / CDCl3) δ 8.20 (br s, 2 H, NH), 7.30-7.20 (m, 20 H, Ar, CH), 6.70 (s, 2 H, 
CHCO), 4.28 (t, J = 7.7 Hz, 2 H, CH), 3.93 (d, J = 7.7 Hz, 4 H, CH2); 13C-NMR 
(100 MHz, MeOD / CDCl3) δ 166.1 (CON), 142.8 (Ar, C), 133.5 (CH), 129.5 (Ar, 
CH), 129.0 (Ar, CH), 127.6 (Ar, CH), 51.0 (CH), 45.1 (CH2); HRMS (ES) calculated 
for C32H30N2O2Na [M+Na]+ 497.2205, found 497.2207. 
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Data were in agreement with those previously reported.80 
 
(E)-4-((2,2-diphenylethyl)amino)-4-oxobut-2-enoic acid (23)118 
 
(E)-ethyl-4-((2,2-diphenylethyl)amino)-4-oxobut-2-enoate (27) (211 mg, 
0.66 mmol, 1.0 eq.) was dissolved in 10 mL DCM / MeOH (9 / 1). 2 M NaOH 
methanol solution (1 mL) was then added. The reaction was stirred for 38 h at RT 
and monitored by TLC. The reaction mixture was acidified with 1 M HCl (2 mL), 
extracted with DCM (3 x 20 mL) and washed with brine (20 mL). The organic 
layers were combined, dried over MgSO4 and concentrated under reduced 
pressure to afford (E)-4-((2,2-diphenylethyl)amino)-4-oxobut-2-enoic acid (23) 
(195 mg, 99%) as a white solid. m.p. >270 °C (decomp) [lit. >270 °C (decomp)]118; 
1H NMR (300 MHz, d6-DMSO) δ 8.09 (s, 1H, NH), 7.41 – 7.09 (m, 10H, Ar, CH), 
6.41 (d, J = 15.4 Hz, 1H, CH), 6.23 (d, J = 15.4 Hz, 1H, CH), 4.26 – 4.21 (m, 1H, 
CH), 3.78 – 3.66 (m, 2H, CH2); 13C NMR (100 MHz, MeOD / CDCl3) δ 174.3 
(COO), 172.0 (CON), 143.4 (Ar, C), 137.8 (CH), 131.6 (CH), 129.8 (Ar, CH), 129.0 
(Ar, CH), 127.9 (Ar, CH), 51.7 (CH), 40.4 (CH2); HRMS (ES-) calculated for 
C18H16NO3 [M-H]- 294.1130, found 294.1132. 
Data were in agreement with those previously reported.118 
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N-(4-aminophenyl)-N-(2,2-diphenylethyl)fumaramide (28) 
 
(E)-4-((2,2-diphenylethyl)amino)-4-oxobut-2-enoic acid (23) (200 mg, 0.67 mmol, 
2.0 eq.) followed by EDC (104 mg, 0.67 mmol, 2.0 eq.) was added to a stirred 
suspension of p-phenylamine (35 mg, 0.33 mmol, 1.0 eq.) in methanol (4 mL). The 
reaction mixture was stirred at RT for 24 h. The reaction mixture was then diluted 
with water and extracted with DCM (3 x 20 mL). The organic layers were 
combined, washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by column chromatography with DCM / 
MeOH (10 / 1) as eluent to afford of N-allyl-N-(2,2-diphenylethyl)fumaramide (28) 
as a white solid (63 mg, 50%). m.p. 178 °C; FTIR (film) max 3313, 2932, 1634, 
1515, 1450, 1402, 1221, 1114, 1029, 739, 698; 1H NMR (300 MHz, MeOD / 
CDCl3) δ 7.37 (d, J = 8.9 Hz, 2H, Ar, CH), 7.32 – 7.14 (m, 10H, Ar, CH), 6.96 (d, J 
= 15.1 Hz, 1H, CH), 6.79 (d, J = 15.1 Hz, 1H, CH), 6.69 (d, J = 8.9 Hz, 2H, Ar, 
CH), 4.29 (t, J = 8.1 Hz, 1H, CH), 3.92 (dd, J = 8.1, 4.0 Hz, 2H, NHCH2); 13C NMR 
(100 MHz, MeOD / CDCl3) δ 167.3 (CON), 166.3 (CON), 142.9 (Ar, C), 134.2 
(CH), 133.3 (CH), 129.2 (Ar, CH), 128.7 (Ar, CH), 127.4 (Ar, CH), 122.5 (Ar, CH), 
116.4 (Ar, CH), 51.1 (CH), 45.1 (CH2); HRMS (EI+) calculated for C24H23N3O2Na 
[M+Na]+ 408.1688, found 408.1677. 
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(2E,2'E)-diethyl 4,4'-(ethane-1,2-diylbis(azanediyl))bis(4-oxobut-2-enoate) 
(32)119 
 
Ethyl fumaroyl chloride (178 mg, 1.1 mmol, 2.2 eq.) was dissolved in dry DCM 
(19 mL) at RT. A solution of ethylenediamine (30 mg, 0.5 mmol, 1.0 eq.) and NEt3 
(0.7 mL, 5.0 mmol, 10 eq.) in dry DCM (19 mL) was added using a syringe pump 
over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
EtOAc as eluent to afford (2E,2'E)-diethyl 4,4'-(ethane-1,2-diylbis(azanediyl))bis(4-
oxobut-2-enoate) (32) as a white solid (72 mg, 46%). m.p. 186 °C [lit. 189 - 
190 °C]119; FTIR (film) max 3290, 3072, 1947, 1711, 1634, 1570, 1437, 1293, 
1161, 1094, 1032, 756, 701; 1H NMR (300 MHz, MeOD / CDCl3) δ 8.20 (br s, 2H, 
NH), 6.80 (q, J = 15.5 Hz, 4H, CH), 4.20 (q, J = 7.1 Hz, 4H, OCH2), 3.41 – 3.40 (m, 
4H, CH2NH), 1.27 (t, J = 7.1 Hz, 6H, CH3); 13C NMR (100 MHz, MeOD / CDCl3) δ 
166.1 (COO), 165.3 (CON), 136.4 (CH), 130.4 (CH), 61.5 (OCH2), 39.4 (CH2NH), 
14.1 (CH3); HRMS (ES+) calculated for C14H20N2O6Na [M+Na]+ 335.1219, found 
335.1210. 
Data were in agreement with those previously reported.119 
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(2E,2'E)-diethyl 4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoate) 
(33) 
 
Ethyl fumaroyl chloride (178 mg, 1.1 mmol, 2.2 eq.) was dissolved in dry DCM 
(19 mL) at RT. A solution of 1,3-diaminopropane (37 mg, 0.5 mmol, 1.0 eq.) and 
NEt3 (0.7 mL, 5.0 mmol, 10 eq.) in dry DCM (19 mL) was added using a syringe 
pump over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
EtOAc as eluent to afford (2E,2'E)-diethyl 4,4'-(propane-1,3-
diylbis(azanediyl))bis(4-oxobut-2-enoate) (33) as a white solid (110 mg, 65%). 
m.p. 135 °C; FTIR (film) max 3263, 3087, 1716, 1626, 1551, 1473, 1294, 1160, 
975, 869, 749, 666; 1H NMR (300 MHz, CDCl3) δ 7.15 – 7.11 (m, 2H, NH), 6.96 (d, 
J = 15.4 Hz, 2H, CH), 6.79 (d, J = 15.4 Hz, 2H, CH), 4.23 (q, J = 7.1 Hz, 4H, 
OCH2), 3.43 – 3.37 (m, 4H, CH2NH), 1.83 – 1.68 (m, 2H, CH2CH2CH2), 1.30 (t, J = 
7.1 Hz, 6H, CH3); 13C NMR (100 MHz, CDCl3) δ 165.7 (COO), 164.6 (CON), 136.4 
(CH), 130.6 (CH), 61.4 (OCH2), 36.6 (CH2NH), 29.5 (CH2), 14.3 (CH3); HRMS 
(ES+) calculated for C15H22N2O6Na [M+Na]+ 349.1376, found 349.1372. 
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(2E,2'E)-diethyl 4,4'-(butane-1,4-diylbis(azanediyl))bis(4-oxobut-2-enoate) (34) 
 
Ethyl fumaroyl chloride (178 mg, 1.1 mmol, 2.2 eq.) was dissolved in dry DCM 
(19 mL) at RT. A solution of 1,4-diaminobutane (44 mg, 0.5 mmol, 1.0 eq.) and 
NEt3 (0.7 mL, 5.0 mmol, 10 eq.) in dry DCM (19 mL) was added using a syringe 
pump over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
EtOAc as eluent to afford (2E,2'E)-diethyl 4,4'-(butane-1,4-diylbis(azanediyl))bis(4-
oxobut-2-enoate) (34) as a white solid (72 mg, 42%). m.p. 143 °C; FTIR (film) max 
3302, 1706, 1619, 1547, 1444, 1174, 1031, 9991, 747, 688; 1H NMR (300 MHz, 
MeOD) δ 8.12 (br s, 2H, NH), 6.89 (d, J = 15.5 Hz, 2H, CH), 6.72 (d, J = 15.5 Hz, 
2H, CH), 4.20 (q, J = 7.1 Hz, 4H, OCH2), 3.27 – 3.25 (m, 4H, CH2NH), 1.55 – 1.51 
(m, 4H, CH2CH2CH2CH2), 1.27 (t, J = 7.1 Hz, 6H, CH3); 13C NMR (100 MHz, 
MeOD) δ 166.3 (COO), 164.8 (CON), 136.8 (CH), 130.0 (CH), 61.5 (OCH2), 39.3 
(CH2NH), 26.5 (CH2), 14.1 (CH3); HRMS (ES+) calculated for C16H24N2O6Na 
[M+Na]+ 363.1532, found 363.1529. 
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(E)-ethyl 4-(1H-benzo[d][1,2,3]triazol-1-yl)-4-oxobut-2-enoate (35) 
 
Thionyl chloride (87 L, 1.2 mmol, 1.2 eq.) was added to a solution of 
benzotriazole (495 mg, 4.2 mmol, 4.2 eq.) in anhydrous THF (5 mL) at 0 °C, and 
the reaction mixture was stirred for 20 min at this temperature. Mono-ethyl 
fumarate (144 mg, 1.0 mmol, 1.0 eq.) was dissolved in dry THF (3 mL) and added 
dropwise to the reaction mixture at 0 °C. The reaction was stirred for 4 h at this 
temperature and was allowed to warm to RT overnight. The precipitate was 
filtered, and the filtrate was concentrated under reduced pressure. The residue 
was diluted with DCM (25 mL) and washed with a saturated aqueous solution of 
Na2CO3 (3 x 10 mL), brine (10 mL) and dried over MgSO4 to afford (E)-ethyl 4-
(1H-benzo[d][1,2,3]triazol-1-yl)-4-oxobut-2-enoate (35) as a white solid (194 mg, 
79%). m.p. 105 °C; FTIR (film) max 3419, 3101, 2978, 1707, 1595, 1487, 1448, 
1375, 1291, 1162, 1067, 975, 869, 745; 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 
15.7 Hz, 1H, CH), 8.37 (d, J = 8.3 Hz, 1H Ar, CH), 8.18 (d, J = 8.3 Hz, 1H Ar, CH), 
7.74 – 7.70 (m, 1H Ar, CH), 7.63 – 7.53 (m, 1H Ar, CH), 7.29 (d, J = 15.7 Hz, 1H, 
CH), 4.37 (q, J = 7.1 Hz, 2H, OCH2), 1.41 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 
MHz, CDCl3) δ 164.5 (COO), 162.5 (CON), 146.5 (Ar, C), 136.8 (CH), 131.3 (CH), 
131.2 (Ar, C), 130.9 (Ar, CH), 126.9 (Ar, CH), 120.6 (Ar, CH), 114.7 (Ar, CH), 61.9 
(OCH2), 14.3 (CH3); HRMS (EI+) calculated for C12H11N3O3 [M]+ 245.0800, found 
245.0797. 
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(2E,2'E)-4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoic acid) (36) 
 
(2E,2'E)-diethyl 4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoate) (33) 
(78 mg, 0.24 mmol, 1.0 eq.) was dissolved in EtOH (10 mL). Then NaOH (20 mg, 
0.5 mmol, 1.2 eq.) dissolved in water (0.5 mL) was added dropwise over a period 
of 5 minutes via syringe. The reaction was stirred for 16 h at RT and monitored by 
TLC. The reaction mixture was acidified with 1 M HCl (0.5 mL), extracted with 
DCM (3 x 20 mL) and washed with brine (20 mL). The organic layers were 
combined, dried over MgSO4 and concentrated under reduced pressure to afford 
(2E,2'E)-4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoic acid) (36) as a 
yellow solid (64 mg, 99%). m.p. >244 °C (decomp); FTIR (film)max 3322, 2926, 
1641, 1561, 1411, 1322, 1261, 1188, 1141, 960, 788; 1H NMR (300 MHz, MeOD) 
δ 9.49 (t, J = 5.6 Hz, 2H, NH), 7.75 (d, J = 15.5 Hz, 2H, CH), 7.32 (d, J = 15.5 Hz, 
2H, CH), 4.06 – 3.89 (m, 4H, CH2NH), 2.52 – 2.34 (m, 2H, CH2CH2CH2); 13C NMR 
(100 MHz, D2O) δ 173.5 (COO), 167.7 (CON), 136.4 (CH), 131.1 (CH), 37.1 
(CH2NH), 27.7 (CH2); HRMS (ES-) calculated for C11H13N2O6 [M-H]- 269.0770, 
found 269.0774. 
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N1-allyl-N6-(2,2-diphenylethyl)fumaramide (39) 
 
(E)-4-((2,2-Diphenylethyl)amino)-4-oxobut-2-enoic acid (23) (200 mg, 0.7 mmol, 
1.0 eq.) then EDC (104 mg, 0.7 mmol, 1.0 eq.) was added to a stirred suspension 
of allylamine (38 mg, 0.7 mmol, 1.0 eq.) in methanol (4 mL). The reaction mixture 
was stirred at RT for 24 h. The reaction mixture was diluted with water and 
extracted with DCM (3 x 20 mL). The organic layers were combined, washed with 
brine, dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography with EtOAc as eluent to afford N1-
allyl-N6-(2,2-diphenylethyl)fumaramide (39) as a white solid (40 mg, 18%).m.p. 
79 °C; FTIR (film) max 2987, 2901, 1696, 1644, 1535, 1452, 1407, 1250, 1066, 
893, 779; 1H NMR (300 MHz, MeOD / CDCl3) δ 7.32 – 7.11 (m, 10H, Ar, CH), 6.71 
(d, J = 15.2 Hz, 2H, CH), 5.85 – 5.72 (m, 1H, CH), 5.18 – 5.09 (m, 2H, CH2), 4.22 
(t, J = 8.0 Hz, 1H, CH), 3.93 – 3.80 (m, 4H, CH2); 13C NMR (100 MHz, MeOD / 
CDCl3) δ 165.3 (CON), 165.1 (CON), 142.0 (Ar, C), 133.3 (CH), 132.6 (CH), 128.7 
(Ar, CH), 128.0 (Ar, CH), 126.9 (Ar, CH), 116.6 (CH2), 50.4 (CH), 44.4 (CH2), 42.2 
(CH2); HRMS (ES+) calculated for C21H22N2O2Na [M+Na]+ 357.1579, found 
357.1567. 
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4.3 Experimental for Section 2.3 
 
Diphenylhydrazo-1,2-dicarboxylate (42)76,120 
 
Hydrazine hydrate (4.8 mL, 100.0 mmol, 1.0 eq.) was dissolved in ethanol (50 mL) 
and cooled to 0°C. Phenyl chloroformate (12.6 mL, 100.0 mmol, 1.0 eq.) was then 
added followed by the simultaneous addition of phenyl chloroformate (12.6 mL, 
100.0 mmol, 1.0 eq.) and Na2CO3 (10.2 g, 100.0 mmol, 1.0 eq.) in water 
(12.5 mL). Once the additions were finished water (15 mL) was added and the 
reaction mixture stirred for 30 minutes at RT. The resulted precipitate was 
collected, washed with ice cold water (200 mL) and dried in vacuo to afford 
diphenylhydrazo-1,2-dicarboxylate (42) as a white solid (24.77 g, 91%). m.p. 
180 °C [lit. 183 - 185 °C]76; 1H NMR (300 MHz, CDCl3) δ 7.45 - 7.35 (m, 10H, Ar, 
CH); 13C NMR (100 MHz, CDCl3) δ 155.0 (COO), 150.6 (Ar, C), 129.6 (Ar, CH), 
126.1 (Ar, CH), 121.5 (Ar, CH); HRMS (ES+) calculated for C14H12N2O4Na [M+Na]+ 
295.0695, found 295.0704. 
Data were in agreement with those previously reported.76,120 
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N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-hydrazodicarboxamide (43)76 
 
Dibenzylamine (2.0 mL, 10.8 mmol, 2.1 eq.) followed by NEt3 (1.5 mL, 10.8 mmol, 
2.1 eq.) were added to a solution of diphenylhydrazo-1,2-dicarboxylate (42) (1.4 g, 
5.1 mmol, 1.0 eq.) in CHCl3 (40 mL). The reaction mixture was heated at reflux for 
15 h. The reaction mixture was cooled, concentrated under reduced pressure and 
the crude product purified by column chromatography with CHCl3 / MeOH (97 / 3) 
as eluent to afford N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-hydrazodicarboxamide 
(43) as a white solid (1.93 g, 75%). m.p. 173 °C [lit. 173 - 174 °C]76; 1H NMR (300 
MHz, CDCl3) δ 7.45 – 7.24 (m, 20H, Ar, CH), 4.55 (br s, 8H, CH2); 13C NMR (100 
MHz, CDCl3) δ 159.5 (CON), 136.9 (Ar, C), 128.8 (Ar, CH), 127.6 (Ar, CH), 127.5 
(Ar, CH), 50.0 (CH2);LR MS (ES+) 501.5 ([M+Na]+, 100%). 
Data were in agreement with those previously reported.76 
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N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-azodicarboxamide (40)76 
Pyridine (0.3 mL, 3.7 mmol, 1.1 eq.) and NBS (0.6 g, 3.4 mmol, 1.0 eq.) were 
added to a solution of N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-hydrazo 
dicarboxamide (43) (1.6 g, 3.4 mmol, 1.0 eq.) in dry DCM (50 mL). The resulting 
orange solution was stirred at RT for 1 h. The reaction mixture was diluted with 
DCM (25 mL) and sequentially washed with water (3 x 50 mL), a saturated 
aqueous solution of Na2S2O3 (50 mL) and a saturated aqueous solution of 
NaHCO3 (2 x 50 mL). The organic phase was dried over anhydrous MgSO4, 
concentrated under reduced pressure and purified by column chromatography with 
CHCl3 / MeOH (98 / 2) as eluent to afford N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-
azodicarboxamide (40) as a yellow solid (1.58 g, 98%). m.p. 148 °C [lit. 151 - 
153 °C]76; 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.24 (m, 16H, Ar, CH), 7.17 – 7.08 
(m, 4H, Ar, CH), 4.61 (s, 4H, CH2), 4.43 (s, 4H, CH2); 13C NMR (100 MHz, CDCl3) 
δ 161.9 (CON), 135.5 (Ar, C), 135.4 (Ar, C), 129.0 (Ar, CH), 128.7, (Ar, CH) 128.1 
(Ar, CH), 127.6 (Ar, CH), 49.1 (CH2), 48.9 (CH2); HRMS (ES+) calculated for 
C30H28N4O2Na [M+Na]+ 499.2110, found 499.2095. 
Data were in agreement with those previously reported.76 
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N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-azodicarboxamide [2]rotaxane (41)76 
 
Et3N (3.4 mL, 24.0 mmol, 24.0 eq.) was added to a stirred solution of N,N,N’,N’-
tetrakis(2,2-diphenylethyl)-1,2-azodicarboxamide (40) (476 mg, 1.0 mmol, 1.0 eq.) 
in anhydrous CHCl3 (400 mL). The solution was stirred vigorously whilst solutions 
of p-xylylene diamine (1.6 g, 12.0 mmol, 12.0 eq.) in anhydrous CHCl3 (63 mL) 
and isophthaloyl dichloride (2.4 g, 12.0 mmol, 12.0 eq.) in anhydrous CHCl3 
(63 mL) were simultaneously added over a period of 4 h using a motor-driven 
syringe pump. After a further 4 h period the resulting suspension was filtered 
through a Celite® pad and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography with CHCl3 / MeOH (96 / 4) 
as eluent to afford the title product (41) as an orange solid (430 mg, 42%). m.p. 
198 °C [lit. 198 - 199 °C]76; 1H NMR (300 MHz, CDCl3) δ 8.11 (dd, J = 7.7, 1.5 Hz, 
4H, Ar, CH, HB), 8.07 (br s, 2H, Ar, CH, HC), 7.49 – 7.30 (m, 12H, 6 Ar, CH, 2 Ar, 
CH, HA, 4 NH), 7.20 – 7.11 (m, 6H, Ar, CH), 7.01 – 6.92 (m, 4H, Ar, CH), 6.84 – 
6.81 (m, 4H, Ar, CH), 6.69 (s, 8H, Ar, CH, HE), 5.01 (br s, 4H, CH2, HD), 4.60 (s, 
4H, CH2), 4.47 (s, 4H, CH2), 3.62 (br s, 4H, CH2, HD); 13C NMR (100 MHz, CDCl3) 
δ 165.5 (CON), 158.8 (CON), 137.6 (Ar, C), 134.6 (Ar, C), 133.7 (Ar, C), 133.2 (Ar, 
Chapter 4 
Experimental 
 
137 
 
CH), 132.2 (Ar, CH), 130.3 (Ar, CH), 129.3 (Ar, CH), 129.1 (Ar, CH), 128.7 (Ar, 
CH), 128.5 (Ar, CH), 126.9 (Ar, CH), 121.9 (Ar, CH), 51.1 (CH2), 50.9 (CH2), 43.6 
(CH2); HRMS (ES+) calculated for C62H56N8O6Na [M+Na]+ 1031.4221, found 
1031.4229. 
Data were in agreement with those previously reported.76 
 
Phenyl N,N-dibenzylaminocarbonylhydrazinecarboxylate (44)76 
 
Dibenzylamine (1.8 mL, 9.2 mmol, 1.0 eq.) followed by NEt3 (1.5 mL, 11.0 mmol, 
1.2 eq.) were added to a solution of diphenylhydrazo-1,2-dicarboxylate (42) (5.0 g, 
18.4 mmol, 2.0 eq.) in CHCl3 (250 mL). The reaction mixture was stirred for 72 h at 
RT after which the reaction was concentrated under reduced pressure and purified 
by column chromatography with CHCl3 / MeOH (97 / 3) as eluent to afford phenyl 
N,N-dibenzylaminocarbonylhydrazinecarboxylate (44) as a white solid (2.78 g, 
81%). m.p. 100 °C [lit. 103 - 105 °C]76; 1H NMR (300 MHz, CDCl3) δ 7.35 - 7.28 
(m, 10H, Ar, CH), 7.19 - 7.15 (m, 5H, Ar, CH), 4.54 (br s, 4 H, CH2); 13C NMR (100 
MHz, CDCl3 / MeOD) δ 158.4 (COO), 155.8 (CON), 151.4 (Ar, C), 137.6 (Ar, C), 
129.5 (Ar, CH), 128.3 (Ar, CH), 126.4 (Ar, CH), 122.4 (Ar, CH), 116.0 (Ar, CH), 
50.0 (CH2); HRMS (ES+) calculated for C22H21N3O3Na [M+Na]+ 398.1481, found 
398.1470. 
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Data were in agreement with those previously reported.76 
 
N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzylhydrazine-1,2-dicarboxamide) (47) 
 
Phenyl N,N-dibenzylaminocarbonylhydrazinecarboxylate (44) (334 mg, 0.9 mmol, 
2.0 eq.) and NEt3 (0.4 mL, 2.9 mmol, 6.4 eq.) were added to a stirred solution of 
1,3-diaminopropane (0.04 mL, 0.5 mmol, 1.0 eq.) in CHCl3 (25 mL). The reaction 
mixture was heated at reflux for 15 h. The reaction mixture was cooled, 
concentrated under reduced pressure and the crude product purified by column 
chromatography on silica gel using a DCM / MeOH (95 / 5) mixture as eluent to 
give the title product as a white solid (108 mg, 38%). m.p. 125 °C; FTIR (film) max 
3267, 2974, 1638, 1528, 1494, 1242, 1080, 968, 889, 744, 669; 1H NMR (300 
MHz, CDCl3) δ 7.43 – 7.25 (m, 20H, Ar, CH), 6.43 (s, 2H, NH), 5.80 (s, 2H, NH), 
4.56 (s, 8H, CH2), 3.44 – 3.42 (m, 4H, CH2NH), 1.86 – 1.83 (m, 2H, CH2); 13C 
NMR (100 MHz, CDCl3) δ 160.3 (CON), 160.0 (CON), 136.9 (Ar, C), 128.9 (Ar, 
CH), 127.7 (Ar, CH), 127.6 (Ar, CH), 50.1 (CH2), 38.8 (CH2NH), 28.7 (CH2); HRMS 
(ES+) calculated for C35H40N8O4Na [M+Na]+ 659.3070, found 659.3066. 
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(1E,1'E)-N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzyldiazene-1,2-
dicarboxamide) (48) 
 
Pyridine (0.2 mL, 2.1 mmol, 2.2 eq.) and NBS (338 mg, 1.9 mmol, 2.0 eq.) were 
added to a solution of N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzylhydrazine-1,2-
dicarboxamide) (47) (607 mg, 1.0 mmol, 1.0 eq.) in dry DCM (30 mL). The 
resulting solution was stirred for 1 h at RT. The reaction was diluted with DCM 
(15 mL) and sequentially washed with water (2 x 30 mL), a saturated aqueous 
solution of Na2S2O3 (30 mL) and a saturated aqueous solution of NaHCO3 (2 x 
30 mL). The organic phase was dried over anhydrous MgSO4, concentrated under 
reduced pressure and purified by column chromatography with DCM / MeOH (95 / 
5) as eluent to afford the title product (48) as a yellow oil (530 mg, 88%). FTIR 
(film) max 3280, 3031, 2938, 1689, 1524, 1495, 1426, 1362, 1217, 1154, 1080, 
1028, 749, 696; 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.12 (m, 20H, Ar, CH), 4.64 
(s, 4H, CH2), 4.50 (s, 4H, CH2), 3.53 – 3.47 (m, 4H, CH2NH), 1.97 – 1.73 (m, 2H, 
CH2); 13C NMR (100 MHz, CDCl3) δ 162.2 (CON), 160.4 (CON), 135.4 (Ar, C), 
129.0 (Ar, CH), 128.5 (Ar, CH), 128.2 (Ar, CH), 127.8 (Ar, CH), 49.3 (CH2), 49.2 
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(CH2), 37.8 (CH2NH), 28.9 (CH2); HRMS (ES+) calculated for C35H36N8O4Na 
[M+Na]+ 655.2757, found 655.2754. 
 
(1E,1'E)-N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzyldiazene-1,2-
dicarboxamide) [2]rotaxane (49) and (50) 
 
Et3N (5.0 mL, 35.3 mmol, 48.0 eq.) was added to a stirred solution of (1E,1'E)-
N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzyldiazene-1,2-dicarboxamide) (48) 
(461 mg, 0.73 mmol, 1.0 eq.) in anhydrous CHCl3 (800 mL). The solution was 
Chapter 4 
Experimental 
 
141 
 
stirred vigorously whilst solutions of p-xylylene diamine (2.4 g, 17.6 mmol, 
24.0 eq.) in anhydrous CHCl3 (126 mL) and isophthaloyl dichloride (3.6 g, 
17.6 mmol, 24.0 eq.) in anhydrous CHCl3 (126 mL) were simultaneously added 
over a period of 4 h using motor-driven syringe pump. After a further 4 h period the 
resulting suspension was filtered through a Celite® pad and the solvent removed 
under reduced pressure. The crude product was purified by HPLC to afford the 
azo [2]rotaxane (49) as a white solid (25 mg, 3%), the hydrazo [2]rotaxane (50) as 
a yellow solid (8 mg, 1%) and the azo [3]rotaxane (51) as a white solid (0.7 mg). 
HPLC (t = 0 → 60 min, 75 : 25 MeOH : H2O): Data for compound 49: Rt 24.31; 
m.p. 127 °C; FTIR (film) max 3286, 3063, 2926, 1637, 1530, 1453, 1356, 1299, 
1080, 965, 818, 729, 697; 1H NMR (300 MHz, MeOD) δ 8.20 (br s, 2H, Ar, CH, 
HC), 8.13 (s, 4H, NH), 7.93 (dd, J = 7.8, 1.6 Hz, 4H, Ar, CH, HB), 7.50 – 7.41 (m, 
2H, Ar, CH, HA), 7.35 – 7.10 (m, 20H, Ar, CH), 6.98 (s, 8H, Ar, CH, HE), 4.57 – 
4.27 (m, 16 H, 8 CH2, HD, 8 CH2), 3.75 - 3.68 (m, 4H, CH2), 2.01 – 1.91 (m, 2H, 
CH2); 13C NMR (100 MHz, MeOD) δ 169.6 (CON), 168.8 (CON), 140.2 (Ar, C), 
138.5 (Ar, C), 136.9 (Ar, C), 136.4 (Ar, C), 135.3 (Ar, C), 132.1 (Ar, CH), 129.8 (Ar, 
CH), 129.6 (Ar, CH), 128.6 (Ar, CH), 48.8 (CH2), 44.9 (CH2), 23.9 (CH2); LRMS 
(ES+) 1187.6 ([M+Na]+, 100%). Data for compound 50: Rt 21.23; m.p. 132 °C; 
FTIR (film) max 3286, 3063, 2926, 1637, 1530, 1453, 1356, 1299, 1080, 965, 818, 
729, 697; 1H NMR (300 MHz, MeOD) δ 8.25 (s, 2H, Ar, CH, HC), 8.19 – 8.15 (m, 
2H, NH), 7.96 (dd, J = 7.8, 1.6 Hz, 4H, Ar, CH, HB), 7.48 (t, J = 7.8 Hz, 2H, Ar, CH, 
HA), 7.35 – 7.10 (m, 16H, Ar, CH), 7.07 – 7.04 (m, 2H, Ar, CH), 7.01 (s, 8H, Ar, 
CH, HE), 6.86 – 6.83 (m, 2H, Ar, CH), 4.67 – 4.18 (m, 16H, 8 CH2, HD, 8 CH2), 
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3.35 – 3.32 (m, 4H, CH2), 1.78 – 1.74 (m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 
168.6 (CON), 168.3 (CON), 137.7 (Ar, C), 136.2 (Ar, C), 135.6 (Ar, C), 134.6, 
131.9 (Ar, CH), 131.7 (Ar, CH), 130.8 (Ar, CH), 130.0 (Ar, CH), 129.9 (Ar, CH), 
129.7 (Ar, CH), 129.5 (Ar, CH), 129.2 (Ar, CH), 128.9 (Ar, CH), 128.4 (Ar, CH), 
128.1 (Ar, CH), 125.8 (Ar, CH), 44.5 (CH2), 41.4 (CH2), 27.0 (CH2); HRMS (ES+) 
calculated for C67H66N12O8Na [M+Na]+ 1189.5024, found 1189,4998. Data for 
compound 51: Rt 32.49; m.p. 144 °C; FTIR (film) max 3315, 2925, 1616, 1529, 
1476, 1454, 1421, 1359, 1304, 1188, 1081, 957, 900, 819, 724, 707, 694; LRMS 
(ES+) 1720.4 ([M+Na]+, 100%). 
 
N1,N1'-(butane-1,4-diyl)bis(N2,N2-dibenzylhydrazine-1,2-dicarboxamide) (52) 
 
Phenyl N,N-dibenzylaminocarbonylhydrazinecarboxylate (44) (750 mg, 2.0 mmol, 
2.0 eq.) and NEt3 (0.9 mL, 6.4 mmol, 6.4 eq.) were added to a stirred solution of 
1,4-diaminobutane (0.1 mL, 1.0 mmol, 1.0 eq.) in CHCl3 (50 mL). The reaction 
mixture was heated at reflux for 15 h. The reaction mixture was then concentrated 
under reduced pressure and purified by column chromatography on silica gel 
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using a DCM / MeOH (96 / 4) mixture as eluent to give the title product as a white 
solid (210 mg, 32%). m.p. 121 °C; FTIR (film) max 3272, 2937, 1673, 1634, 1530, 
1495, 1251, 1080, 967, 885, 756, 730, 696; 1H NMR (300 MHz, MeOD / CDCl3) δ 
7.44 – 7.03 (m, 20H, Ar, CH), 4.48 (s, 8H, CH2), 3.10 – 3.09 (m, 4H, CH2NH), 1.42 
– 1.41 (m, 4H, CH2); 13C NMR (75 MHz, MeOD / CDCl3) δ 161.3 (CON), 160.2 
(CON), 137.9 (Ar, C), 129.4 (Ar, CH), 128.3 (Ar, CH), 128.1 (Ar, CH), 50.4 (CH2), 
40.2 (CH2NH), 27.8 (CH2); HRMS (ES+) calculated for C36H42N8O4Na [M+Na]+ 
673.3227, found 673.3223. 
 
(1E,1'E)-N1,N1'-(butane-1,4-diyl)bis(N2,N2-dibenzyldiazene-1,2-dicarboxamide) 
(53) 
 
Pyridine (0.1 mL, 1.1 mmol, 2.2 eq.) and NBS (178 mg, 1.0 mmol, 2.0 eq.) were 
added to a solution of N1,N1'-(butane-1,4-diyl)bis(N2,N2-dibenzylhydrazine-1,2-
dicarboxamide) (52) (330 mg, 0.5 mmol, 1.0 eq.) in dry DCM (10 mL). The 
resulting solution was stirred for 1 h at RT. The reaction was then diluted with 
DCM (5 mL) and sequentially washed with water (2 x 10 mL), a saturated aqueous 
solution of Na2S2O3 (10 mL) and a saturated aqueous solution of NaHCO3 (2 x 10 
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mL). The organic phase was dried over anhydrous MgSO4, concentrated under 
reduced pressure and purified by column chromatography with DCM / MeOH (95 / 
5) as eluent to afford the title product (53) as a yellow oil (237 mg, 73%). FTIR 
(film) max 3281, 3031, 2936, 1686, 1524, 1495, 1425, 1361, 1219, 1157, 1081, 
1029, 732, 696; 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.10 (m, 20H, Ar, CH), 4.63 
(s, 4H, CH2), 4.49 (s, 4H, CH2), 3.45 – 3.46 (m, 4H, CH2NH), 1.69 – 1.68 (m, 4H, 
CH2); 13C NMR (100 MHz, CDCl3) δ 162.3 (CON), 160.2 (CON), 135.2 (Ar, C), 
128.9 (Ar, CH), 128.4 (Ar, CH), 128.2 (Ar, CH), 128.1 (Ar, CH), 127.8 (Ar, CH), 
49.2 (CH2), 49.1 (CH2), 40.5 (CH2NH), 26.4 (CH2); HRMS (ES+) calculated for 
C36H38N8O4Na [M+Na]+ 669.2914, found 669.2930. 
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(1E,1'E)-N1,N1'-(propane-1,3-diyl)bis(N2,N2-dibenzyldiazene-1,2-
dicarboxamide) [2]rotaxane (54) and (55) 
 
Et3N (5.0 mL, 35.3 mmol, 48.0 eq.) was added to a stirred solution of (1E,1'E)-
N1,N1'-(butane-1,4-diyl)bis(N2,N2-dibenzyldiazene-1,2-dicarboxamide) (53) 
(472 mg, 0.73 mmol, 1.0 eq.) in anhydrous CHCl3 (800 mL). The solution was 
stirred vigorously whilst solutions of p-xylylene diamine (2.4 g, 17.6 mmol, 
24.0 eq.) in anhydrous CHCl3 (126 mL) and isophthaloyl dichloride (3.6 g, 
17.6 mmol, 24.0 eq.) in anhydrous CHCl3 (126 mL) were simultaneously added 
over a period of 4 h using a motor-driven syringe pump. After a further 4 h period 
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the resulting suspension was filtered through a Celite® pad and the solvent 
removed under reduced pressure. The crude product was purified by HPLC to 
afford the azo [2]rotaxane (54) as a white solid (43 mg, 5%), the hydrazo 
[2]rotaxane (55) as a yellow solid (9 mg, 1%) and the azo [3]rotaxane (56) as a 
white solid (1 mg). HPLC (t = 0 → 60 min, 75 : 25 MeOH : H2O): Data for 
compound 54: Rt 27.30; m.p. 158 °C; FTIR (film) max 3307, 3043, 2939, 1693, 
1640, 1525, 1453, 1422, 1359, 1273, 1222, 1081, 1029, 759, 726, 694; 1H NMR 
(500 MHz, MeOD) δ 8.21 (s, 2H, Ar, CH, HC), 7.95 (dd, J = 7.8, 1.6 Hz, 4H, Ar, 
CH, HB), 7.47 (t, J = 7.8 Hz, 2H, Ar, CH, HA), 7.31 - 7.29 (m, 6H, Ar, CH), 7.21 - 
7.19 (m, 6H, Ar, CH), 7.15 - 7.14 (m, 4H, Ar, CH), 7.00 – 6.94 (m, 12H, 4 Ar, CH, 
8 Ar, CH, HE), 4.41 (s, 4H, CH2), 4.38 (s, 8H, CH2, HD), 4.33 (s, 4H, CH2), 3.42 - 
3.39 (m, 4H, CH2), 1.74 - 1.71 (m, 4H, CH2); 13C NMR (100 MHz, MeOD) δ 168.6 
(CON), 160.4 (CON), 137.7 (Ar, C), 136.2 (Ar, C), 135.6 (Ar, C), 134.7 (Ar, CH), 
134.6 (Ar, C), 131.7 (Ar, CH), 130.0 (Ar, CH), 129.7 (Ar, CH), 129.5 (Ar, CH), 
129.2 (Ar, CH), 129.1 (Ar, CH), 128.9 (Ar, CH), 128.4 (Ar, CH), 128.1 (Ar, CH), 
44.5 (CH2), 41.4 (CH2), 27.0 (CH2); HRMS (ES+) calculated for C68H66N12O8Na 
[M+Na]+ 1201.5024, found 1201.5077. Data for compound 55: Rt 23.78; m.p. 146 
°C; FTIR (film) max 3299, 1639, 1525, 1359, 1262, 1082, 697; 1H NMR (300 MHz, 
MeOD) δ 8.26 (s, 2H, Ar, CH, HC), 7.99 (dd, J = 7.7, 1.7 Hz, 4H, Ar, CH, HB), 7.51 
(t, J = 7.7 Hz, 2H, Ar, CH, HA), 7.35 – 7.12 (m, 16H, Ar, CH), 7.10 – 7.06 (m, 2H, 
Ar, CH), 7.00 (s, 8H, Ar, CH, HE), 6.92 – 6.85 (m, 2H, Ar, CH), 4.58 - 4.53 (m, 4H, 
CH2), 4.44 - 4.41 (m, 6H, CH2, HD), 4.32 – 4.23 (m, 6H, 2 CH2, HD, 4 CH2), 3.43 – 
3.38 (m, 2H, CH2), 3.21 - 3,16 (m, 2H, CH2), 1.73 – 1.61 (m, 2H, CH2), 1.56 - 1.48 
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(m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 168.5 (CON), 138.4 (Ar, C), 135.2 
(Ar, C), 132.2 (Ar, CH), 130.3 (Ar, CH), 130.1 (Ar, CH), 129.8 (Ar, CH), 129.7 (Ar, 
CH), 128.6 (Ar, CH), 128.3 (Ar, CH), 126.1 (Ar, CH), 50.5 (CH2), 44.9 (CH2), 29.1 
(CH2); HRMS (ES+) calculated for C68H68N12O8Na [M+Na]+ 1203.5181, found 
1203.5150. Data for compound 56: m.p. 108 °C; FTIR (film) max 3310, 2926, 
1645, 1530, 1421, 1359, 1297, 1267, 1082, 1021, 820, 700; LRMS (ES+) 1735.7 
([M+Na]+, 100%). 
 
N1,N1'-(pentane-1,5-diyl)bis(N2,N2-dibenzylhydrazine-1,2-dicarboxamide) (57) 
 
Phenyl N,N-dibenzylaminocarbonylhydrazinecarboxylate (44) (334 mg, 0.9 mmol, 
2.0 eq.) and NEt3 (0.4 mL, 2.9 mmol, 6.4 eq.) were added to a stirred solution of 
cadaverine (0.05 mL, 0.45 mmol, 1.0 eq.) in CHCl3 (25 mL). The reaction mixture 
was heated at reflux for 15 h. The reaction mixture was cooled, concentrated 
under reduced pressure and the crude product purified by column chromatography 
on silica gel using a DCM / MeOH (98 / 2) mixture as eluent to give the title 
product as a yellow oil (87 mg, 29%). FTIR (film) max 3267, 2929, 1632, 1535, 
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1495, 1453, 1407, 1240, 1081, 1029, 970, 888, 733, 697; 1H NMR (300 MHz, 
CDCl3) δ 7.30 – 7.17 (m, 20H, Ar, CH), 4.44 (s, 8H, CH2), 3.05 – 3.03 (m, 4H, 
CH2NH), 1.25 – 1.12 (m, 6H, CH2CH2CH2); 13C NMR (100 MHz, CDCl3) δ 160.1 
(CON), 159.6 (CON), 137.0 (Ar, C), 128.8 (Ar, CH), 127.5 (Ar, CH), 50.0 (CH2), 
39.4 (CH2), 28.9 (CH2), 23.1 (CH2); HRMS (ES+) calculated for C37H44N8O4Na 
[M+Na]+ 687.3383, found 687.3364. 
 
(1E,1'E)-N1,N1'-(pentane-1,5-diyl)bis(N2,N2-dibenzyldiazene-1,2-
dicarboxamide) (58) 
 
Pyridine (26 L, 0.3 mmol, 2.2 eq.) and NBS (54 mg, 0.3 mmol, 2.0 eq.) were 
added to a solution of N1,N1'-(pentane-1,5-diyl)bis(N2,N2-dibenzylhydrazine-1,2-
dicarboxamide) (57) (101 mg, 0.15 mmol, 1.0 eq.) in dry DCM (2 mL). The 
resulting solution was stirred for 1 h at RT. It was then diluted with DCM (1 mL) 
and sequentially washed with water (2 x 3 mL), a saturated aqueous solution of 
Na2S2O3 (3 mL) and saturated aqueous solution of NaHCO3 (2 x 3 mL). The 
organic phase was dried over anhydrous MgSO4, concentrated under reduced 
pressure and purified by column chromatography with DCM / MeOH (98 / 2) as 
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eluent to give the title product (58) as a yellow oil (86 mg, 87%). FTIR (film) max 
3281, 3031, 2936, 1686, 1524, 1495, 1425, 1361, 1219, 1157, 1081, 1029, 732, 
696; 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.04 (m, 20H, Ar, CH), 4.64 (s, 4H, CH2), 
4.49 (s, 4H, CH2), 3.46 – 3.40 (m, 4H, CH2NH), 1.73 – 1.63 (m, 4H, CH2CH2CH2), 
1.53 – 1.39 (m, 2H, CH2CH2CH2); 13C NMR (100 MHz, CDCl3) δ 162.5 (CON), 
160.0 (CON), 135.4 (Ar, C), 129.0 (Ar, CH), 128.6 (Ar, CH), 128.3 (Ar, CH), 128.2 
(Ar, CH), 127.8 (Ar, CH), 49.2 (CH2), 49.1 (CH2), 40.9 (CH2NH), 28.9 (CH2), 24.0 
(CH2); HRMS (ES+) calculated for C37H40N8O4Na [M+Na]+ 683.3070, found 
683.3078. 
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(1E,1'E)-N1,N1'-(pentane-1,5-diyl)bis(N2,N2-dibenzyldiazene-1,2-
dicarboxamide) [2]rotaxanes (59) and (60) and [3]rotaxane (61) 
 
Et3N (5.0 mL, 35.3 mmol, 48.0 eq.) was added to a stirred solution of (1E,1'E)-
N1,N1'-(pentane-1,5-diyl)bis(N2,N2-dibenzyldiazene-1,2-dicarboxamide) (58) 
(482 mg, 0.73 mmol, 1.0 eq.) in anhydrous CHCl3 (800 mL). The solution was 
stirred vigorously whilst solutions of p-xylylene diamine (2.4 g, 17.6 mmol, 
24.0 eq.) in anhydrous CHCl3 (126 mL) and isophthaloyl dichloride (3.6 g, 
17.6 mmol, 24.0 eq.) in anhydrous CHCl3 (126 mL) were simultaneously added 
over a period of 4 h using a motor-driven syringe pump. After a further 4 h period 
the resulting suspension was filtered through a Celite® pad and the solvent 
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removed under reduced pressure. The crude product was purified by HPLC to 
afford the azo [2]rotaxane (59) as a white solid (58 mg, 7%), the hydrazo 
[2]rotaxane (60) as a yellow solid (44 mg, 5%) and the azo [3]rotaxane (61) as a 
white solid (34 mg, 3%). HPLC (t = 0 → 60 min, 75 : 25 MeOH : H2O): Data for 
compound 59: Rt 20.47; m.p. 135 °C; FTIR (film) max 3286, 3063, 2926, 1637, 
1530, 1453, 1356, 1299, 1080, 965, 818, 729, 697; 1H NMR (400 MHz, MeOD) δ 
8.22 (br s, 2H, Ar, CH, HC), 7.98 - 7.96 (m, 4H, Ar, CH, HB), 7.49 (t, J = 7.8 Hz, 2H, 
Ar, CH, HA), 7.31 - 7.29 (m, 6H, Ar, CH), 7.23 - 7.21 (m, 6H, Ar, CH), 7.18 - 7.17 
(m, 4H, Ar, CH), 7.01 - 7.00 (m, 4H, Ar, CH), 6.99 (s, 8H, Ar, CH, HE), 4.45 - 4.39 
(m, 4H, CH2), 4.40 - 4.39 (m, 12H, 8 CH2, HD, 4 CH2), 3.35 - 3.31 (m, 4H, CH2), 
1.67 - 1.64 (m, 4H, CH2), 1.44 - 1.41 (m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 
168.5 (CON), 162.4 (CON), 161.6 (CONH), 138.5 (Ar, C), 136.9 (Ar, C), 136.4 (Ar, 
C), 135.2 (Ar, C), 132.2 (Ar, CH), 130.1 (Ar, CH), 129.9 (Ar, CH), 129.8 (Ar, CH), 
129.7 (Ar, CH), 129.2 (Ar, CH), 129.1 (Ar, CH), 128.6 (Ar, CH), 126.1 (Ar, CH), 
51.0 (CH2), 50.8 (CH2), 44.8 (CH2), 41.9 (CH2), 29.6 (CH2), 25.2 (CH2); HRMS 
(ES+) calculated for C69H68N12O8Na [M+Na]+ 1215.5181, found 1215.5200. Data 
for compound 60: Rt 17.52; m.p. 142 °C; FTIR (film) max 3286, 3063, 2926, 1637, 
1530, 1453, 1356, 1299, 1080, 965, 818, 729, 697; 1H NMR (400 MHz, MeOD) δ 
8.23 (br s, 2H, Ar, CH, HC), 7.99 - 7.97 (m, 4H, Ar, CH, HB), 7.50 (t, J = 7.8 Hz, 2H, 
Ar, CH, HA), 7.32 - 7.29 (m, 8H, Ar, CH), 7.22 - 7.15 (m, 8H, Ar, CH), 7.11 - 7.09 
(m, 2H, Ar, CH), 7.01 (s, 8H, Ar, CH, HE), 6.90 - 6.88 (m, 2H, Ar, CH), 4.53 - 4.26 
(m, 16H, 8 CH2, HD, 8 CH2), 3.22 - 3.19 (m, 2H, CH2), 3.05 - 3.02 (m, 2H, CH2), 
1.55 - 1.52 (m, 2H, CH2), 1.40 - 1.37 (m, 2H, CH2), 1.31 - 1.29 (m, 2H, CH2); 13C 
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NMR (100 MHz, MeOD) δ 168.5 (CON), 161.9 (CONH), 160.9 (CON), 160.6 
(CONH), 160.5 (CONH), 138.5 (Ar, C), 136.9 (Ar, C), 136.2 (Ar, C), 135.2 (Ar, C), 
132.2 (Ar, CH), 130.2 (Ar, CH), 130.1 (Ar, CH), 129.8 (Ar, CH), 129.7 (Ar, CH), 
129.3 (Ar, CH), 129.2 (Ar, CH), 129.1 (Ar, CH), 129.0 (Ar, CH), 128.6 (Ar, CH), 
128.4 (Ar, CH), 126.2 (Ar, CH), 51.3 (CH2), 51.1 (CH2), 50.5 (CH2), 44.8 (CH2), 
42.4 (CH2), 40.4 (CH2), 30.8 (CH2), 29.5 (CH2), 25.1 (CH2); LRMS (ES+) 1233.5 
([M+K]+, 31%), 1217.5 ([M+Na]+, 100%). Data for compound 61: Rt 40.17; m.p. 
168 °C; FTIR (film) max 3291, 3062, 2924, 1638, 1607, 1532, 1442, 1429, 1383, 
1360, 1294, 1187, 1080, 1034, 974, 950, 818, 753, 732, 698; 1H NMR (400 MHz, 
MeOD) δ 8.17 (br s, 4H, Ar, CH, HC), 7.94 - 7.92 (m, 8H, Ar, CH, HB), 7.45 (t, J = 
7.8 Hz, 4H, Ar, CH, HA), 7.28 - 7.27 (m, 6H, Ar, CH), 7.14 - 7.13 (m, 6H, Ar, CH), 
7.05 - 7.04 (m, 4H, Ar, CH), 6.98 (s, 16H, Ar, CH, HE), 6.81 - 6.80 (m, 4H, Ar, CH), 
4.46 - 4.29 (m, 16H, CH2, HD), 4.32 - 4.27 (m, 8H, CH2), 3.25 - 3.22 (m, 4H, CH2), 
1.65 - 1.62 (m, 4H, CH2), 1.37 - 1.36 (m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 
168.4 (CON), 160.5 (CON), 160.2 (CONH), 138.3 (Ar, C), 136.6 (Ar, C), 135.9 (Ar, 
C), 135.1 (Ar, C), 132.0 (Ar, CH), 130.1 (Ar, CH), 130.0 (Ar, CH), 129.7 (Ar, CH), 
129.6 (Ar, CH), 129.5 (Ar, CH), 129.2 (Ar, CH), 128.9 (Ar, CH), 128.1 (Ar, CH), 
126.0 (Ar, CH), 51.1 (CH2), 51.0 (CH2), 44.8 (CH2), 42.2 (CH2), 29.5 (CH2), 25.3 
(CH2); LRMS (ES+) 1763.8 ([M+K]+, 23%), 1747.8 ([M+Na]+, 100%). 
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4.4 Experimental for Section 2.4 
 
N1,N1,N6,N6-tetrabenzylfumaramide (62) 
 
Fumaryl chloride (0.5 mL, 4.6 mmol, 1.0 eq.) was dissolved in dry dichloromethane 
(20 mL) at RT. A solution of dibenzylamine (1.9 mL, 9.7 mmol, 2.1 eq.) and NEt3 
(1.4 mL, 10.0 mmol, 2.2 eq.) in dry dichloromethane (20 mL) was added using a 
syringe pump over a period of 1 h at 0 ºC. The reaction was stirred overnight and 
the solvent was removed in vacuo. The crude product was purified by column 
chromatography with EtOAc / pet (1 / 1) as eluent to afford N1,N1,N6,N6-
tetrabenzylfumaramide (62) as a white solid (1.35 g, 62%). m.p. 98 °C; FTIR (film) 
max 3034, 2923, 1723, 1621, 1493, 1440, 1357, 1315, 1269, 1181, 1080, 950, 
750, 695; 1H NMR (300 MHz, CDCl3) δ 7.61 (s, 2H, CH), 7.42 – 7.14 (m, 20H, Ar, 
CH), 4.65 (s, 4H, CH2), 4.59 (s, 4H, CH2); 13C NMR (100 MHz, CDCl3) δ 166.0 
(CO), 136.8 (Ar, C), 136.1 (Ar, C), 132.5 (CH), 129.1 (Ar, CH), 128.8 (Ar, CH), 
128.5 (Ar, CH), 128.0 (Ar, CH), 127.8 (Ar, CH), 126.9 (Ar, CH), 50.2 (CH2), 48.7 
(CH2); HRMS (ES+) calculated for C32H30N2O2Na [M+Na]+ 497.2205, found 
497.2220. 
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N1,N1,N6,N6-tetrabenzylfumaramide [2]rotaxane (63) 
 
Et3N (6.7 mL, 48.0 mmol, 24.0 eq.) was added to a stirred solution of N1,N1,N6,N6-
tetrabenzylfumaramide (62) (1.3 g, 2.6 mmol, 1.0 eq.) in anhydrous CHCl3 
(1000 mL). The solution was stirred vigorously whilst solutions of p-xylylene 
diamine (3.27 g, 24.0 mmol, 12.0 eq.) in anhydrous CHCl3 (95 mL) and 
isophthaloyl dichloride (4.88 g, 24.0 mmol, 12.0 eq.) in anhydrous CHCl3 (95 mL) 
were simultaneously added over a period of 4 h using a motor-driven syringe 
pump. After a further 4 h period the resulting suspension was filtered through a 
Celite® pad and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography with CHCl3 / MeOH (96 / 4) as eluent to 
afford N1,N1,N6,N6-tetrabenzylfumaramide [2]rotaxane (63) as a white solid (2.22 
g, 84%). m.p. 182 °C; FTIR (film) max 3347, 3030, 1656, 1600, 1525, 1476, 1434, 
1363, 1284, 1265, 1195, 1079, 946, 822, 729, 698; 1H NMR (300 MHz, CDCl3) δ 
8.43 (s, 2H, Ar, CH, HC), 8.25 (dd, J = 7.8, 1.4 Hz, 4H, Ar, CH, HB), 7.56 (t, J = 7.8 
Hz, 2H, Ar, CH, HA), 7.39 – 7.27 (m, 10H, Ar, CH), 7.16 (d, J = 7.4 Hz, 2H, Ar, 
CH), 7.05 (t, J = 7.4 Hz, 4H, Ar, CH), 6.76 (d, J = 7.4 Hz, 4H, Ar, CH), 6.71 (s, 8H, 
Ar, CH, HE), 6.04 (s, 2H, CH), 5.09 (br s, 4H, CH2, HD), 4.49 (s, 4H, CH2), 4.31 (s, 
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4H, CH2), 3.52 – 3.40 (m, 4H, CH2, HD); 13C NMR (100 MHz, CDCl3) δ 166.1 
(CON), 165.4 (CON), 138.0 (Ar, C), 135.7 (Ar, C), 134.4 (CH), 133.4 (CH), 132.3 
(Ar, CH), 130.0 (Ar, CH), 129.9 (Ar, CH), 129.5 (Ar, CH), 129.2 (Ar, CH), 128.5 
(Ar, CH), 125.8 (Ar, CH), 122.2 (Ar, CH), 51.9 (CH2), 51.6 (CH2), 43.4 (CH2); 
HRMS (ES+) calculated for C64H58N6O6Na [M+Na]+ 1029.4316, found 1029.4349. 
 
(E)-ethyl 4-(dibenzylamino)-4-oxobut-2-enoate (64) 
 
Ethyl fumaroyl chloride (400 mg, 2.5 mmol, 1.0 eq.) was dissolved in dry DCM 
(25 mL) at RT. A solution of dibenzylamine (0.47 mL, 2.5 mmol, 1.0 eq.) and NEt3 
(0.35 mL, 2.5 mmol, 1.0 eq.) in dry DCM (25 mL) was added using a syringe pump 
over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
CHCl3 / MeOH (98 / 2) as eluent to afford (E)-ethyl 4-(dibenzylamino)-4-oxobut-2-
enoate (64) as a yellow solid (779 mg, 98%). m.p. 98 °C; FTIR (film) max 3030, 
2982, 1938, 1880, 1719, 1654, 1627, 1432, 1285, 1159, 1082, 1027, 970, 740, 
694; 1H NMR (300 MHz, CDCl3) δ 7.33 (d, J = 15.2 Hz, 1H, CH), 7.23 – 6.96 (m, 
10H, Ar, CH), 6.82 (d, J = 15.2 Hz, 1H, CH), 4.49 (s, 2H, CH2), 4.36 (s, 2H, CH2), 
4.04 (q, J = 7.1 Hz, 2H, OCH2), 1.11 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, 
CDCl3) δ 165.5 (COO), 165.3 (CONH), 136.7 (Ar, C), 136.0 (Ar, C), 133.8 (CH), 
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132.2 (CH), 129.0 (Ar, CH), 128.7 (Ar, CH), 128.4 (Ar, CH), 128.3 (Ar, CH), 128.0 
(Ar, CH), 127.7 (Ar, CH), 127.6 (Ar, CH), 126.7 (Ar, CH), 61.1 (CH2), 50.2 (CH2), 
48.5 (CH2), 14.2 (CH3); HRMS (ES+) calculated for C20H21NO3Na [M+Na]+ 
346.1419, found 346.1429. 
 
(E)-4-(dibenzylamino)-4-oxobut-2-enoic acid (65) 
 
(E)-ethyl 4-(dibenzylamino)-4-oxobut-2-enoate (64) (468 mg, 1.45 mmol, 1.0 eq.) 
was dissolved in EtOH (50 mL). A solution of NaOH (70 mg, 1.74 mmol, 1.2 eq.) in 
water (2.5 mL) was added dropwise. The reaction mixture was stirred for 8 h at 
RT. The reaction mixture was then acidified with 1 M HCl (10 mL), extracted with 
DCM (3 x 20 mL) and washed with brine (20 mL). The organic layers were 
combined, dried over MgSO4 and concentrated under reduced pressure to afford 
(E)-4-(dibenzylamino)-4-oxobut-2-enoic acid (65) (427 mg, 99%) as a white solid. 
m.p. 174 °C; FTIR (film) max 3031, 2928, 1607, 1572, 1448, 1401, 1367, 1244, 
1169, 1080, 1027, 978, 780, 695; 1H NMR (300 MHz, d6-DMSO) δ 7.36 – 7.14 (m, 
10H, Ar, CH), 6.94 (d, J = 15.1 Hz, 1H, CH), 6.69 (d, J = 15.1 Hz, 1H, CH), 4.58 (s, 
2H, CH2), 4.52 (s, 2H, CH2); 13C NMR (100 MHz, d6-DMSO) δ 169.7 (COO), 167.3 
(CON), 143.2 (CH), 137.5 (Ar, C), 129.1 (Ar, CH), 128.7 (Ar, CH), 128.1 (Ar, CH), 
127.8 (Ar, CH), 127.7 (Ar, CH), 127.6 (Ar, CH), 126.9 (Ar, CH), 126.0 (Ar, CH), 
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50.4 (CH2), 48.8 (CH2); HRMS (ES+) calculated for C18H17NO3Na2 [M+2Na]+ 
340.0926, found 340.0932. 
 
(E)-N1,N1'-(ethane-1,2-diyl)bis(N6,N6-dibenzylfumaramide) (66) 
 
(E)-4-(dibenzylamino)-4-oxobut-2-enoic acid (65) (300 mg, 1.0 mmol, 3.2 eq.) and 
thionyl chloride (1 mL) were dissolved in THF (10 mL) and heated at reflux for 3 h. 
The crude acid chloride formed was evaporated to dryness and the resulting 
residue was dissolved in CHCl3 (10 mL) and cooled to 0°C. NEt3 (0.26 mL, 
1.9 mmol, 6.4 eq.) and ethylenediamine (32 L, 0.3 mmol, 1.0 eq.) were added 
using a motor-driven syringe pump over a period of 2 h. The reaction was stirred 
overnight and the solvent was removed in vacuo. The crude product was purified 
by column chromatography with CHCl3 / MeOH (95 / 5) as eluent to give the title 
product as a yellow solid (121 mg, 66%). m.p. 168 °C; FTIR (film) max 3294, 3063, 
1614, 1539, 1495, 1427, 1295, 1186, 1080, 1029, 966, 729, 695; 1H NMR 
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(300 MHz, CDCl3) δ 7.34 – 6.96 (m, 20H, Ar, CH, 4H, CH), 4.49 (s, 4H CH2), 4.43 
(s, 4H, CH2), 3.17 (s, 4H, CH2); 13C NMR (100 MHz, CDCl3) δ 166.2 (CON), 165.1 
(CON), 136.6 (Ar, C), 135.9 (CH), 135.7 (CH), 129.8 (Ar, CH), 128.9 (Ar, CH), 
128.1 (Ar, CH), 127.7 (Ar, CH), 126.9 (Ar, CH), 50.5 (CH2), 48.7 (CH2), 39.9 (CH2); 
HRMS (ES+) calculated for C38H38N4O4Na [M+Na]+ 637.2791, found 637.2794. 
 
(E)-N1,N1'-(ethane-1,2-diyl)bis(N6,N6-dibenzylfumaramide) [3]rotaxane (67) 
 
Et3N (1.3 mL, 9.5 mmol, 48.0 eq.) was added to a stirred solution of (E)-N1,N1'-
(ethane-1,2-diyl)bis(N6,N6-dibenzylfumaramide) (66) (121 mg, 0.2 mmol, 1.0 eq.) 
in anhydrous CHCl3 (100 mL). The solution was stirred vigorously whilst solutions 
of p-xylylene diamine (643 mg, 4.7 mmol, 24.0 eq.) in anhydrous CHCl3 (20 mL) 
and isophthaloyl dichloride (960 mg, 4.7 mmol, 24.0 eq.) in anhydrous CHCl3 
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(20 mL) were simultaneously added over a period of 3 h using a motor-driven 
syringe pump. After a further 4 h period the resulting suspension was filtered 
through a Celite® pad and the solvent removed under reduced pressure. The 
crude product was purified by HPLC to afford (E)-N1,N1'-(ethane-1,2-diyl)bis(N6,N6-
dibenzylfumaramide) [3]rotaxane (67) as a white solid (25 mg, 8%). HPLC (t = 0 → 
60 min, 85 : 15 MeOH : H2O): Rt 42.45; m.p. 176 °C; FTIR (film) max 3300, 3064, 
1637, 1601, 1529, 1464, 1423, 1353, 1274, 1079, 956, 818, 753, 729, 695; 1H 
NMR (400 MHz, d6-DMSO) δ 8.69 (s, 2H, NH), 8.42 (s, 4H, Ar, CH, HC), 8.01 – 
7.92 (m, 16H, 8 Ar, CH, HB, 8 NH), 7.54 (t, J = 7.7 Hz, 4H, Ar, CH, HA), 7.30 – 7.25 
(m, 6H, Ar, CH), 7.16 – 7.11 (m, 4H, Ar, CH), 6.98 – 6.91 (m, 6H, Ar, CH), 6.87 (s, 
16H, Ar, CH, HE), 6.69 (d, J = 7.2 Hz, 4H, Ar, CH), 6.00 – 5.88 (m, 4H, CH), 4.40 – 
4.24 (m, 16H, CH2, HD), 4.08 (dd, J = 13.9, 4.0 Hz, 8H, CH2), 3.10 (br s, 4H, CH2); 
13C NMR (100 MHz, d6-DMSO) δ 165.3 (CON), 165.2 (CON), 164.9 (CON), 136.9 
(Ar, C), 136.0 (Ar, C), 133.7 (Ar, C), 132.9 (CH), 130.8 (CH), 128.5 (Ar, CH), 128.3 
(Ar, CH), 127.5 (Ar, CH), 127.1 (Ar, CH), 126.0 (Ar, CH), 125.5 (Ar, CH), 124.0 
(Ar, CH), 50.7 (CH2), 50.3 (CH2), 43.0 (CH2), 37.7 (CH2); HRMS (ES+) calculated 
for C102H94N12O12Na [M+Na]+ 1701.7012, found 1701.7054. 
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(E)-N1,N1'-(propane-1,3-diyl)bis(N6,N6-dibenzylfumaramide) (68) 
 
(E)-4-(dibenzylamino)-4-oxobut-2-enoic acid (65) (300 mg, 1.0 mmol, 3.2 eq.) and 
thionyl chloride (1 mL) were dissolved in THF (10 mL) and heated at reflux for 3 h. 
The crude acid chloride formed was evaporated to dryness and the resulting 
residue was dissolved in CHCl3 (10 mL) and cooled to 0 °C. NEt3 (0.26 mL, 
1.9 mmol, 6.4 eq.) and 1,3-diaminopropane (32 L, 0.3 mmol, 1.0 eq.) were added 
using a motor-driven syringe pump over a period of 2 h. The reaction was stirred 
overnight and the solvent was removed in vacuo. The crude product was purified 
by column chromatography with CHCl3 / MeOH (95 / 5) as eluent to give the title 
product as a yellow solid (79 mg, 42%). m.p. 146 °C; FTIR (film) max 3296, 3064, 
3030, 2926, 1612, 1545, 1495, 1428, 1358, 1310, 1186, 1080, 1029, 964; 1H NMR 
(300 MHz, CDCl3) δ 7.41 – 7.00 (m, 24H, 20 Ar, CH, 4 CH), 4.56 - 4.48 (m, 8H, 
CH2), 3.31 - 3.16 (m, 4H, CH2), 1.55 (s, 2H, CH2); 13C NMR (100 MHz, CDCl3) δ 
166.1 (CON), 164.8 (CON), 136.7 (Ar, C), 136.0 (CH), 129.9 (Ar, CH), 128. 9 (Ar, 
CH), 128.1 (Ar, CH), 127.8 (Ar, CH), 126.9 (Ar, CH), 50.4 (CH2), 48.7 (CH2), 36.4 
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(CH2), 29.5 (CH2); HRMS (ES+) calculated for C39H40N4O4Na [M+Na]+ 651.2947, 
found 651.2946. 
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6,N6-dibenzylfumaramide) [3]rotaxane (69) 
 
Et3N (0.87 mL, 6.24 mmol, 48.0 eq.) was added to a stirred solution of (E)-N1,N1'-
(propane-1,3-diyl)bis(N6,N6-dibenzylfumaramide) (68) (79 mg, 0.13 mmol, 1.0 eq.) 
in anhydrous CHCl3 (100 mL). The solution was stirred vigorously whilst solutions 
of p-xylylene diamine (424 mg, 3.12 mmol, 24.0 eq.) in anhydrous CHCl3 (20 mL) 
and isophthaloyl dichloride (633 mg, 3.12 mmol, 24.0 eq.) in anhydrous CHCl3 
(20 mL) were simultaneously added over a period of 3 h using a motor-driven 
syringe pump. After a further 4 h period the resulting suspension was filtered 
through a Celite® pad and the solvent removed under reduced pressure. The 
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crude product was purified by HPLC to afford (E)-N1,N1'-(propane-1,3-
diyl)bis(N6,N6-dibenzylfumaramide) [3]rotaxane (69) as a white solid (37 mg, 17%). 
HPLC (t = 0 → 60 min, 85 : 15 MeOH : H2O): Rt 46.96; m.p. 187 °C; FTIR (film) 
max 3285, 3061, 2922, 1640, 1528, 1476, 1421, 1358, 1299, 1192, 1080, 1022, 
959, 820, 695; 1H NMR (400 MHz, d6-DMSO) δ 8.48 (s, 1H, NH), 8.38 (s, 4H, Ar, 
CH, HC), 7.97 – 7.99 (m, 12H, 8 Ar, CH, HB, 4 NH), 7.56 (t, J = 7.7 Hz, 4H, Ar, CH, 
HA), 7.25 – 7.26 (m, 6H, Ar, CH), 7.11 – 7.12 (m, 4H, Ar, CH), 7.02 – 6.93 (m, 6H, 
Ar, CH), 6.86 (s, 16H, Ar, CH, HE), 6.71 – 6.73 (m, 4H, Ar, CH), 6.00 – 5.82 (m, 
4H, CH), 4.33 (dd, J = 21.1, 14.1 Hz, 16H, CH2, HD), 4.09 (d, J = 13.9 Hz, 8H, 
CH2), 3.11 - 3.15 (m, 4H, CH2), 1.71 – 1.62 (m, 2H, CH2); 13C NMR (100 MHz, d6-
DMSO) δ 165.3 (CON), 165.2 (CON), 165.1 (CON), 165.0 (CON), 136.7 (Ar, C), 
135.8 (Ar, C), 133.7 (Ar, C), 133.1 (CH), 130.7 (CH), 128.9 (Ar, CH), 128.5 (Ar, 
CH), 128.2 (Ar, CH), 127.5 (Ar, CH), 127.1 (Ar, CH), 125.6 (Ar, CH), 124.2 (Ar, 
CH), 50.7 (CH2), 50.2 (CH2), 43.1 (CH2), 37.6 (CH2), 28.4 (CH2); HRMS (ES+) 
calculated for C103H96N12O12Na [M+Na]+ 1715.7168, found 1715.7144.  
 
(E)-ethyl 4-(benzyl(phenyl)amino)-4-oxobut-2-enoate (70)81 
 
Ethyl fumaroyl chloride (3.2 g, 20.0 mmol, 1.2 eq.) was dissolved in dry DCM 
(100 mL) at RT. A solution of N-benzylaniline (3.0 g, 16.7 mmol, 1.0 eq.) and NEt3 
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(2.8 mL, 20.0 mmol, 1.2 eq.) in dry DCM (25 mL) was added using a syringe pump 
over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
hexane / EtOAc (9 / 1) as eluent to afford (E)-ethyl 4-(benzyl(phenyl)amino)-4-
oxobut-2-enoate (70) as a yellow oil (4.37 g, 85%).1H NMR (300 MHz, CDCl3) δ 
7.30 – 7.03 (m, 8H, Ar, CH), 6.95 – 6.65 (m, 4H, 2 Ar, CH, 2 CH), 4.87 (s, 2H, 
CH2), 4.00 (q, J = 7.1 Hz, 2H, OCH2), 1.08 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 
MHz, CDCl3) δ 165.4 (COO), 163.8 (CON), 141.0 (Ar, C), 136.8 (Ar, C), 134.3 
(CH), 131.4 (CH), 129.7 (Ar, CH), 128.7 (Ar, CH), 128.4 (Ar, CH), 128.3 (Ar, CH), 
128.0 (Ar, CH), 127.5 (Ar, CH), 60.9 (CH2), 53.4 (CH2), 14.0 (CH3); HRMS (ES+) 
calculated for  C19H19NO3Na [M+Na]+ 332.1263, found 332.1262. 
Data were in agreement with those previously reported.81 
 
(E)-4-(benzyl(phenyl)amino)-4-oxobut-2-enoic acid (71)81 
 
A solution of LiOH·H2O (1.2 g, 28.0 mmol, 8.0 eq.) in water (29 mL) was added to 
a solution of (E)-ethyl4-(benzyl(phenyl)amino)-4-oxobut-2-enoate (70) (4.3 g, 
14.0 mmol, 4.0 eq.) in THF (87 mL) at RT. After 36 h, the reaction mixture was 
poured into 1 M HCl (60 mL). The aqueous layer was extracted with EtOAc (3 x 
80 mL) and the combined fractions were dried over MgSO4 and concentrated 
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under reduced pressure. The crude product was recrystallised from hexane / Et2O 
/ DCM (29 / 70 / 1) to afford title product as a white solid (2.7 g, 68%). m.p. 95 °C 
[lit. 95 - 98 °C]81; 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.17 (m, 8H, Ar, CH), 7.03 - 
6.93 (m, 2H, Ar, CH), 6.94 – 6.80 (m, 2H, CH), 5.00 (s, 2H, CH2); 13C NMR (100 
MHz, CDCl3) δ 169.4 (COO), 163.8 (CON), 141.0 (Ar, C), 136.4 (Ar, C), 130.4 
(CH), 129.9 (Ar, CH), 128.9 (Ar, CH), 128.6 (Ar, CH), 128.2 (Ar, CH), 127.8 (Ar, 
CH), 53.7 (CH2); LRMS (ES-) 280.1 ([M-H]-, 100%). 
Data were in agreement with those previously reported.81 
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6-benzyl-N6-phenylfumaramide) (72) 
 
(E)-4-(benzyl(phenyl)amino)-4-oxobut-2-enonic acid (71) (2.7 g, 9.5 mmol, 4.8 eq.) 
and thionyl chloride (10 mL) were heated for 3 h at reflux. The crude acid chloride 
formed was evaporated to dryness and the resulting residue was dissolved in 
DCM (50 mL). The mixture was cooled to 0 °C. NEt3 (1.32 mL, 9.5 mmol, 4.8 eq.) 
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and 1,3-diaminopropane (290 L, 2.0 mmol, 1.0 eq.) were added using a syringe 
pump over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
EtOAc / pet (1 / 1) as eluent to give the title product as a white solid (1.0 g, 84%). 
m.p. 128 °C; FTIR (film) max 3228, 3062, 2930, 1628, 1593, 1558, 1493, 1391, 
1327, 1191, 970, 751, 694; 1H NMR (400 MHz, MeOD / CDCl3) δ 7.37 – 7.30 (m, 
6H, Ar, CH), 7.25 – 7.19 (m, 6H, Ar, CH), 7.17 – 7.13 (m, 4H, Ar, CH), 7.03 – 6.97 
(m, 4H, Ar, CH), 6.89 (d, J = 15.0 Hz, 2H, CH), 6.71 (d, J = 15.0 Hz, 2H, CH), 4.97 
(s, 4H, CH2), 3.18 (t, J = 6.8 Hz, 4H, CH2CH2NH), 1.68 – 1.61 (m, 2H, CH2); 13C 
NMR (100 MHz, MeOD / CDCl3) δ 166.5 (CO), 142.2 (Ar, C), 137.9 (Ar, C), 135.6 
(CH), 131.8 (CH), 131.0 (Ar, CH), 129.9 (Ar, CH), 129.7 (Ar, CH), 129.4 (Ar, CH), 
128.9 (Ar, CH), 54.8 (CH2), 38.2 (CH2), 29.9 (CH2); HRMS (ES+) calculated for 
C37H36N4O4Na [M+Na]+ 623.2634, found 623.2629. 
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(E)-N1,N1'-(propane-1,3-diyl)bis(N6-benzyl-N6-phenylfumaramide) [2]rotaxane 
(74) and [3]rotaxane (73) 
 
Et3N (0.7 mL, 4.8 mmol, 48.0 eq.) was added to a stirred solution of (E)-N1,N1'-
(propane-1,3-diyl)bis(N6-benzyl-N6-phenylfumaramide) (72) (60 mg, 0.1 mmol, 
1.0 eq.) in anhydrous CHCl3 (30 mL). The solution was stirred vigorously whilst 
solutions of p-xylylene diamine (327 mg, 2.4 mmol, 24.0 eq.) in anhydrous CHCl3 
(10 mL) and isophthaloyl dichloride (487 mg, 2.4 mmol, 24.0 eq.) in anhydrous 
CHCl3 (10 mL) were simultaneously added over a period of 4 h using a motor-
driven syringe pump. After a further 4 h period the resulting suspension was 
filtered through a Celite® pad and the solvent removed under reduced pressure. 
The crude product was purified by column chromatography with EtOAc / MeOH (9 
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/ 1) as eluent to give the [3]rotaxane (73) as a white solid (67 mg, 40%) and the 
[2]rotaxane (74) as a white solid (3 mg, 2%). Data for compound 74: m.p. 162 °C; 
FTIR (film) max 3301, 3063, 2929, 1639, 1534, 1493, 1420, 1296, 1188, 1110, 
1080, 967, 820, 696; 1H NMR (400 MHz, MeOD / CDCl3) δ 8.34 (br s, 2H, Ar, CH, 
HC), 8.22 – 8.14 (m, 5H, 4 Ar, CH, HB, 1 NH), 7.64 (t, J = 7.8 Hz, 2H, Ar, CH, HA), 
7.27 – 7.16 (m, 6H, Ar, CH), 7.09 – 7.00 (m, 8H, Ar, CH), 6.95 (s, 8H, Ar, CH, HE), 
6.84 (d, J = 8.0 Hz, 6H, Ar, CH), 6.31 (d, J = 14.8 Hz, 2H, CH), 6.04 (d, J = 14.8 
Hz, 2H, CH), 4.77 (s, 4H, CH2), 4.32 (s, 8H, CH2, HD), 3.21 (t, J = 6.8 Hz, 4H, 
CH2CH2NH), 1.74 – 1.66 (m, 2H, CH2); 13C NMR (100 MHz, MeOD / CDCl3) δ 
166.8 (CO), 165.7 (CO), 165.1 (CO), 140.6 (Ar, C), 137.4 (Ar, C), 136.4 (Ar, C), 
134.2 (CH), 133.7 (Ar, C), 133.4 (CH), 131.9 (Ar, CH), 129.8 (Ar, CH), 129.6 (Ar, 
CH), 129.4 (Ar, CH), 129.2 (Ar, CH), 128.9 (Ar, CH), 128.7 (Ar, CH), 128.2 (Ar, 
CH), 127.9 (Ar, CH), 124.2 (Ar, CH), 54.3 (CH2), 43.9 (CH2), 37.3 (CH2CH2NH), 
29.0 (CH2); HRMS (ES+) calculated for C69H64N8O8Na [M+Na]+ 1155.4745, found 
1155.4785. Data for compound 73: m.p. 178 °C; FTIR (film) max 3283, 3066, 
2926, 1639, 1609, 1588, 1530, 1495, 1415, 1305, 1272, 1174, 1079, 960, 698; 1H 
NMR (400 MHz, d2-DCM / MeOD) δ 8.30 (br s, 4H, Ar, CH, HC), 8.13 (dd, J = 7.8, 
1.7 Hz, 8H, Ar, CH, HB), 7.64 (t, J = 7.8 Hz, 4H, Ar, CH, HA), 7.30 – 7.20 (m, 7H, 
Ar, CH), 7.04 – 6.95 (m, 21H, 16 Ar, CH, HE, 5 m, Ar, CH), 6.88 (t, J = 7.8 Hz, 4H, 
Ar, CH), 6.81 – 6.75 (m, 4H, Ar, CH), 6.44 (br s, 2H, NH), 5.86 (d, J = 14.9 Hz, 2H, 
CH), 5.46 (d, J = 14.9 Hz, 2H, CH), 4.66 (s, 4H, CH2), 4.39 (d, J = 14.2 Hz, 8H, 
CH2, HD), 4.22 (d, J = 14.2 Hz, 8H, CH2, HD), 3.31 – 3.24 (m, 4H, CH2CH2NH), 
1.91 – 1.75 (m, 2H, CH2); 13C NMR (100 MHz, d2-DCM / MeOD) δ 167.3 (CO), 
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166.5 (CO), 165.4 (CO), 140.8 (Ar, C), 137.9 (Ar, C), 136.8 (Ar, C), 134.3 (Ar, C), 
133.0 (CH), 132.1 (CH), 130.0 (Ar, CH), 129.9 (Ar, CH), 129.8 (Ar, CH), 129.7 (Ar, 
CH), 129.1 (Ar, CH), 129.0 (Ar, CH), 128.7 (Ar, CH), 128.1 (Ar, CH), 127.7 (Ar, 
CH), 124.9 (Ar, CH), 55.0 (CH2), 44.2 (CH2), 38.6 (CH2CH2NH), 29.5 (CH2); LRMS 
(ES+) 1688.8 ([M+Na]+, 25%), 855.9 ([M+2Na]2+, 100%). 
 
4.5 Experimental for Section 2.5 
 
N,N,N’,N’-tetrakis(2,2-diphenylethyl)-1,2-hydrazodicarboxamide [2]rotaxane 
(77) 
 
A solution of borane (10.0 mL, 10.0 mmol, 147.0 eq.) in THF was added to 
rotaxane 41 (69 mg, 0.07 mmol, 1.0 eq.) and the mixture was refluxed for 24 h. 
Water (5 mL) was added to quench the excess of borane and the mixture was 
evaporated to dryness. 6 M HCl (2 mL) was added to the residue. The reaction 
mixture was heated at reflux for 6 h, then made alkaline with aqueous 10% NaOH 
(10 mL) and extracted with DCM (3 x 20 mL). The combined organic fractions 
were washed with water (50 mL), dried over MgSO4 and evaporated to dryness. 
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The crude product was purified by column chromatography with CHCl3 / MeOH (90 
/ 10) as eluent to afford the title compound (77) as a white solid (23 mg, 36%). 
m.p. 126 °C; FTIR (film) max 2924, 2852, 1645, 1495, 1452, 1231, 1077, 1028, 
964, 805, 736, 697; 1H NMR (400 MHz, MeOD / CDCl3) δ 7.32 – 7.17 (m, 20H, Ar, 
CH), 7.02 (br s, 8H, Ar, CH), 6.96 – 6.88 (m, 8H, Ar, CH), 4.21 (br s, 8H, CH2), 
3.83 (br s, 8H, CH2NH), 3.75 (br s, 8H, CH2NH); 13C NMR (100 MHz, MeOD / 
CDCl3) δ 158.5 (CON), 137.1 (Ar, C), 129.7 (Ar, CH), 129.5 (Ar, CH), 129.1 (Ar, 
CH), 128.1 (Ar, CH), 127.8 (Ar, CH), 53.8 (CH2), 53.7 (CH2), 50.7 (CH2); HRMS 
(ES+) calculated for C62H67N8O2 [M+H]+ 955.5387, found 955.5370. 
 
(E)-ethyl 4-(diphenylamino)-4-oxobut-2-enoate (81) 
 
Ethyl fumaroyl chloride (972 mg, 6.0 mmol, 1.2 eq.) was dissolved in dry DCM 
(20 mL) at RT. A solution of diphenylamine (845 mg, 5.0 mmol, 1.0 eq.) and NEt3 
(0.84 mL, 6.0 mmol, 1.2 eq.) in dry DCM (5 mL) was added using a syringe pump 
over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
pet / EtOAc (8 / 2) as eluent to afford (E)-ethyl 4-(diphenylamino)-4-oxobut-2-
enoate (81) as a yellow oil (1.12 g, 76%). FTIR (film) max 3060, 2980, 1716, 1667, 
1640, 1590, 1489, 1346, 1295, 1189, 1150, 1025, 970, 760, 692; 1H NMR (300 
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MHz, CDCl3) δ 7.51 (s, 5H, Ar, CH), 7.18 – 6.96 (m, 5H, Ar, CH), 6.96 – 6.89 (m, 
2H, CH), 4.20 (q, J = 7.1 Hz, 2H, OCH2), 1.27 (t, J = 7.1 Hz, 3H, CH3); 13C NMR 
(100 MHz, CDCl3) δ 165.7 (COO), 164.2 (CON), 143.2 (Ar, C), 142.7 (Ar, C), 
135.4 (CH), 131.8 (CH), 129.9 (Ar, CH), 129.2 (Ar, CH), 128.4 (Ar, CH), 126.4 (Ar, 
CH), 61.2 (CH2), 14.2 (CH3); HRMS (ES+) calculated for C18H17NO3Na [M+Na]+ 
318.1106, found 318.1107. 
 
(E)-4-(diphenylamino)-4-oxobut-2-enoic acid (82) 
 
LiOH·H2O (313 mg, 7.5 mmol, 2.0 eq.) in water (9 mL) was added to a solution of 
(E)-ethyl 4-(diphenylamino)-4-oxobut-2-enoate (81) (1.1 g, 3.7 mmol, 1.0 eq.) in 
THF (38 mL) at RT. After 36 h, the reaction mixture was poured into 1 M HCl 
(18 mL). The aqueous layer was extracted with EtOAc (3 x 24 mL) and the 
combined organic fractions were dried over MgSO4 and concentrated under 
reduced pressure. The crude product was recrystallised from hexane / Et2O / DCM 
(29 / 70 / 1) to afford title product as a white solid (680 mg, 68%). m.p. 178 °C; 
FTIR (film) νmax 3061, 1717, 1656, 1616, 1589, 1452, 1374, 1282, 1254, 1180, 
1155, 1075, 974, 861, 797, 756, 693; 1H NMR (300 MHz, CDCl3) δ 10.25 (s, 1H, 
OH), 7.47 - 7.35 (m, 5H, Ar, CH), 7.30 - 7.21 (m, 5H, Ar, CH), 7.03 (d, J = 15.3 Hz, 
1H, CH), 6.92 (d, J = 15.3 Hz, 1H, CH); 13C NMR (100 MHz, CDCl3) δ 170.1 
(COO), 164.1 (CON), 142.0 (Ar, C), 141.5 (Ar, C), 137.1 (CH), 130.9 (CH), 130.0 
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(Ar, CH), 129.2 (Ar, CH), 128.4 (Ar, CH), 126.9 (Ar, CH), 126.4 (Ar, CH); HRMS 
(ES-) calculated for C16H12NO3 [M-H]- 266.0817, found 266.0815. 
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6 ,N6-diphenylfumaramide) (83) 
 
(E)-4-(diphenylamino)-4-oxobut-2-enoic acid (82) (643 mg, 2.4 mmol, 2.4 eq.) was 
dissolved in toluene (5 mL). Thionyl chloride (1.2 mL) was added and the mixture 
was heated at reflux for 3 h. The crude acid chloride formed was evaporated to 
dryness, the resulting residue was dissolved in DCM (10 mL) and the mixture was 
cooled to 0°C. NEt3 (0.3 mL, 2.2 mmol, 2.2 eq.) and 1,3-diaminopropane (84 L, 
1.0 mmol, 1.0 eq.) were added using a syringe pump over a period of 2 h. The 
reaction was stirred overnight and the solvent was removed in vacuo. The crude 
product was purified by column chromatography with EtOAc / pet (9 / 1) as eluent 
to give the title product as a white solid (242 mg, 42%). m.p. 241 °C; FTIR (film) 
max 3321, 3059, 2932, 1631, 1593, 1539, 1490, 1357, 1206, 1159, 1075, 974, 
763, 698; 1H NMR (400 MHz, MeOD) δ 7.37 (s, 10H, Ar, CH), 7.24 – 7.22 (m, 10H, 
Ar, CH), 7.01 (d, J = 14.9 Hz, 2H, CH), 6.90 (d, J = 14.9 Hz, 2H, CH), 3.20 – 3.16 
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(m, 4H, CH2), 1.62 – 1.59 (m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 165.6 (CO), 
165.3 (CO), 141.9 (Ar, C), 135.2 (CH), 131.4 (CH), 130.2 (Ar, CH), 129.4 (Ar, CH), 
128.6 (Ar, CH), 127.3 (Ar, CH), 126.8 (Ar, CH), 37.2 (CH2), 28.9 (CH2); HRMS 
(ES+) calculated for C35H32N4O4Na [M+Na]+ 595.2321, found 595.2314. 
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6 ,N6-diphenylfumaramide) [2]rotaxane (85) 
and [3]rotaxane (84)  
 
Et3N (1.14 mL, 8.16 mmol, 48.0 eq.) was added to a stirred solution of (E)-N1,N1'-
(propane-1,3-diyl)bis(N6 ,N6-diphenylfumaramide) (83) (97 mg, 0.17 mmol, 1.0 eq.) 
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in anhydrous CHCl3 (100 mL). The solution was stirred vigorously whilst solutions 
of p-xylylene diamine (555 mg, 4.08 mmol, 24.0 eq.) in anhydrous CHCl3 (20 mL) 
and isophthaloyl dichloride (828 mg, 4.08 mmol, 24.0 eq.) in anhydrous CHCl3 
(20 mL) were simultaneously added over a period of 2 h using a motor-driven 
syringe pump. After a further 4 h period the resulting suspension was filtered 
through a Celite® pad and the solvent removed under reduced pressure. The 
crude product was purified by HPLC to afford the [3]rotaxane (84) as a white solid 
(22 mg, 8%) and the [2]rotaxane (85) as a white solid (9 mg, 5%). HPLC (t = 0 → 
30 min, 75 : 25 MeOH : H2O; t = 30 → 40 min, 75 → 95% H2O in MeOH, t = 40 → 
60 min, 95 : 5 MeOH : H2O): Data for compound 85: Rt 31.27; m.p. 159 °C; FTIR 
(film) max 3293, 3064, 1635, 1531, 1490, 1355, 1309, 1271, 1211, 1160, 1078, 
966, 820, 759, 694; 1H NMR (400 MHz, CDCl3) δ 8.07 – 8.05 (m, 6H, 2 Ar, CH, HC, 
4 Ar, CH, HB), 7.78 (t, J = 6.1 Hz, 2H, NH), 7.49 (t, J = 7.7 Hz, 2H, Ar, CH, HA), 
7.41 (br s, 4H, NH), 7.18 – 7.10 (m, 5H, Ar, CH), 7.09 – 6.98 (m, 17H, 8 Ar, CH, 
HE, 9 Ar, CH), 6.93 – 6.92 (m, 4H, Ar, CH), 6.85 – 6.83 (m, 2H, Ar, CH), 6.62 – 
6.57 (m, 2H, CH), 6.28 – 6.20 (m, 2H, CH), 4.35 (s, 8H, CH2, HD), 3.07 – 2.88 (m, 
4H, CH2CH2NH), 1.38 – 1.24 (m, 2H, CH2); 13C NMR (100 MHz, CDCl3) δ 166.6 
(CO), 165.4 (CO), 164.9 (CO), 141.8 (Ar, C), 140.7 (Ar, C), 137.6 (Ar, C), 134.5 
(CH), 133.9 (CH), 131.6 (Ar, CH), 129.9 (Ar, CH), 129.4 (Ar, CH), 129.2 (Ar, CH), 
128. 7 (Ar, CH), 127.9 (Ar, CH), 127.2 (Ar, CH), 126.1 (Ar, CH), 124.2 (Ar, CH), 
44.2 (CH2), 36.4 (CH2CH2NH), 29.4 (CH2); HRMS (ES+) calculated for 
C67H60N8O8Na [M+Na]+ 1127.4432, found 1127.4442. Data for compound 84: Rt 
37.57; m.p. 185 °C; FTIR (film) max 3301, 3065, 1636, 1531, 1490, 1355, 1308, 
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1161, 1077, 967, 760, 695; 1H NMR (400 MHz, MeOD / CDCl3) δ 8.16 (br s, 4H, 
Ar, CH, HC), 8.04 (dd, J = 7.8, 1.7 Hz, 8H Ar, CH, HB), 7.59 – 7.58 (m, 4H, Ar, CH, 
HA), 7.22 – 7.10 (m, 19H, 16 Ar, CH, HE, 3 Ar, CH), 7.09 – 7.05 (m, 3H, Ar, CH), 
7.00 - 6.98 (m, 4H, Ar, CH), 6.91 – 6.85 (m, 7H, Ar, CH), 6.49 – 6.45 (m, 3H, Ar, 
CH), 6.08 (d, J = 14.9 Hz, 2H, CH), 5.67 (d, J = 14.9 Hz, 2H, CH), 4.53 (d, J = 14.3 
Hz, 8H, CH2, HD), 4.32 (br s, 8H, NH), 4.23 (d, J = 14.3 Hz, 8H, CH2, HD), 3.35 – 
3.33 (m, 4H, CH2CH2NH), 1.92 – 1.87 (m, 2H, CH2); 13C NMR (100 MHz, MeOD / 
CDCl3) δ 167.8 (CO), 166.4 (CO), 165.5 (CO), 141.8 (Ar, C), 140.8 (Ar, C), 137.9 
(Ar, C), 134.4 (Ar, C), 134.3 (CH), 131.9 (CH), 130.2 (Ar, CH), 129.8 (Ar, CH), 
129.7 (Ar, CH), 129.0 (Ar, CH), 128.3 (Ar, CH), 127.9 (Ar, CH), 126.3 (Ar, CH), 
125.4 (Ar, CH), 121.2 (Ar, CH), 44.5 (CH2), 38.5 (CH2CH2NH), 29.3 (CH2); HRMS 
(ES+) calculated for C99H88N12O12Na [M+Na]+ 1659.6542, found 1659.6563. 
 
(E)-ethyl 4-(bis(4-bomophenyl)amino)-4-oxobut-2-enoate (86) 
 
Ethyl fumaroyl chloride (468 mg, 3.0 mmol, 1.2 eq.) was dissolved in dry DCM 
(10 mL) at RT. A solution of bis(4-bromophenyl)amine (800 mg, 2.5 mmol, 1.0 eq.) 
and NEt3 (0.4 mL, 3.0 mmol, 1.2 eq.) in dry DCM (5 mL) was added using a 
syringe pump over a period of 2 h. The reaction was stirred for an additional hour 
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and the solvent was removed in vacuo. The crude product was purified by column 
chromatography with pet / EtOAc (8 / 2) as eluent to afford (E)-ethyl 4-(bis(4-
bromophenyl)amino)-4-oxobut-2-enoate (86) as a yellow oil (379 mg, 33%). FTIR 
(film) max 3066, 2981, 1718, 1665, 1639, 1584, 1486, 1333, 1293, 1187, 1151, 
1070, 1011, 972, 826, 760, 728, 682; 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 4H, Ar, 
CH), 7.08 – 7.06 (m, 4H, Ar, CH), 6.98 – 6.86 (m, 2H, CH), 4.20 (q, J = 7.1 Hz, 2H, 
OCH2), 1.27 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 165.4 (COO), 
163.9 (CON), 140.8 (Ar, CBr), 140.3 (Ar, CBr), 134.5 (CH), 133.3 (CH), 132.6 (Ar, 
CH), 132.4 (Ar, CH), 129.8 (Ar, CH), 127.8 (Ar, CH), 61.4 (CH2), 14.2 (CH3); 
HRMS (ES+) calculated for C18H15NO3Br2Na [M+Na]+ 473.9316, found 473.9318. 
 
(E)-4-(bis(4-bromophenyl)amino)-4-oxobut-2-enoic acid (87) 
 
A solution of LiOH·H2O (71 mg, 1.7 mmol, 2.0 eq.) in water (3 mL) was added to a 
solution of (E)-ethyl 4-(bis(4-bromophenyl)amino)-4-oxobut-2-enoate (86) (379 mg, 
0.8 mmol, 1.0 eq.) in THF (10 mL) at RT. After 36 h, the reaction mixture was 
poured into 1 M HCl (6 mL). The aqueous layer was extracted with EtOAc (3 x 
8 mL) and the combined fractions were dried over MgSO4 and concentrated under 
reduced pressure. The crude product was recrystallised from hexane / Et2O / DCM 
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(29 / 70 / 1) to afford the title product as a yellow solid (148 mg, 42%). 
m.p. 168 °C; FTIR (film) max 3098, 1702, 1666, 1488, 1412, 1328, 1282, 1205, 
1186, 1073, 972, 830, 785, 759, 680; 1H NMR (400 MHz, CDCl3) δ 7.55 – 7.49 (m, 
4H, Ar, CH), 7.08 – 7.07 (m, 4H, Ar, CH), 6.98 (d, J = 15.3 Hz, 1H, CH), 6.92 (d, J 
= 15.3 Hz, 1H, CH); 13C NMR (100 MHz, CDCl3) δ 169.4 (COO), 163.6 (CON), 
140.6 (Ar, CBr), 136.6 (CH), 133.5 (Ar, CH), 132.5 (Ar, CH), 131.4 (CH), 129.8 (Ar, 
CH), 127.9 (Ar, CH); HRMS (ES-) calculated for C16H10NO3Br2 [M-H]- 423.9184, 
found 423.9174. 
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6,N6-bis(4-bromophenyl)fumaramide) (88) 
 
(E)-4-(bis(4-bromophenyl)amino)-4-oxobut-2-enoic acid (87) (148 mg, 0.35 mmol, 
3.5 eq.) was dissolved in toluene (1 mL). Thionyl chloride (0.2 mL) was added and 
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the mixture was heated at reflux for 3 h. The crude acid chloride formed was 
evaporated to dryness, the resulting residue was dissolved in DCM (1 mL) and 
cooled to 0 °C. NEt3 (30 L, 0.3 mmol, 3.0 eq.) and 1,3-diaminopropane (8.4 L, 
0.1 mmol, 1.0 eq.) were added using a syringe pump over a period of 2 h. The 
reaction was stirred overnight and the solvent was removed in vacuo. The crude 
product was purified by column chromatography with EtOAc / MeOH (10 / 1) as 
eluent to give the title product as a brown solid (17 mg, 19%). m.p. 240 °C; FTIR 
(film) max 3323, 1645, 1543, 1485, 1330, 1070, 1011, 969, 823, 681; 1H NMR 
(300 MHz, CDCl3) δ 7.45 – 7.39 (m, 8H, Ar, CH), 7.15 (d, J = 14.9 Hz, 2H, CH), 
7.11 – 7.05 (m, 8H, Ar, CH), 6.72 (d, J = 14.9 Hz, 2H, CH), 3.02 - 2.96 (m, 4H, 
CH2), 1.19 – 1.17 (m, 2H, CH2); 13C NMR (100 MHz, CDCl3) δ 164.7 (CO), 163.9 
(CO), 142.0 (Ar, CBr), 140.3 (Ar, CBr), 137.8 (CH), 133.6 (Ar, CH), 132.2 (Ar, CH), 
130.3 (CH), 128.8 (Ar, CH), 128.7 (Ar, CH), 38.8 (CH2), 27.3 (CH2); HRMS (ES+) 
calculated for C35H28N4O4Br4Na [M+Na]+ 910.8701, found 910.8709. 
 
9-[(N-benzylamino)methyl]anthracene121  
 
Benzylamine (0.3 mL, 2.5 mmol, 1.0 eq.) was added dropwise using a syringe 
over a period of 20 min to a stirred solution of 9-anthraldehyde (515 mg, 2.5 mmol, 
1.0 eq.) in a mixture of DCM / methanol (1 / 1, 20 mL). The reaction was stirred 
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overnight and NaBH4 (200 mg, 5.3 mmol, 2.1 eq.) was added to the reaction 
mixture. The mixture was stirred for 5 h and then concentrated under reduced 
pressure. The crude product was dissolved in DCM (25 mL) and filtered to remove 
the excess of NaBH4. The solvent was removed in vacuo and the crude product 
was purified by column chromatography with hexane / EtOAc (2 / 1) as eluent to 
afford 9-[(N-benzylamino)methyl]anthracene as a light brown solid (382 mg, 51%). 
m.p. 146 °C [lit. 148 - 151 °C]121; 1H NMR (300 MHz, CDCl3) δ 8.40 (s, 1H, Ar, 
CH), 8.32 – 8.16 (m, 2H, Ar, CH), 8.09 – 7.91 (m, 2H, Ar, CH), 7.67 – 7.25 (m, 9H, 
Ar, CH), 4.69 (s, 2H, CH2), 4.05 (s, 2H, CH2), 1.87 (s, 1H, NH); 13C NMR (100 
MHz, CDCl3) δ 140.4 (Ar, C), 131.6 (Ar, C), 130.4 (Ar, C), 129.2 (Ar, CH), 128.5 
(Ar, CH), 127.3 (Ar, CH), 127.2 (Ar, CH), 126.1 (Ar, CH), 125.0 (Ar, CH), 124.3 
(Ar, CH), 54.3 (CH2), 44.9 (CH2); LRMS (ES+) 320.2 ([M+Na]+, 100%). 
Data were in agreement with those previously reported.121 
 
Ethyl 16-benzyl-17-oxo-16-azapentacyclo[6.6.5.0.0.0]nonadeca-
2(7),3,5,9(14),10,12-hexaene-19-carboxylate (89) 
 
Ethyl fumaroyl chloride (250 mg, 1.5 mmol, 1.2 eq.) was dissolved in dry DCM 
(10 mL) at RT. A solution of 9-[(N-benzylamino)methyl]anthracene (382 mg, 
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1.3 mmol, 1.0 eq.) and NEt3 (0.21 mL, 1.5 mmol, 1.2 eq.) in dry DCM (5 mL) was 
added using a syringe pump over a period of 20 minutes. The reaction was stirred 
overnight and the solvent was removed in vacuo. The crude product was purified 
by column chromatography with hexane / EtOAc (8 / 2) as eluent to afford ethyl 
16-benzyl-17-oxo-16-azapentacyclo[6.6.5.0.0.0]nonadeca-2(7),3,5,9(14),10,12-
hexaene-19-carboxylate (89) as a white solid (523 mg, 97%). m.p. 78 °C; FTIR 
(film) max 3312, 3064, 2935, 1727, 1690, 1642, 1585, 1538, 1493, 1420, 1304, 
1228, 1197, 1028, 820, 754, 698;1H NMR (400 MHz, CDCl3) δ 7.35 – 7.12 (m, 7H, 
Ar, CH), 7.08 – 6.90 (m, 4H, Ar, CH), 6.86 (t, J = 7.6 Hz, 1H, Ar, CH), 6.58 (d, J = 
7.6 Hz, 1H, Ar, CH), 4.60 - 4.56 (m, 2H, CH, CH2), 4.35 (d, J = 14.5 Hz, 1H, CH2), 
4.17 – 3.95 (m, 4H, OCH2, CH2), 3.10 (d, J = 6.8 Hz, 1H, CH), 2.95 (dd, J = 6.8, 
1.9 Hz, 1H, CH), 1.18 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 172.5 
(COO), 172.3 (CON), 144.6 (Ar, C), 143.2 (Ar, C), 139.7 (Ar, C), 138.4 (Ar, C), 
136.4 (Ar, C), 129.1 (Ar, CH), 128.9 (Ar, CH), 128.0 (Ar, CH), 126.7 (Ar, CH), 
126.5 (Ar, CH), 126.3 (Ar, CH), 126.2 (Ar, CH), 125.7 (Ar, CH), 123.3 (Ar, CH), 
121.9 (Ar, CH), 119.4 (Ar, CH), 61.4 (OCH2), 52.8 (CH), 49.5 (C), 48.3 (CH), 47.4 
(CH2), 45.8 (CH2), 44.8 (CH), 14.4 (CH3); HRMS (ES+) calculated for 
C28H25NO3Na [M+Na]+ 446.1732, found 446.1742. 
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N-tritylaniline88,122  
 
Aniline (4.2 mL, 46.0 mmol, 1.0 eq.) was dissolved in dry DCM (50 mL) at RT. 
Trityl chloride (14.2 g, 50.0 mmol, 1.1 eq.) and NEt3 (13.0 mL, 92.0 mmol, 2.0 eq.) 
were added portionwise over a period of 20 min. The reaction was stirred 
overnight, diluted with DCM (100 mL), washed with H2O (3 x 100 mL) and the 
combined organic fractions were dried over MgSO4. After the solvent was removed 
in vacuo and the crude product was recrystallised from EtOH to afford 
N-tritylaniline as a white solid (16.7 g, 99%). m.p. 146 °C [lit. 151 - 152 °C]88; 1H 
NMR (300 MHz, CDCl3) δ 7.40 – 7.13 (m, 15H, Ar, CH), 6.90 (t, J = 7.4 Hz, 2H, Ar, 
CH), 6.55 (t, J = 7.4 Hz, 1H, Ar, CH), 6.39 – 6.28 (m, 2H, Ar, CH), 5.01 (br s, 1H, 
NH); 13C NMR (100 MHz, CDCl3) δ 146.4 (Ar, C), 145.5 (Ar, C), 129.4 (Ar, CH), 
128.3 (Ar, CH), 128.0 (Ar, CH), 127.4 (Ar, CH), 126.9 (Ar, CH), 117.4 (Ar, CH), 
116.2 (Ar, CH), 71.6 (C); HRMS (ES+) calculated for C25H21NNa [M+Na]+ 
358.1572, found 358.1560. 
Data were in agreement with previously those reported.88,122 
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Tri(phenyl)methanamine123,124  
 
A solution of trityl chloride (27.8 g, 100.0 mmol, 1.0 eq.) in toluene (100 mL) was 
added dropwise to a vigorously stirred solution of NH4Cl (5.4 g, 100.0 mmol, 
1.0 eq.) in aqueous ammonia (100 mL, 35%). The reaction was stirred for 24 h at 
RT. The reaction mixture was extracted with EtOAc (3 x 300 mL). The organic 
combined phases were dried over Na2SO4. After the solvent was removed in 
vacuo and the crude product was recrystallised from hexane to afford 
tri(phenyl)methanamine as a white solid (22 g, 85%). m.p. 100 °C [lit. 102 - 
104 °C]123; 1H NMR (300 MHz, CDCl3) δ 7.47 – 6.82 (m, 15H, Ar, CH), 2.18 (br s, 
2H, NH2); 13C NMR (100 MHz, CDCl3) δ 148.6 (Ar, C), 128.1 (Ar, CH), 127.9 (Ar, 
CH), 127.3 (Ar, CH), 126.6 (Ar, CH), 66.3 (C); HRMS (ES+) calculated for 
C19H17NNa [M+Na]+ 282.1259, found 282.1260. 
Data were in agreement with those previously reported.123,124 
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(E)-ethyl 4-oxo-4-(tritylamino)but-2-enoate (91) 
 
Ethyl fumaroyl chloride (18 mg, 0.11 mmol, 1.1 eq.) was dissolved in dry DCM 
(10 mL) at RT. A solution of tri(phenyl)methanamine (26 mg, 0.10 mmol, 1.0 eq.) 
and NEt3 (15 L, 0.11 mmol, 1.1 eq.) in dry DCM (0.5 mL) was added using a 
syringe pump over a period of 2 h. The reaction was stirred overnight and the 
solvent was removed in vacuo. The crude product was purified by column 
chromatography with pet / EtOAc (9/1) as eluent to afford (E)-ethyl 4-oxo-4-
(tritylamino)but-2-enoate (91) as a white solid (30 mg, 78%). m.p. 138 °C; FTIR 
(film) max 3238, 3050, 3024, 1716, 1681, 1659, 1637, 1525, 1490, 1446, 1293, 
1265, 1158, 1036, 905, 767, 730, 697; 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.15 
(m, 15H, Ar, CH), 7.06 (d, J = 15.3 Hz, 1H, CH), 7.01 (br s, 1H, NH), 6.79 (d, J = 
15.3 Hz, 1H, CH), 4.22 (q, J = 7.1 Hz, 2H, OCH2), 1.31 (t, J = 7.1 Hz, 3H, CH3); 13C 
NMR (100 MHz, CDCl3) δ 165.7 (COO), 162.7 (CONH), 144.2 (Ar, C), 137.0 (CH), 
131.1 (CH), 128.9 (Ar, CH), 128.8 (Ar, CH), 128.2 (Ar, CH), 128.1 (Ar, CH), 128.0 
(Ar, CH), 127.4 (Ar, CH), 126.9 (Ar, CH), 71.2 (C), 61.3 (OCH2), 14.3 (CH3); 
HRMS (ES+) calculated for C25H23NO3Na [M+Na]+ 408.1576, found 408.1587. 
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(E)-4-oxo-4-(tritylamino)but-2-enoic acid (92) 
 
A solution of LiOH·H2O (1.2 g, 28.3 mmol, 2.0 eq.) in water (29 mL) was added to 
a solution of (E)-ethyl 4-oxo-4-(tritylamino)but-2-enoate (91) (4.0 g, 10.6 mmol, 
1.0 eq.) in THF (87 mL). The reaction mixture was heated to 60 °C. After 32 h the 
reaction mixture was cooled and poured into a solution of 1 M HCl (60 mL). The 
aqueous layer was extracted with Et2O (3 x 80 mL) and the combined organic 
fractions were dried over MgSO4 and concentrated under reduced pressure. The 
resulting solid was recrystallised from hexane / Et2O / DCM (29 / 70 / 1) to afford 
(E)-4-oxo-4-(tritylamino)but-2-enoic acid (92) (3 g, 81%) as a white solid. m.p. 
195 °C; FTIR (film) max 3029, 1698, 1641, 1522, 1491, 1447, 1311, 1185, 1036, 
970, 904, 768, 697; 1H NMR (400 MHz, MeOD / CDCl3) δ 7.30 – 7.11 (m, 15H, Ar, 
CH), 7.07 (d, J = 15.4 Hz, 1H, CH), 6.64 (d, J = 15.4 Hz, 1H, CH); 13C NMR 
(100 MHz, MeOD / CDCl3) δ 167.4 (COOH), 163.2 (CONH), 144.0 (Ar, C), 137.2 
(CH), 130.9 (CH), 128.6 (Ar, CH), 127.9 (Ar, CH), 127.1 (Ar, CH), 71.0 (C);13C 
NMR (100 MHz, MeOD / CDCl3) δ 127.1, 127.9 (Ar, CH), 128.6 (Ar, CH), 130.9 
(Ar, CH), 137.2 (Ar, CH), 144.0, 163.2, 167.4; HRMS (ES+) calculated for 
C23H19NO3Na [M+Na]+ 380.1263, found 340.1275. 
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(E)-N1,N1'-(propane-1,3-diyl)bis(N6-tritylfumaramide) (93) 
 
(E)-4-oxo-4-(tritylamino)but-2-enoic acid (92) (716 mg, 2.0 mmol, 4.0 eq.) and 
thionyl chloride (1 mL) were dissolved in THF (5 mL) and heated at reflux for 3 h. 
The crude acid chloride formed was evaporated to dryness, the resulting residue 
was dissolved in DCM (10 mL) and cooled to 0°C. NEt3 (0.3 mL, 2.0 mmol, 
4.0 eq.) and 1,3-diaminopropane (42 L, 0.5 mmol, 1.0 eq.) were added using a 
syringe pump over a period of 2 h. The reaction was stirred overnight and the 
solvent was removed in vacuo. The crude product was purified by column 
chromatography with EtOAc / MeOH (95 / 5) as eluent to give the title product as a 
yellow solid (76 mg, 20%). m.p. 208 °C; FTIR (film) max 3331, 3251, 3027, 1681, 
1635, 1526, 1489, 1448, 1333, 1218, 1181, 978, 903, 770, 699; 1H NMR (400 
MHz, d6-DMSO) δ 9.18 (s, 2H, NH), 8.42 – 8.22 (m, 2H, CH2NH), 7.36 – 7.12 (m, 
32H, 30 Ar, CH, 2 CH), 6.65 (d, J = 15.2 Hz, 2H, CH), 3.15 (dt, J = 12.6, 6.5 Hz, 
4H, CH2CH2NH), 1.68 – 1.47 (m, 2H, CH2); 13C NMR (100 MHz, d6-DMSO) δ 163.8 
(CO), 163.5 (CO), 144.4 (Ar, C), 133.6 (CH), 132.8 (CH), 128.5 (Ar, CH), 127.5 
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(Ar, CH), 126.4 (Ar, CH), 69.6 (C), 36.6 (CH2CH2NH), 28.9 (CH2); HRMS (ES+) 
calculated for C49H44N4O4Na [M+Na]+ 775.3226, found 775.3274.  
 
(E)-N1,N1'-(propane-1,3-diyl)bis(N6-tritylfumaramide) [2]rotaxane (94) 
 
Et3N (0.5 mL, 3.8 mmol, 48.0 eq.) was added to a stirred solution of (E)-N1,N1'-
(propane-1,3-diyl)bis(N4-tritylfumaramide) (93) (60 mg, 0.08 mmol, 1.0 eq.) in 
anhydrous CHCl3 (30 mL). The solution was stirred vigorously whilst solutions of 
p-xylylene diamine (261 mg, 1.9 mmol, 24.0 eq.) in anhydrous CHCl3 (10 mL) and 
isophthaloyl dichloride (390 mg, 1.9 mmol, 24.0 eq.) in anhydrous CHCl3 (10 mL) 
were simultaneously added over a period of 4 h using a motor-driven syringe 
pump. After a further 4 h period the resulting suspension was filtered through a 
Celite® pad and the solvent removed under reduced pressure. The crude product 
was purified by HPLC to afford (E)-N1,N1'-(propane-1,3-diyl)bis(N6-
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tritylfumaramide) [2]rotaxane (94) as a white solid (15 mg, 15%). HPLC (t = 0 → 
30 min, 75 : 25 MeOH : H2O; t = 30 → 40 min, 75 → 95% H2O in MeOH, t = 40 → 
60 min, 95 : 5 MeOH : H2O): Rt 42.35; m.p. 232 °C; FTIR (film) max 3287, 3060, 
2925, 2853, 1636, 1520, 1491, 1447, 1316, 1185, 1036, 972, 901, 749, 698; 1H 
NMR (400 MHz, d6-DMSO) δ 9.19 (s, 2H, NH), 8.42 (br s, 2H, Ar, CH, HC), 8.33 (t, 
J = 5.2 Hz, 6H, NH), 8.00 (dd, J = 7.7, 1.4 Hz, 4H, Ar, CH, HB), 7.60 (t, J = 7.7 Hz, 
2H, Ar, CH, HA), 7.28 – 7.11 (m, 30H, Ar, CH), 6.92 (s, 8H, Ar, CH, HE), 6.74 (d, J 
= 15.1 Hz, 2H, CH), 6.12 (d, J = 15.1 Hz, 2H, CH), 4.28 (d, J = 5.0 Hz, 8H, CH2, 
HD), 3.08 (dd, J = 12.7, 6.6 Hz, 4H, CH2CH2NH), 1.64 – 1.49 (m, 2H, CH2); 13C 
NMR (100 MHz, d6-DMSO) δ 165.9 (CON), 164.6 (CON), 163.8 (CON), 144.2 (Ar, 
C), 136.7 (Ar, C), 134.4 (Ar, C), 132.3 (CH), 131.3 (CH), 130.6 (Ar, CH), 128.7 (Ar, 
CH), 128.5 (Ar, CH), 127.5 (Ar, CH), 126.5 (Ar, CH), 125.3 (Ar, CH), 69.8 (C), 43.1 
(CH2), 36.9 (CH2CH2NH), 28.5 (CH2); LRMS (ES+) 1308.0 ([M+Na]+, 100%). 
 
(E)-ethyl 4-oxo-4-(tritylphenylamino)but-2-enoate (95) 
 
Ethyl fumaroyl chloride (1.0 g, 6.0 mmol, 1.1 eq.) was dissolved in dry DCM 
(40 mL) at RT. A solution of 4-tritylaniline (1.9 g, 5.5 mmol, 1.0 eq.) and NEt3 
(1.0 mL, 6.0 mmol, 1.1 eq.) in dry DCM (10 mL) was added using a syringe pump 
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over a period of 2 h. The reaction was stirred overnight and the solvent was 
removed in vacuo. The crude product was purified by column chromatography with 
pet / EtOAc (9/1) as eluent to afford (E)-ethyl 4-oxo-4-(tritylphenylamino)but-2-
enoate (95) as a white solid (1.5 g, 59%). m.p. 112 °C; FTIR (film) max 3031, 
1721, 1672, 1654, 1599, 1546, 1491, 1442, 1349, 1277, 1039, 984, 827, 745, 700; 
1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H, NH), 7.54 (d, J = 8.8 Hz, 2H, Ar, CH), 
7.39 – 7.09 (m, 18H, 17 Ar, CH, 1 CH), 6.98 (d, J = 15.3 Hz, 1H, CH), 4.28 (q, J = 
7.1 Hz, 2H, OCH2), 1.33 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 
166.0 (COO), 161.8 (CONH), 146.7 (Ar, C), 143.8 (Ar, C), 137.1 (CH), 135.4 (Ar, 
C), 131.9 (Ar, CH), 131.3 (CH), 131.2 (Ar, CH), 127.7 (Ar, CH), 126.1 (Ar, CH), 
119.3 (Ar, CH), 64.7 (C), 61.6 (OCH2), 14.2 (CH3); HRMS (ES+) calculated for 
C31H27NO3Na [M+Na]+ 484.1889, found 484.1887. 
 
(E)-4-oxo-4-(tritylphenylamino)but-2-enoic acid (96) 
 
A solution of LiOH·H2O (271 mg, 6.5 mmol, 2.0 eq.) in water (10 mL) was added to 
a solution of (E)-ethyl 4-oxo-4-(tritylphenylamino)but-2-enoate (95) (1.5 g, 
3.2 mmol, 1.0 eq.) in THF (43 mL). The reaction mixture was heated to 60 °C. 
After 32 h, the reaction mixture was cooled and poured into 1 M HCl (30 mL). The 
aqueous layer was extracted with Et2O (3 x 40 mL) and the combined organic 
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fractions were dried over MgSO4 and concentrated under reduced pressure. The 
resulting solid was recrystallised from hexane / Et2O / DCM (29 / 70 / 1) to afford 
(E)-4-oxo-4-(tritylphenylamino)but-2-enoic acid (96) (1.11 g, 79%) as a white solid. 
m.p. 216 °C; FTIR (film) max 3655, 3300, 3059, 1736, 1703, 1666, 1643, 1597, 
1540, 1490, 1441, 1406, 1345, 1290, 1179, 973, 830, 749, 697; 1H NMR (300 
MHz, MeOD) δ 7.59 (s, 1H, NH), 7.53 (d, J = 8.9 Hz, 2H, Ar, CH), 7.33 – 7.01 (m, 
18H, 17 Ar, CH, 1 CH), 6.81 (d, J = 15.4 Hz, 1H, CH), 3.35 (s, 1H, OH); 13C NMR 
(100 MHz, MeOD) δ 168.1 (COOH), 163.6 (CONH), 147.4 (Ar, C), 144.1 (Ar, C), 
137.8 (CH), 136.6(Ar, C), 132.2 (Ar, CH), 131.7 (Ar, CH), 128.1 (Ar, CH), 126.6 
(Ar, CH), 119.8 (Ar, CH) 65.3 (C); HRMS (ES+) calculated for C29H23NO3Na 
[M+Na]+ 456.1576, found 456.1588. 
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(E)-N1,N1'-(propane-1,3-diyl)bis(N4-(4-tritylphenyl)fumaramide) (97) 
 
(E)-4-oxo-4-(tritylphenylamino)but-2-enoic acid (96) (1.1 g, 2.6 mmol, 2.6 eq.) and 
thionyl chloride (1.5 mL) were dissolved in THF (30 mL) and heated at reflux for 
3 h. The crude acid chloride formed was evaporated to dryness, the resulting 
residue was dissolved in DCM (25 mL) and cooled to 0 °C. NEt3 (0.4 mL, 2.6 
mmol, 2.6 eq.) and 1,3-diaminopropane (83 L, 1.0 mmol, 1.0 eq.) were added 
using a syringe pump over a period of 2 h. The reaction was stirred overnight and 
the solvent was removed in vacuo. The crude product was purified by column 
chromatography with EtOAc / MeOH (95 / 5) as eluent to give the title product as a 
brown solid (208 mg, 23%). m.p. 154 °C; FTIR (film) max 1726, 1689, 1598, 1499, 
1456, 1382, 1324, 1305, 1200, 1029, 922, 863, 754, 725, 706, 688; 1H NMR (400 
MHz, MeOD) δ 7.53 (s, 4H, Ar, CH), 7.51 (s, 2H, NH), 7.25 – 7.12 (m, 34H, Ar, 
CH), 7.00 (d, J = 15.1 Hz, 2H, CH), 6.91 (d, J = 15.1 Hz, 2H, CH), 3.37 – 3.32 (m, 
4H, CH2CH2NH), 1.82 - 1.77 (m, 2H, CH2); 13C NMR (100 MHz, MeOD) δ 166.1 
(CO), 147.3 (Ar, C), 143.9 (Ar, C), 136.5 (Ar, C), 133.9 (CH), 132.2 (CH), 131.6 
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(Ar, CH), 128.0 (Ar, CH), 126.5 (Ar, CH), 119.6 (Ar, CH), 65.2 (C), 49.7 
(CH2CH2NH), 37.6 (CH2); HRMS (ES+) calculated for C61H52N4O4Na [M+Na]+ 
927.3886, found 927.3902.  
 
4.6 Experimental for Section 2.6 
 
Bis-p-xylyl-bis-m-xylyldiamine (102) 
 
m-Xylylenediamine (1.2 g, 9.0 mmol, 1.0 eq.) in MeCN (280 mL) was added 
dropwise over a period of 1.5 h using a dropping funnel to a solution of 
terephthalaldehyde (1.2 g, 9 mmol, 1.0 eq.) in MeCN (150 mL). The mixture was 
stirred for 24 h at RT. The resulting precipitate was filtered and washed with cold 
Et2O (15 mL). The crude tetraimine (1.5 g, 3.2 mmol) was dissolved in MeOH 
(150 mL) and heated to 45 ºC. NaBH4 (890 mg, 24.0 mmol, 2.7 eq.) was added 
portionwise and the reaction mixture was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo. Water (10 mL) and DCM (100 mL) 
were added to the resulting residue and the product was extracted with EtOAc (3 x 
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200 mL). The combined organic phases were dried over MgSO4 and the solvent 
was removed in vacuo to afford bis-p-xylyl-bis-m-xylyldiamine (102) as a white 
solid (1.3 g, 30%). m.p. 143 °C; FTIR (film) max 3021, 2835, 2806, 1644, 1606, 
1587, 1449, 1358, 906, 845, 824, 779, 725, 693; 1H NMR (300 MHz, CDCl3) δ 
7.45 (s, 2H, NH), 7.34 (s, 8H, Ar, CH), 7.32 – 7.28 (m, 3H, Ar, CH), 7.22 (d, J = 8.0 
Hz, 5H, Ar, CH), 3.82 (s, 8H, CH2), 3.79 (s, 8H, CH2); 13C NMR (100 MHz, CDCl3) 
δ 140.7 (Ar, C), 139.2 (Ar, C), 128.5 (Ar, CH), 127.6 (Ar, CH), 127.1 (Ar, CH), 52.7 
(CH2), 52.5 (CH2); HRMS (ES+) calculated for C32H37N4 [M+H]+ 477.3018, found 
477.3015. 
 
Molecular cage (105) 
 
                                                                                                                  
(2E,2'E)-diethyl 4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoate) (33) 
(33 mg, 0.1 mmol, 1.0 eq.) was dissolved in CHCl3 (10 mL). Bis-p-xylyl-bis-m-
xylyldiamine 102 (95 mg, 0.2 mmol, 2.0 eq.) was added and the solution was 
stirred for 20 min at RT followed by addition of '-dibromo-p-xylene (220 mg, 
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0.8 mmol, 8.0 eq.). The reaction was monitored via MALDI spectrometry. After 
3 weeks the solvent was removed in vacuo and the residue was recrystallised 
from MeCN (10 mL). The solid was purified by column chromatography with CHCl3 
/ MeOH (95 / 5) as eluent to afford the enriched molecular cage 105 (37 mg, 27%, 
however not completely pure). m.p. 172 °C; FTIR (film) max 3345, 2926, 1717, 
1666, 1547, 1436, 1366, 1297, 1163, 1019, 974, 807, 751, 700; 1H NMR (400 
MHz, CDCl3) δ 8.03 – 6.89 (m, 48H, Ar, CH), 4.32 – 3.08 (m, 48H, CH2); 13C NMR 
(100 MHz, CDCl3) δ 140.4 (Ar, C), 140.1 (Ar, C), 139.9 (Ar, C), 138.9 (Ar, C), 
138.6 (Ar, C), 130.3 (Ar, CH), 130.1 (Ar, CH), 129.4 (Ar, CH), 129.0 (Ar, CH), 
128.6 (Ar, CH), 128.0 (Ar, CH), 127.7 (Ar, CH), 127.1 (Ar, CH), 58.9 (CH2), 58.2 
(CH2), 58.0 (CH2), 57.8 (CH2). LRMS (MALDI+) 1363.0 ([M+H]+, 100%), 1261.0 
(8%). 
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(2E,2'E)-di(prop-2-yn-1-yl) 4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-
2-enoate) (111) 
 
A solution of (2E,2'E)-4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoic 
acid) (36) (270 mg, 1.0 mmol, 1.0 eq.) in DCM (1 mL) was added to a solution of 
propargyl alcohol (60 L, 2.0 mmol, 2.0 eq.), N,N’-dicyclohexylcarbodiimide 
(453 mg, 2.2 mmol, 2.2 eq.) and 4-(dimethylamino)pyridine (25 mg, 0.2 mmol, 
0.2 eq.) in DCM (10 mL) at 4 ºC. After being stirred for 4 h at 0 ºC, the reaction 
mixture was allowed to warm to RT. The reaction was stirred overnight and the 
solvent was removed in vacuo. The crude product was purified by column 
chromatography with EtOAc / pet (1 / 1) as eluent to afford of (2E,2'E)-di(prop-2-
yn-1-yl) 4,4'-(propane-1,3-diylbis(azanediyl))bis(4-oxobut-2-enoate) (111) as a 
white solid (90 mg, 26%). m.p. 145 °C; FTIR (film) max 3296, 1718, 1666, 1632, 
1547, 1370, 1291, 1158, 1032, 984, 665; 1H NMR (300 MHz, d6-DMSO) δ 8.60 – 
8.58 (m, 2H, NH), 7.05 (d, J = 15.5 Hz, 2H, CH), 6.58 (d, J = 15.5 Hz, 2H, CH), 
4.83 – 4.82 (m, 4H, OCH2), 3.64 – 3.62 (m, 2H, CH), 3.24 – 3.13 (m, 4H, CH2NH), 
1.67 – 1.57 (m, 2H, CH2CH2CH2); 13C NMR (100 MHz, MeOD / CDCl3) δ 165.4 
(COO), 165.2 (CON), 138.0 (CH), 129.3 (CH), 77.4 (C), 75.9 (CH), 53.0 (OCH2), 
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37.5 (CH2NH), 29.0 (CH2); HRMS (ES+) calculated for C17H18N2O6Na [M+Na]+ 
369.1063, found 369.1060. 
 
(Azidomethanetriyl)tribenzene125,126  
 
H2SO4 (conc., 9 mL) was added dropwise using a pipette to a suspension of 
sodium azide (4.2 g, 64.5 mmol, 1.7 eq.) in CHCl3 (13 mL) at 0 ºC. The reaction 
mixture was allowed to warm to RT and a solution of triphenylmethanol (10.0 g, 
38.5 mmol, 1.0 eq.) in CHCl3 (40 mL) was added via dropping funnel over a period 
of 1 h. After additional 30 min of stirring, ice (75 g) was slowly added and the 
mixture was stirred overnight. The aqueous phase was extracted with Et2O (3 x 
100 mL) and the combined organic layers were dried over MgSO4. The solvent 
was removed in vacuo to afford (azidomethanetriyl)tribenzene as a yellow solid 
(9.87 g, 90%). m.p. 60 °C [lit. 60 - 62 °C]125; 1H NMR (300 MHz, CDCl3) δ 7.51 – 
7.32 (m, 1H, Ar, CH); 13C NMR (100 MHz, CDCl3) δ 143.1 (Ar, C), 128.4 (Ar, CH), 
128.1 (Ar, CH), 127.6 (Ar, CH), 82.1 (C); HRMS (ES+) calculated for C19H16 [M-
N3+H]+ 243.1174, found 243.1175. 
Data were in agreement with those previously reported.125,126 
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(2E,2'E)-diethyl 4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-oxobut-2-
enoate) (113) 
 
Ethyl fumaroyl chloride (1.8 g, 11.0 mmol, 2.2 eq.) was dissolved in dry DCM 
(100 mL) at RT. A solution of dimethyl-1,3-propanediamine (0.6 mL, 5.0 mmol, 1.0 
eq.) and NEt3 (1.5 mL, 11.0 mmol, 2.2 eq.) in dry DCM (10 mL) was added using a 
syringe pump over a period of 2 h. The reaction was stirred overnight and the 
solvent was removed in vacuo. The crude product was purified by column 
chromatography using CHCl3 / MeOH (94 / 6) as eluent to afford (2E,2'E)-diethyl 
4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-oxobut-2-enoate) (113) as a white 
solid (2.80 g, 72%). m.p. 168 °C; FTIR (film) max 3529, 3469, 2987, 2941, 1718, 
1620, 1484, 1415, 1286, 1267, 1174, 1025, 886, 765, 743; 1H NMR (300 MHz, 
CDCl3) δ 7.26 – 7.11 (m, 2H, CH), 6.68 – 6.45 (m, 2H, CH), 4.04 (q, J = 7.1 Hz, 
4H, OCH2CH3), 3.40 – 3.16 (m, 4H, CH2NH), 2.97 – 2.82 (m, 6H, NCH3), 1.76 – 
1.66 (m, 2H, CH2CH2CH2), 1.10 (t, J = 7.1 Hz, 6H, CH3); 13C NMR (100 MHz, 
CDCl3) δ 165.1 (COO), 164.5 (CON), 133.5 (CH), 133.3 (CH), 131.1 (CH), 130.8 
(CH), 60.7 (OCH2CH3), 47.5 (CH2NH), 45.4 (CH2NH), 45.0 (CH2NH), 35.2 (NCH3), 
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33.5 (NCH3), 26.3 (CH2), 24.2 (CH2), 13.8 (CH3); HRMS (ES+) calculated for 
C17H26N2O6Na [M+Na]+ 377.1689, found 377.1692. 
 
(2E,2'E)-4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-oxobut-2-enoic acid) 
(114) 
 
(2E,2'E)-diethyl 4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-oxobut-2-enoate) 
(113) (354 mg, 1.0 mmol, 1.0 eq.) was dissolved in EtOH (35 mL). Then NaOH (96 
mg, 2.4 mmol, 2.4 eq.) dissolved in water (3 mL) was added dropwise over a 
period of 5 minutes via a syringe. The reaction was stirred for 16 h at RT and 
monitored by TLC. The reaction mixture was acidified with 1 M HCl (5 mL), 
extracted with DCM (3 x 80 mL) and washed with brine (80 mL). The organic 
layers were combined, dried over MgSO4 and concentrated under reduced 
pressure to afford (2E,2'E)-4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-
oxobut-2-enoic acid) (114) as a yellow solid (295 mg, 99%). m.p. >256 °C 
(decomp); FTIR (film) max 3322, 2937, 1716, 1613, 1594, 1404, 1271, 1174, 1029, 
971, 765; 1H NMR (400 MHz, d6-DMSO) δ 7.42 – 7.25 (m, 2H, CH), 6.59 – 6.41 
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(m, 2H, CH), 3.42 – 3.32 (m, 4H, CH2NH), 3.07 – 2.90 (m, 6H, NCH3), 1.77 – 1.68 
(m, 2H, CH2CH2CH2); 13C NMR (100 MHz, d6-DMSO) δ 166.4 (COO), 163.9 
(CON), 134.4 (CH), 134.1 (CH), 131.0 (CH), 47.1 (CH2NH), 46.6 (CH2NH), 45.0 
(CH2NH), 44.6 (CH2NH), 35.0 (NCH3), 33.3 (NCH3), 26.1 (CH2); HRMS (ES-) 
calculated for C13H17N2O6 [M-H]- 297.1087, found 297.1102. 
 
(2E,2'E)-di(prop-2-yn-1-yl) 4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-
oxobut-2-enoate) (115) 
 
A solution of (2E,2'E)-4,4'-(propane-1,3-diylbis(methylazanediyl))bis(4-oxobut-2-
enoic acid) (114) (536 mg, 1.8 mmol, 1.0 eq.) in DCM (1 mL) was added to a 
solution of propargyl alcohol (0.12 mL, 4.0 mmol, 2.0 eq.), N,N’-
dicyclohexylcarbodiimide (906 mg, 4.4 mmol, 2.2 eq.) and 4-(dimethylamino) 
pyridine (50 mg, 0.4 mmol, 0.2 eq.) in DCM (10 mL) at 4 ºC. After being stirred for 
4 h at 0 ºC, the reaction mixture was allowed to warm to RT. The reaction was 
stirred overnight and the solvent was removed in vacuo. The crude product was 
purified by column chromatography with EtOAc / pet (7 / 3) as eluent to afford 
Chapter 4 
Experimental 
 
198 
 
(2E,2'E)-di(prop-2-yn-1-yl) 4,4'-(propane-1,3-diylbis(methylazanediyl)) bis(4-
oxobut-2-enoate) (115) as a white solid (121 mg, 18%). m.p. 128 °C; FTIR (film) 
max 3266, 2940, 1723, 1649, 1617, 1488, 1404, 1273, 1157, 1029, 970, 763, 696; 
1H NMR (300 MHz, CDCl3) δ 7.55 – 7.34 (m, 2H, CH), 6.93 – 6.73 (m, 2H, CH), 
4.82 (br s, 4H, OCH2), 3.57 – 3.37 (m, 4H, CH2NH), 3.16 – 3.05 (m, 6H, NCH3), 
2.60 – 2.44 (m, 2H, CH), 1.96 – 1.82 (m, 2H, CH2CH2CH2); 13C NMR (100 MHz, 
CDCl3) δ 164.9 (COO), 164.3 (CON), 135.0 (CH), 134.6 (CH), 130.7 (CH), 130.3 
(CH), 77.3 (C), 75.4 (CH), 52.7 (OCH2), 48.0 (CH2N), 46.0 (CH2N), 45.6 (CH2N), 
35.9 (NCH3), 35.8 (NCH3), 34.2 (NCH3), 26.9 (CH2), 24.7 (CH2); HRMS (ES+) 
calculated for C19H22N2O6Na [M+Na]+ 397.1379, found 397.1376. 
 
1,2-Hydrazodicarboxamide-allyl-thread (117) 
 
Phenyl N,N-dibenzylaminocarbonylhydrazinecarboxylate (44) (334 mg, 0.9 mmol, 
2 eq.) and NEt3 (0.4 mL, 2.9 mmol, 6.4 eq.) were added to a stirred solution of 
allylamine (33 L, 0.45 mmol, 1 eq.) in CHCl3 (25 mL). The reaction mixture was 
stirred at reflux for 15 h. The reaction mixture was then concentrated under 
reduced pressure and purified by column chromatography on silica gel using a 
DCM / MeOH (98 / 2) mixture as eluent to give the title product as a white solid 
(162 mg, 99%). m.p. 83 °C; FTIR (film) max 3245, 3031, 1655, 1533, 1495, 1453, 
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1405, 1361, 1217, 1079, 1028, 912, 744, 696; 1H NMR (300 MHz, CDCl3) δ 7.09 – 
6.90 (m, 10H, Ar, CH), 5.57 (s, 1H, NH), 5.51 – 5.38 (m, 1H, CH2CH), 4.89 – 4.67 
(m, 2H, CH2CH), 4.20 (s, 4H, CH2), 3.45 – 3.31 (m, 2H, NHCH2); 13C NMR (100 
MHz, CDCl3) δ 159.7 (CON), 159.4 (CON), 136.9 (Ar, C), 135.0 (CH2CH), 128.8 
(Ar, CH), 127.5 (Ar, CH), 127.4 (Ar, CH), 115.3 (CH2CH), 49.9 (CH2), 42.3 
(CH2NH); HRMS (ES+) calculated for C19H22N4O2Na [M+Na]+ 361.1640, found 
361.1646. 
 
(E)-N1-allyl-N2,N2-dibenzyldiazene-1,2-dicarboxamide (118) 
 
Pyridine (40 L, 0.47 mmol, 1.1 eq.) and NBS (77 mg, 0.43 mmol, 1.0 eq.) were 
added to a solution of 1,2-hydrazodicarboxamide-allyl-thread (117) (144 mg, 
0.42 mmol, 1.0 eq.) in dry DCM (10 mL). The resulting solution was stirred for 1 h 
at RT. It was then diluted with DCM (5 mL) and sequentially washed with H2O (2 x 
10 mL), a saturated aqueous solution of Na2S2O3 (10 mL) and a saturated 
aqueous solution of NaHCO3 (2 x 10 mL). The combined organic phases were 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography with DCM / MeOH (98 / 2) 
as eluent to afford the title product (118) as a yellow oil (75 mg, 53%).1H NMR 
(300 MHz, CDCl3) δ 7.47 – 7.17 (m, 10H, Ar, CH), 5.95 – 5.86 (m, 1H, CH2CH), 
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5.32 – 5.19 (m, 2H, CH2CH), 4.66 (s, 2H, CH2), 4.52 (s, 2H, CH2), 4.07 (tt, J = 6.0, 
1.5 Hz, 2H, NHCH2). 13C NMR (100 MHz, CDCl3) δ 162.1 (CON), 159.7 (CON), 
135.4 (Ar, C), 135.2 (Ar, C), 132.6 (CH2CH), 128.9 (Ar, CH), 128.5 (Ar, CH), 128.2 
(Ar, CH), 127.8 (Ar, CH), 117.6 (CH2CH), 49.2 (CH2), 49.1 (CH2), 43.3 (CH2NH); 
HRMS (ES+) calculated for C19H20N4O2Na [M+Na]+ 359.1484, found 359.1481.  
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Appendix 
1H NMR and 13C NMR of [2]rotaxane 49. 
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1H NMR and 13C NMR of [2]rotaxane 50. 
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1H NMR and 13C NMR of [2]rotaxane 54. 
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1H NMR and 13C NMR of [2]rotaxane 55. 
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1H NMR and COSY of [2]rotaxane 59. 
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13C NMR and HSQC of [23]rotaxane 59. 
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1H NMR and COSY of [2]rotaxane 60. 
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13C NMR and HSQC of [2]rotaxane 60. 
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1H NMR and COSY of [3]rotaxane 61. 
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13C NMR and HSQC of [3]rotaxane 61. 
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Table 1.  Crystal data and structure refinement for [3]rotaxane 61. 
Empirical formula                                   C37H40N8O4, 2(C32H28N4O4), 5.55(CH4O), 
1.65(H2O) 
Formula weight  1933.50 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 11.4654(3) Å = 98.271(1)° 
 b = 17.8750(7) Å = 97.941(2)° 
 c = 25.5552(10) Å  = 102.821(2)° 
Volume 4974.6(3) Å3 
Z 2 
Density (calculated) 1.291 Mg/m3 
Absorption coefficient 0.090 mm-1 
F(000) 2053 
Crystal size 0.24 x 0.06 x 0.03 mm3 
  range for data collection 2.91 to 25.03°. 
Index ranges -13<=h<=13, -21<=k<=21, -30<=l<=30 
Reflections collected 54011 
Independent reflections 17271 [R(int) = 0.0938] 
Completeness to   = 25.03° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9973 and 0.9787 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 17271 / 108 / 1307 
Goodness-of-fit on F2 1.135 
Final R indices [I>2 (I)] R1 = 0.1572, wR2 = 0.2847 
R indices (all data) R1 = 0.2502, wR2 = 0.3340 
Largest diff. peak and hole 0.753 and -0.446 e.Å-3 
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Table 2.  Hydrogen bonds for [3]rotaxane 61 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N(4)-H(4A)...O(101) 0.88 1.98 2.834(10) 164.1 
 N(102)-H(102)...O(1) 0.88 2.08 2.942(9) 167.0 
 N(103)-H(10C)...O(2) 0.88 2.18 3.032(10) 163.5 
 N(104)-H(10D)...O(2) 0.88 2.35 3.227(9) 173.0 
 N(201)-H(201)...O(4) 0.88 2.25 3.115(9) 169.1 
 N(202)-H(202)...O(4) 0.88 2.48 3.279(9) 150.9 
 N(203)-H(20E)...O(3) 0.88 2.29 3.046(9) 144.4 
_______________________________________________________________________ 
 
1H NMR and 13C NMR of [2]rotaxane 63. 
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Table 1.  Crystal data and structure refinement for [2]rotaxane 63. 
Empirical formula  C32H30N2O2, C32H28N4O4, 4(CHCl3)  
Formula weight  1484.64 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 10.1643(2) Å = 90° 
 b = 31.3646(5) Å = 112.9800(10)° 
 c = 11.6751(2) Å  = 90° 
Volume 3426.64(10) Å3 
Z 2 
Density (calculated) 1.439 Mg/m3 
Absorption coefficient 4.897 mm-1 
F(000) 1528 
Crystal size 0.18 x 0.16 x 0.14 mm3 
  range for data collection 6.35 to 70.06°. 
Index ranges -12<=h<=11, -36<=k<=38, -12<=l<=14 
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Reflections collected 30442 
Independent reflections 6437 [R(int) = 0.0281] 
Completeness to   = 70.06° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.5472 and 0.4727 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6437 / 0 / 415 
Goodness-of-fit on F2 1.025 
Final R indices [I>2 (I)] R1 = 0.0366, wR2 = 0.0950 
R indices (all data) R1 = 0.0406, wR2 = 0.0981 
Largest diff. peak and hole 0.511 and -0.415 e.Å-3 
 
Table 2.  Hydrogen bonds for [2]rotaxane 63 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N(101)-H(101)...O(1)#1 0.88 2.42 3.2685(19) 163.2 
 N(102)-H(102)...O(1)#1 0.88 2.10 2.9772(18) 172.3 
_______________________________________________________________________ 
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1H NMR and 13C NMR of [3]rotaxane 67. 
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1H NMR and 13C NMR of [3]rotaxane 69. 
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Table 1.  Crystal data and structure refinement for [3]rotaxane 69. 
Empirical formula  C110H117N12O15.50 
Formula weight  1855.16 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1  
Unit cell dimensions a = 10.8101(6) Å  = 110.488(8)° 
 b = 21.2231(13) Å  = 97.325(7)° 
 c = 22.7870(16) Å   = 97.504(7)° 
Volume 4770.1(5) Å3 
Z 2 
Density (calculated) 1.292 Mg / m3 
Absorption coefficient 0.087 mm1 
F(000) 1970 
Crystal size 0.20  0.03  0.02 mm3 
 range for data collection 2.99  25.03° 
Index ranges 10  h  12, 25  k  25, 27  l  26 
Reflections collected 33613 
Independent reflections 16656 [Rint = 0.0637] 
Completeness to  = 25.03° 98.9 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 0.9983 and 0.9828 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 16656 / 405 / 1316 
Goodness-of-fit on F2 1.053 
Final R indices [F2 > 2(F2)] R1 = 0.0816, wR2 = 0.1913 
R indices (all data) R1 = 0.1513, wR2 = 0.2292 
Largest diff. peak and hole 0.743 and 0.674 e Å3 
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Table 2.  Hydrogen bonds for [2]rotaxane 69 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N5H5...O4 0.88 2.05 2.877(5) 155.2 
 N6H6N...O3 0.88 2.21 3.080(4) 168.8 
 N7H7N...O3 0.88 2.23 3.080(5) 161.0 
 N9H9...O1 0.88 2.05 2.889(4) 158.4 
 N10H10N...O2 0.88 2.10 2.960(4) 165.2 
 N11H11N...O2 0.88 2.52 3.398(5) 176.6 
_______________________________________________________________________ 
 
1H NMR of thread 72 (in blue) and [3]rotaxane 73 (in red).  
 
Arrows highlight the shielding of the olefinic protons. 
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1H NMR and 13C NMR of [3]rotaxane 73. 
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Table 1.  Crystal data and structure refinement for [3]rotaxane 73. 
Empirical formula  C101H92N12O12, 0.5(C2H5OH), 0.5(CH3OH), 
2(H2O) 
Formula weight  1740.95 
Temperature  120(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 10.0536(3) Å = 90° 
 b = 38.7489(11) Å = 92.610(2)° 
 c = 11.7046(3) Å  = 90° 
Volume 4555.0(2) Å3 
Z 2 
Density (calculated) 1.269 Mg/m3 
Absorption coefficient 0.699 mm-1 
F(000) 1840 
Crystal size 0.21 x 0.13 x 0.06 mm3 
  range for data collection 6.35 to 66.58°. 
Index ranges -11<=h<=11, -46<=k<=46, -13<=l<=13 
Reflections collected 27608 
Independent reflections 13650 [R(int) = 0.0274] 
Completeness to   = 66.58° 94.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9593 and 0.8671 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13650 / 6 / 1191 
Goodness-of-fit on F2 1.075 
Final R indices [I>2 (I)] R1 = 0.0509, wR2 = 0.1353 
R indices (all data) R1 = 0.0549, wR2 = 0.1385 
Absolute structure parameter 0.08(17) 
Largest diff. peak and hole 0.611 and -0.215 e.Å-3 
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Table 2.  Hydrogen bonds for [3]rotaxane 73 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
N(101)-H(101)...O(1) 0.88 2.20 3.072(4) 170.8 
 N(102)-H(102)...O(1) 0.88 2.09 2.934(4) 161.4 
 N(103)-H(10C)...O(2) 0.88 2.16 3.002(3) 159.3 
 N(104)-H(10D)...O(2) 0.88 2.12 2.978(4) 165.5 
 N(201)-H(201)...O(3) 0.88 2.24 3.082(4) 160.5 
 N(202)-H(202)...O(3) 0.88 2.22 3.066(4) 162.5 
 N(203)-H(20E)...O(4) 0.88 2.11 2.969(3) 166.4 
 N(204)-H(20F)...O(4) 0.88 2.26 3.127(3) 171.0 
_______________________________________________________________________ 
 
1H NMR and 13C NMR of [2]rotaxane 74. 
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1H NMR and 13C NMR of [2]rotaxane 77. 
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1H NMR and 13C NMR of [3]rotaxane 84. 
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1H NMR and 13C NMR of [2]rotaxane 85. 
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Table 1.  Crystal data and structure refinement for Diels-Alder adduct 89. 
Empirical formula  C28H25NO3 
Formula weight  423.49 
Temperature  120(2) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 9.0489(1) Å = 67.170(1)° 
 b = 10.6951(1) Å = 79.463(1)° 
 c = 12.5935(2) Å  = 81.782(1)° 
Volume 1100.87(2) Å3 
Z 2 
Density (calculated) 1.278 mg/m3 
Absorption coefficient 0.657 mm-1 
F(000) 448 
Crystal size 0.20 x 0.17 x 0.12 mm3 
  range for data collection 6.45 to 66.60°. 
Index ranges -10<=h<=10, -12<=k<=12, -14<=l<=14 
Reflections collected 10832 
Independent reflections 3784 [R(int) = 0.0555] 
Completeness to   = 66.60° 97.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9253 and 0.8798 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3784 / 0 / 290 
Goodness-of-fit on F2 1.028 
Final R indices [I>2 (I)] R1 = 0.0581, wR2 = 0.1567 
R indices (all data) R1 = 0.0616, wR2 = 0.1635 
Largest diff. peak and hole            0.317 and -0.375 e.Å-3 
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MALDI profile for the formation of box 105 with thread 33 (with the spectrum colour as 
followed: 1 day shown in red, 2 days shown in brown, 5 days shown in black, 1 week in 
purple, 2 weeks shown in green and 3 weeks shown in red). 
 
MALDI profile for the formation of box 105 without thread 33 (same colour coded spectra). 
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8661364.2
1261.1946.5 1362.2
1365.2
1366.2 1627.1
dfw7638f 62 (1.036) TOF LD+ 
1.67e31364.3
1261.3
946.8
1362.2
1365.4
1366.3
1628.31518.4
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
%
0
100
%
0
100
%
0
100
%
0
100
dfw7639 7 (0.116) TOF LD+ 
2.55e3478.2 946.2
479.1 944.2
500.1 580.2 764.2
948.2
1260.5949.2 1158.51056.5
1363.6
1365.6
dfw7639b 6 (0.100) TOF LD+ 
326478.0
476.0
1260.5946.1
479.0
500.2 764.1580.1 866.2 1159.5949.1
1363.5
1263.5 1365.6 1444.4
dfw7639c 10 (0.167) TOF LD+ 
2.39e3946.0478.0
944.0
479.0
1363.41260.4
949.0
1158.3950.0
1262.3
1263.3
1365.3
1627.0
dfw7639d 13 (0.216) TOF LD+ 
6551363.9
478.3 946.4
944.4
479.3 1260.9948.4
1364.9
1365.9 1627.8
dfw7639e 12 (0.200) TOF LD+ 
2.38e31364.2
946.5478.3
944.6479.3
1261.1
949.5
1366.2
1627.11367.1
dfw7639f 1 (0.018) TOF LD+ 
8241363.8
946.3
478.3 1260.7
1364.8
1365.8
1627.7
Appendix 
 
 
228 
 
1H NMR and 13C NMR of molecular cage 105. 
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1H NMR of thread 115 (in red) after addition of 1 eq. of macrocycle 102 (in green) 
and 2 eq. of macrocycle 102 (in blue). 
 
 
References 
 
 
230 
 
References 
(1) Lehn, J. M. Angew. Chem. Int. Ed. 1988, 27, 89. 
(2) Beer, P. D.; Gale, P. A.; Smith, D. K. Supramolecular Chemistry; Oxford 
University Press: Oxford, 2003. 
(3) Lichtenthaler, F. W. Angew. Chem. Int. Ed. 1995, 33, 2364. 
(4) Watson, J. D.; Crick, F. H. C. Nature 1953, 171, 964. 
(5) Amabilino, D. B.; Stoddart, J. F. Chem. Rev. 1995, 95, 2725. 
(6) Johnston, A. G.; Leigh, D. A.; Pritchard, R. J.; Deegan, M. D. Angew. 
Chem. Int. Ed. 1995, 34, 1209. 
(7) Aricó, F.; Badjic, J. D.; Cantrill, S. J.; Flood, A. H.; Leung, K. C.-F.; Liu, Y.; 
Stoddart, J. F. Templated Synthesis of Interlocked Molecules; Springer Berlin / 
Heidelberg: Los Angeles, 2005; Vol. 249. 
(8) Blanco, M.-J.; Chambron, J.-C.; Jimenez, M. C.; Sauvage, J.-P. Transition-
Metal-Templated Synthesis of Rotaxanes; John Wiley & Sons, Inc.: Illinois, 2003; 
Vol. Volumen 23. 
(9) Harrison, I. T.; Harrison, S. J. Am. Chem. Soc. 1967, 89, 5723. 
(10) Schill, G.; Zollkopf, H. Nachr. Chem. Techn. 1967, 15, 149. 
(11) Cao, J.; Fyfe, M. C. T.; Stoddart, J. F.; Cousins, G. R. L.; Glink, P. T. J. Org. 
Chem. 2000, 65, 1937. 
(12) Tachibana, Y.; Kihara, N.; Ohga, Y.; Takata, T. Chem. Lett. 2000, 806. 
(13) Cantrill, S. J.; Fulton, D. A.; Heiss, A. M.; Pease, A. R.; Stoddart, J. F.; 
White, A. J. P.; Wiliams, D. J. Chem. Eur. J. 2000, 6, 2274. 
(14) Asakawa, M.; Brancato, G.; Fanti, M.; Leigh, D. A.; Shimizu, T.; Sawin, A. 
M. Z.; Wong, J. K. Y.; Zerbetto, F.; Zhang, S. J. Am. Chem. Soc. 2002, 124, 2939. 
(15) Wisner, J. A.; Beer, P. D.; Drew, M. G. B.; Sambrook, M. R. J. Am. Chem. 
Soc. 2002, 124, 12469. 
(16) Glink, P. T.; Oliva, A. I.; Stoddart, J. F.; White, A. J. P.; Wiliams, D. J. 
Angew. Chem. Int. Ed. 2001, 40, 1870. 
(17) Cantrill, S. J.; Preece, J. A.; Stoddart, J. F.; Wang, Z.-H.; White, A. J. P.; 
Wiliams, D. J. Tetrahedron 2000, 56, 6675. 
(18) Ashton, P. R.; Baxter, I.; Fyfe, M. C. T.; Raymo, F. M.; Spencer, N.; 
Stoddart, J. F.; White, A. J. P.; Wiliams, D. J. J. Am. Chem. Soc. 1998, 120, 2297. 
(19) Händel, M.; Plevoest, M.; Gestermann, S.; Vögtle, F. Angew. Chem. Int. Ed. 
1997, 36, 1199. 
(20) Dietrich-Buchecker, C. O.; Sauvage, J. P. Tetrahedron Lett. 1983, 24, 5091. 
(21) Ashton, P. R.; Ballardini, R.; Balzani, V.; Belohradsky, M.; Gandolfi, M. T.; 
Philip, D.; Prodi, L.; Raymo, F. M.; Reddington, M. V.; Spencer, N.; Stoddart, J. F.; 
Venturi, M.; Wiliams, D. J. J. Am. Chem. Soc. 1996, 118, 4931. 
(22) Ashton, P. R.; Glink, P. T.; Stoddart, J. F.; Tasker, P. A.; White, A. J. P.; 
Wiliams, D. J. Chem. Eur. J. 1996, 729. 
(23) Browne, W. R.; Feringa, B. L. Nature nanotechnology 2006, 1, 25. 
(24) Anelli, P. L.; Spencer, N.; Stoddart, J. F. J. Am. Chem. Soc. 1991, 113, 
5131. 
References 
 
 
231 
 
(25) Pons, M.; Millet, O. Prog. Nucl. Magn. Reson. Spectrosc. 2001, 38, 267. 
(26) Hunter, C. A. J. Am. Chem. Soc. 1992, 114, 5303. 
(27) Vögtle, F.; Händel, M.; Meier, S.; Ottens‐Hildebrandt, S.; Ott, F.; Schmidt, 
T. Liebigs Annalen 1995, 739. 
(28) Parham, A. H.; Windisch, B.; Vögtle, F. Eur. J. Org. Chem. 1999, 1233. 
(29) Brancato, G.; Coutrot, F.; Leigh, D. A.; Murphy, A.; Wong, J. K. Y.; Zerbetto, 
F. PNAS 2002, 99, 4967. 
(30) Carver, F. J.; Hunter, C. A.; Shannon, R. J. J. Chem. Soc., Chem. 
Commun. 1994, 1277. 
(31) Johnston, A. G.; Leigh, D. A.; Pritchard, R. J.; Deegan, M. D. Angew. 
Chem. Int. Ed. 1995, 34, 1209. 
(32) Gatti, F. G.; Leigh, D. A.; Nepogodiev, S. A.; Slawin, A. M. Z.; Teat, S. J.; 
Wong, J. K. Y. J. Am. Chem. Soc. 2001, 123, 5983. 
(33) Belowich, M. E.; Valente, C.; Smaldone, R. A.; Friedman, D. C.; Thiel, J.; 
Cronin, L.; Stoddart, J. F. J. Am. Chem. Soc. 2012, 134, 5243. 
(34) Moonen, N.; Flood, A.; Fernández, J.; Stoddart, J. Molecular Machines 
2005, 99. 
(35) Fyfe, M. C. T.; Stoddart, J. F. Acc. Chem. Res. 1997, 30, 393. 
(36) Lane, A. S.; Leigh, D. A.; Murphy, A. J. Am. Chem. Soc. 1997, 119, 11092. 
(37) Keaveney, C. M.; Leigh, D. A. Angew. Chem. Int. Ed. 2004, 43, 1222. 
(38) Murakami, H.; Kawabuchi, A.; Matsumoto, R.; Ido, T.; Nakashima, N. J. Am. 
Chem. Soc. 2005, 127, 15891. 
(39) Kay, E.; Leigh, D. Molecular Machines 2005, 133. 
(40) Tian, H.; Wang, Q. C. Chem. Soc. Rev. 2006, 35, 361. 
(41) Yang, W.; Li, Y.; Liu, H.; Chi, L.; Li, Y. Small 2012, 8, 504. 
(42) Langton, M. J.; Beer, P. D. Chem. Eur. J. 2012, 18, 14406  
(43) Davis, J. J.; Beer, P. D. Org. Biomol. Chem. 2009, 7, 415. 
(44) Williams, A. R.; Northrop, B. H.; Chang, T.; Stoddart, J. F.; White, A. J. P.; 
Williams, D. J. Angew. Chem. Int. Ed. 2006, 45, 6665. 
(45) Chichak, K. S.; Cantrill, S. J.; Pease, A. R.; Chiu, S. H.; Cave, G. W. V.; 
Atwood, J. L.; Stoddart, J. F. Science 2004, 304, 1308. 
(46) Radha Kishan, M.; Parham, A.; Schelhase, F.; Yoneva, A.; Silva, G.; Chen, 
X.; Okamoto, Y.; Vögtle, F. Angew. Chem. Int. Ed. 2006, 45, 7296. 
(47) Lukin, O.; Vögtle, F. Angew. Chem. Int. Ed. 2005, 44, 1456. 
(48) Fujita, M.; Ogura, K. Bull. Chem. Soc. Jpn. 1996, 69, 1471. 
(49) Fujita, M.; Oguro, D.; Miyazawa, M.; Oka, H.; Yamaguchi, K.; Ogura, K. 
Nature 1995, 378, 469. 
(50) Murase, T.; Horiuchi, S.; Fujita, M. J. Am. Chem. Soc. 2010, 131, 2866. 
(51) Nishiyabu, R.; Kubo, Y.; James, T. D.; Fossey, J. S. Chem. Commun. 2011, 
47, 1124. 
(52) Nishiyabu, R.; Kubo, Y.; James, T. D.; Fossey, J. S. Chem. Commun. 2011, 
47, 1106. 
(53) Nishimura, N.; Kobayashi, K. Angew. Chem. Int. Ed. 2008, 47, 6255. 
(54) Icli, B.; Sheepwash, E.; Riis-Johannessen, T.; Schenk, K.; Filinchuk, Y.; 
Scopelliti, R.; Severin, K. Chem. Sci. 2011, 2, 1719. 
References 
 
 
232 
 
(55) Hasell, T.; Schmidtmann, M.; Stone, C. A.; Smith, M. W.; Cooper, A. I. 
Chem. Commun. 2012, 48, 4689. 
(56) Ariga, K.; Vinu, A.; Miyahara, M.; Hill, J. P.; Mori, T. J. Am. Chem. Soc. 
2007, 129, 11022. 
(57) Varpness, Z.; Peters, J.; Young, M.; Douglas, T. Nano Lett. 2005, 5, 2306. 
(58) Meeuwissen, J.; Reek, J. N. H. Nat. Chem. 2010, 2, 615. 
(59) Hart-Cooper, W. M.; Clary, K. N.; Toste, F. D.; Bergman, R. G.; Raymond, 
K. N. J. Am. Chem. Soc. 2012, 134, 17873. 
(60) Balaji, T.; El Safty, S. A.; Matsunaga, H.; Hanaoka, T.; Mizukami, F. Angew. 
Chem. 2006, 118, 7360. 
(61) Horcajada, P.; Serre, C.; Vallet‐Regí, M.; Sebban, M.; Taulelle, F.; Férey, 
G. Angew. Chem. 2006, 118, 6120. 
(62) Crowley, J. D.; Lewis, J.; Gavey, E.; Cameron, S. A. Chem. Sci. 2012, 3, 
778. 
(63) Han, S. S.; Choi, S.-H.; van Duin, A. C. T. Chem. Commun. 2010, 46, 5713. 
(64) Farrusseng, D. Metal-Organic Frameworks; Wiley-VCH, 2011. 
(65) Vukotic, V. N.; Harris, K. J.; Zhu, K.; Schurko, R. W.; Loeb, S. J. Nat. Chem. 
2012, 4, 456. 
(66) Yang, J.; Ma, J. F.; Batten, S. R. Chem. Commun. 2012, 48, 7899. 
(67) Lin, Z.; Sun, J.; Efremovska, B.; Warmuth, R. Chem. Eur. J. 2012, 18, 
12864. 
(68) Kang, J.; Rebek, J. Nature 1997, 385, 50. 
(69) Stang, P. J. J. Am. Chem. Soc. 2012, 134, 11829. 
(70) Feng, X.; Ding, X.; Jiang, D. Chem. Soc. Rev. 2012, 41, 6010. 
(71) Thompson, M. A. Planaria Software LLC, Seattle, WA 2004. 
(72) Macrae, C. F.; Bruno, I. J.; Chisholm, J. A.; Edgington, P. R.; Mccabe, P.; 
Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; Streek, J.; Wood, P. A. J. Appl. 
Crystallogr. 2008, 41, 466. 
(73) Allen, C. L.; Williams, J. M. J. Chem. Soc. Rev. 2011, 40, 3405. 
(74) Katritzky, A. R.; Avan, I.; Tala, S. R. J. Org. Chem. 2009, 74, 8690. 
(75) Han, C.; Lee, J. P.; Lobkovsky, E.; Porco, J. A. J. Am. Chem. Soc. 2005, 
127, 10039. 
(76)  ern ,  .;  la ar n, M.; Orenes, R. A. J. Am. Chem. Soc. 2010, 132, 10741. 
(77) Kenner, G. W.; Seely, J. H. J. Am. Chem. Soc. 1972, 94, 3259. 
(78) Johnston, A. G.; Leigh, D. A.; Murphy, A.; Smart, J. P.; Deegan, M. D. J. 
Am. Chem. Soc. 1996, 118, 10662. 
(79) Berná, J.; Alajarín, M.; Marín-Rodríguez, C.; Franco-Pujante, C. Chem. Sci. 
2012, 3, 2314. 
(80) Gatti, F. G.; Leigh, D. A.; Nepogodiev, S. A.; Slawin, A. M. Z.; Simon, J.; 
Wong, J. K. Y. J. Am. Chem. Soc. 2001, 123, 5983. 
(81) Alvarez-Pérez, M.; Goldup, S. M.; Leigh, D. A.; Slawin, A. M. Z. J. Am. 
Chem. Soc. 2008, 130, 1836. 
(82) Watanabe, N.; Furusho, Y.; Kihara, N.; Takata, T.; Kinbara, K.; Saigo, K. 
Bull. Chem. Soc. Jpn. 2001, 74, 149. 
(83) Furusho, Y.; Shoji, J.; Watanabe, N.; Kihara, N.; Adachi, T.; Takata, T. Bull. 
Chem. Soc. Jpn. 2001, 74, 139. 
References 
 
 
233 
 
(84) Fu, N.; Gassensmith, J. J.; Smith, B. D. Supramol. Chem. 2009, 21, 118. 
(85) Ciganek, E. J. Org. Chem. 1980, 45, 1497. 
(86) Hahn, W. E.; Szalecki, W.; Boszczyk, W. Pol. J. Chem. 1978, 52, 2497. 
(87) Schalley, C. A.; Beizai, K.; Vögtle, F. Acc. Chem. Res. 2001, 34, 465. 
(88) Maender, O. W.; Janzen, E. G. J. Org. Chem. 1969, 34, 4072. 
(89) Theodorou, V.; Ragoussis, V.; Strongilos, A.; Zelepos, E.; Eleftheriou, A.; 
Dimitriou, M. Tetrahedron Lett. 2005, 46, 1357. 
(90) Goldeman, W.; Soroka, M. ARKIVOC 2010, 11, 360. 
(91) Semlyen, J. A. Large ring molecules; John Wiley & Son Ltd, 1996. 
(92) Atkinson, I. M.; Lindoy, L. F. Self assembly in supramolecular systems; 
Royal Society of Chemistry, 2000; Vol. 7. 
(93) Anelli, P. L.; Ashton, P. R.; Spencer, N.; Slawin, A. M. Z.; Stoddart, J. F.; 
Williams, D. J. Angew. Chem. Int. Ed. 1991, 30, 1036. 
(94) Ashton, P. R.; Odell, B.; Reddington, M. V.; Slawin, A. M. Z.; Stoddart, J. F.; 
Williams, D. J. Angew. Chem. Int. Ed. 1988, 27, 1550. 
(95) Ashton, P. R.; Philip, D.; Spencer, N.; Stoddart, J. F. J. Chem. Soc., Chem. 
Commun. 1991, 1677. 
(96) Gong, C.; Balanda, P. B.; Gibson, H. W. Macromolecules 1998, 31, 5278. 
(97) Trabolsi, A.; Hmadeh, M.; Khashab, N. M.; Friedman, D. C.; Belowich, M. 
E.; Humbert, N.; Elhabiri, M.; Khatib, H. A.; Albrecht-Gary, A. M.; Stoddart, J. F. 
New J. Chem. 2009, 33, 254. 
(98) McNitt, K. A.; Parimal, K.; Share, A. I.; Fahrenbach, A. C.; Witlicki, E. H.; 
Pink, M.; Bediako, D. K.; Plaisier, C. L.; Le, N.; Heeringa, L. P. J Am Chem Soc 
2009, 131, 1305. 
(99) Schalley, C. A. Analytical Methods in Supramolecular Chemistry; John 
Wiley & Sons, 2007. 
(100) Huang, Y. L.; Hung, W. C.; Lai, C. C.; Liu, Y. H.; Peng, S. M.; Chiu, S. H. 
Angew. Chem. Int. Ed. 2007, 46, 6629. 
(101) Leigh, D. A.; Thomson, A. R. Org. Lett. 2006, 8, 5377. 
(102) Chen, M.; Han, S.; Jiang, L.; Zhou, S.; Jiang, F.; Xu, Z.; Liang, J.; Zhang, S. 
Chem. Commun. 2010, 46, 3932. 
(103) Kaufmann, L.; Dzyuba, E. V.; Malberg, F.; Loew, N. L.; Groschke, M.; 
Brusilowskij, B.; Huuskonen, J.; Rissanen, K.; Kirchner, B.; Schalley, C. Org. 
Biomol. Chem. 2012, 10, 5954. 
(104) Chen, D.; Martell, A. E. Tetrahedron 1991, 47, 6895. 
(105) Murakami, Y.; Kikuchi, J.; Ohno, T.; Hirayama, T.; Hisaeda, Y.; Nishimura, 
H.; Snyder, J. P.; Steliou, K. J. Am. Chem. Soc. 1991, 113, 8229. 
(106) Murakami, Y.; Ohno, T.; Hayashida, O.; Hisaeda, Y. J. Chem. Soc., Chem. 
Commun. 1991, 950. 
(107) Vidonne, A.; Philp, D. Tetrahedron 2008, 64, 8464. 
(108) Hassan, N. I.; del Amo, V.; Calder, E.; Philp, D. Org. Lett. 2011, 13, 458. 
(109) Gololobov, Y. G.; Zhmurova, I.; Kasukhin, L. Tetrahedron 1981, 37, 437. 
(110) Huisgen, R.; Knorr, R.; Möbius, L.; Szeimies, G. Chem. Ber. 1965, 98, 
4014. 
(111) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. 
Chem. Int. Ed. 2002, 41, 2596. 
References 
 
 
234 
 
(112) Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057. 
(113) Dzyuba,  .  .;  aufmann, L.; L w, N. L.; Meyer, A. K.; Winkler, H. D. F.; 
Rissanen, K.; Schalley, C. A. Org. Lett. 2011, 13, 4838. 
(114) Alcaide, B.; Almendros, P.; Alonso, J. M. Chem. Eur. J. 2003, 9, 5793. 
(115) Gildersleeve, J.; Pascal Jr, R. A.; Kahne, D. J. Am. Chem. Soc. 1998, 120, 
5961. 
(116) Fernandes, A.; Viterisi, A.; Coutrot, F.; Potok, S.; Leigh, D. A.; Aucagne, V.; 
Papot, S. Angew. Chem. Int. Ed. 2009, 48, 6443. 
(117) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, 62, 7512. 
(118) Bottari, G.; Leigh, D. A.; Pérez, E. M. J. Am. Chem. Soc. 2003, 125, 13360. 
(119) Quirós, M.; Astorga, C.; Rebolledo, F.; Gotor, V. Tetrahedron 1995, 51, 
7715. 
(120) Harris, J. M.; McDonald, R.; Vederas, J. C. J. Chem. Soc., Perkin Trans. 1 
1996, 2669. 
(121) Gray, C. W.; Johnson, L. L.; Walker, B. T.; Sleevi, M. C.; Campbell, A. S.; 
Plourde, R.; Houston, T. A. Bioorg. Med. Chem. Lett. 2005, 15, 5416. 
(122) Pattanayak, S.; Sinha, S. Tetrahedron Lett. 2011, 52, 34. 
(123) Branchaud, B. P. J. Org. Chem. 1983, 48, 3531. 
(124) Canle, M.; Clegg, W.; Demirtas, I.; Elsegood, M. R. J.; Maskill, H. J. Chem. 
Soc., Perkin Trans. 2 1999, 85. 
(125) Kricheldorf, H. R. Chem. Ber. 1973, 106, 3765. 
(126) Kitamura, M.; Yano, M.; Tashiro, N.; Miyagawa, S.; Sando, M.; Okauchi, T. 
Eur. J. Org. Chem. 2011, 2011, 458. 
 
 
